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Abstract 
The introduction of antibiotics into medicine has protected patients from 
pathogenic infection acquired in the community or the hospital. Global misuse of 
these antibacterial drugs has encouraged resistance to develop and disseminate. 
The isolation of community-acquired total drug resistant pathogens forewarns 
that antibiotic-therapy may soon become ineffective at treating infections, and 
medical practice may retrogress to amputation of infected limbs to prevent the 
systemic spread of disease-causing microbes. Methicillin resistant 
Staphylococcus aureus has become ubiquitous in hospitals and general 
communities. Antibiotic-therapy is becoming less effective against these bacteria, 
creating an urgent need for the development of new antimicrobial agents to 
control these and other antibiotic resistant microorganisms. Antimicrobial 
peptides may become a viable treatment option, either alone or in combination 
with other antibacterial agents, for controlling MRSA infections. It is believed that 
because the mechanism of action of these peptides targets the fundamental 
physiology of the bacterial cell, resistance development is unlikely to occur. 
However, conflicting reports place doubt on this hypothesis. Exploratory 
experiments investigating their effectiveness under physiological conditions as 
well as the possibility of using them with other antimicrobial drugs or devices will 
allow researchers to better judge the therapeutic potential of antimicrobial 
peptides. 
A simple and rapid technique for homogenising and extracting bio-active 
compounds from plant, fungal and invertebrate material was developed. Using 
this technique, 31 different aqueous extracts from 24 different species were 
tested for antibacterial activity. Fourteen of the thirty-one extracts showed 
antibacterial activity. Proteinase treatment of these extracts showed that only 
Juniperus comminus, Capscium chinese and Elettaria cardamomum had 
antibacterial activity with proteinaceous origin. Isolation and characterisation of 
these potential antibacterial peptides were planned, but not conducted due to 
time constraints   
Clinical application of antimicrobial peptides, as with conventional antibiotics, 
may be compromised by the development of bacterial resistance.  Using the 
antibacterial peptide melittin as a model, we found that three strains of methicillin 
resistant S. aureus and one methicillin sensitive strain became equally resistant 
to melittin when grown in sub-lethal concentrations over seven days. The minimal 
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lethal concentration of melittin increased from 5 g/ml to 170 g/ml in 
bactopeptone medium depending on the strain. The same experiments repeated 
with three S. aureus strains and an un-related peptide, bac8c, showed bacteria 
developed resistance to bac8c to levels comparable with strains which developed 
resistance to melittin. Scanning electron microscopy revealed that resistance to 
melittin did not change the morphology of the cells. Melittin-naïve cells treated 
with melittin appeared shrivelled or disintegrated, whereas resistant cells treated 
with melittin appeared to retain their original structure, with a few cells showing 
surface blebbing or a shrivelled morphology. 
Eight subcultures of a melittin-resistant strain without melittin reduced the minimal 
lethal concentration to 30 g/ml, and 24h growth with 12 g/ml melittin restored it 
to 100 g/ml. However, for melittin-resistant bacteria, the minimal lethal 
concentration in phosphate buffer never exceeded 3 g/ml. Further investigations 
with stock cultures of MRSA showed that the minimal lethal concentration of 
melittin was proportional to NaCl and protein content of the media. Survival of 
parental strain bacteria in phosphate buffer with melittin also decreased when 
incubation temperatures were increased.  
Exposing melittin naïve and resistant bacteria to a cationic fluorophore, and 
measuring the binding affinity of this probe to the cells using flow cytometry, 
indicated that melittin resistance coincides with a decreased nett negative charge 
on the bacterial surface. The increased binding affinity of the anionic dye eosin to 
the melittin resistant cells appeared to support this hypothesis. Pulsed-field 
electrophoresis was used to separate smaI digested DNA from antimicrobial 
peptide-naïve and resistant bacteria to investigate whether resistance coincided 
with any major gain or loss of genetic material. The four S. aureus strains made 
resistant to melittin and three strains made resistant to bac8c showed no 
difference in banding pattern compared to their wild-type counterparts. This 
suggested that resistance may already be intrinsic, or may be related to the up-
regulation of normal metabolic pathways, in some S. aureus strains.   
It was hypothesised that melittin-resistant bacteria which mask the anionic 
charges on their membrane may reduce their tolerance to other antimicrobial 
agents, especially those with an anionic charge. Although the anionic 
antimicrobial peptide, AP1, was ineffective against wildtype and melittin-resistant 
bacteria, resistance to melittin in the MRSA strain WBG 8287 coincided with an 
increased sensitivity to eleven antibiotics with different physiochemical and 
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electrostatic properties. The melittin-resistant bacteria appeared especially 
sensitive to fusidic acid, so for further investigations, four S. aureus strains were 
made resistant to fusidic acid by exposure to sublethal doses of the antibiotic. 
These strains were then made resistant to melittin. Two of the four strains 
showed an increased sensitivity to fusidic acid after being made resistant to 
melittin. In strain W17S, resistance to melittin, and subsequent loss of resistance 
to fusidic acid, appeared to coincide with the loss of the fusidic acid resistance 
genes FusB and FusC.  
Melittin was haemolytic at low concentrations. A truncated analogue of melittin, 
melfrag12-26, has been reported to have the same antibacterial activity as full 
length melittin but without the haemolytic potential. This study found that 
melfrag12-26, and other analogues derived from melittin, had no antibacterial 
activity but were also non-haemolytic. Electroporation of the bacteria in the 
presence of 50 µg/ml of melfrag12-26, killed off 99.3% of the cells. The 
antibacterial activity of whole melittin and bac8c also improved when inserted into 
the bacteria using electroporation. Using a low concentration of the mild ionic 
detergent, Triton X-100, to permeabilize the cells also improved the peptides 
bactericidal activity and, together with the electroporation experiments, 
suggested that the peptides used in this study may have intracellular antibacterial 
activity. 
The silver nanoparticle-loaded antibacterial gauze, Acticoat, is routinely used in 
the hospital to prevent infection of vulnerable wounds. This study found that, in a 
semi-solid agar medium, the silver particles were able to diffuse off the Acticoat 
and inhibit growth around the gauze. However, when Acticoat was overlain on 
agar with a blistered surface, bacteria were able to grow underneath the 
antibacterial strips. In addition, Acticoat that had been overlain on inoculated agar 
over three days and blotted on fresh agar indicated that bacteria were possibly 
growing on the surface of Acticoat. Scanning electron microscopy confirmed this, 
and when the number of surviving bacteria growing on inoculated pig skin 
underneath, and on the surface of Acticoat were quantified, it appeared that the 
antibacterial activity of Acticoat may not be sufficient to prevent MRSA infection. 
However, when Acticoat was coated with glycerol, lysozyme and an antimicrobial 
peptide, the gauze was able to prevent the survival of bacteria on a densely 
inoculated pig skin sample.      
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Results from this study indicated that attempts to treat topical MRSA infections 
with antibacterial peptides could be most effective with prolonged application of 
warm, low ionic strength solutions without extraneous proteins. The substantial 
resistance developed in protein-rich saline environments suggests that attempts 
to use cationic peptides to treat systemic bacterial infections could allow rapid 
development of resistance, possibly sufficient to render treatment ineffective. 
However, resistance does not appear stable in a population without selection 
pressures. The mechanisms by which bacteria use to resist antimicrobial 
peptides may also sensitise them to other antimicrobial drugs, and the peptides 
were shown to enhance the bactericidal activity of an antibacterial gauze. 
Therefore, it appears that antimicrobial peptides may become a powerful tool to 
prevent pathogenic infection, especially when used in conjunction with another 
antibacterial drug or device.   
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1. Literature Review 
1.1.Staphylococcus aureus 
By the end of the 19th century human understanding of the nature and cause of 
disease had allowed many medical advances, such as vaccination and antiseptic 
techniques, which have saved many lives worldwide (1). In 1880 the Scottish 
physician Sir Alexander Ogston opened a patient’s putrefied abscess and 
prepared a smear slide of the subcutaneous exudate (2). What he observed 
under the microscope were lines and bunches of round organisms which he 
termed Staphylococcus after the Greek terms staphyle, for bunch of grapes and 
kokkos for berry (2). In 1884 Dr Anton Julius Rosenbach isolated two strains of 
Staphylococcus, one with a golden pigment and one with a white pigment and 
sub-classified them aureus and albus respectively (S. albus has since been 
renamed S. epidermidis: 2, 3). Staphylococcus aureus is a Gram-positive coccoid 
bacterium which colonises the epidermal surfaces of human nares, skin, rectum, 
axillae and oropharynx (Figure 1.1: 4, 5). Generally, S. aureus is commensal or 
asymptomatic with human hosts (5, 6). However, if host homeostasis is disrupted 
S. aureus can cause pathogenic infections that range from benign to life 
threatening (5, 6).  
 
 
 
 
 
 
 
 
 
Figure 1.1 Scanning electron microscopy image of Staphylococcus aureus 
in a grape-like cluster 
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1.1.2. Staphylococcus aureus Infections and Diseases 
Staphylococcus aureus commonly colonises the epidermal layers of the skin, 
nares and throat asymptomatically (7, 8). People carrying S. aureus can suffer 
from benign medical conditions such as boils, blisters, and impetigo (9). 
However, if the bacteria overcome the superficial barriers of the body and host 
defence mechanisms, the infection can spread into the blood stream and become 
life threatening (10, 11). The development of S. aureus bacteraemia, via access 
through the respiratory system or infected wounds, can lead to pathologies such 
as osteomyelitis, endocarditis and pneumonia (7, 10).  Individuals most at risk of 
invasive S. aureus infections include those suffering from leukaemia, diabetes 
mellitus type 1 or cystic fibrosis. Invasive surgery, haemodialysis or implantation 
of indwelling medical implants such as catheters, stents, pacemakers, breast 
implants and prosthetic valves also put patients in serious risk of infection (10, 
12, 13). Prior to the introduction of antibiotics into clinical therapy, over 80% of 
invasive S. aureus infections were fatal (14). During this time only one study 
described the recovery of a patient suffering from S. aureus-acquired 
endocarditis (SAE:15). The patient was hospitalised for 42 weeks and was 
confined to a wheel-chair for most of her treatment (15). In contrast, advances in 
medicine have reduced the mortality rate of SAE to around 40% with non-
invasive therapy periods of 4-6 weeks (16). However, development of antibiotic 
resistance in pathogens is greatly reducing the effectiveness of treatment for 
infectious pathogenic diseases such as endocarditis and pneumonia (17, 18).  
 
1.2. Antibiotic resistance 
Penicillin was serendipitously discovered by Alexander Flemming in 1928 and 
eventually received much interest from the medical community as it proved to be 
highly effective against S. aureus infections (19, 20). A team of Oxford 
researchers, under the direction of Sir Howard Florey, Professor Ernst Boris 
Chain, and Dr Norman Heatley, vastly expanded the research into penicillin and 
in 1941, North American pharmaceutical companies began mass production of 
the antibiotic (19, 20). In 1940 the penicillin deactivating β-lactamase enzyme 
was identified in Escherichia coli (21). By the mid-1940s almost 40% of all S. 
aureus strains isolated from hospital patients carried the enzyme (22). Methicillin 
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resistant S. aureus (MRSA) is resistant to all broad spectrum β-lactam antibiotics 
as well as many other classes of antibiotics (23, 24). The U.S Centres for 
Disease Control and Prevention reported that, in 2011, of the 80,000 reported 
cases of MRSA infections in North America, 11,000 were fatal: a higher mortality 
rate than Pseudomonas aeruginosa and Clostridium difficile combined (25). Most 
pathogens can now only be treated with a limited range of antibiotics (24, 25). 
The problem is exacerbated by the dearth of new antimicrobial agents in the 
development pipeline (17, 26). Without proper intervention strategies to combat 
antibiotic resistance, humanity could face apocalyptic epidemics leading to global 
recessions and decimation of populations (26, 27). 
 
1.2.1. Mechanisms of Antibiotic Resistance 
The different classes of antibiotics can target a multitude of bacterial enzymes to 
disrupt metabolic pathways (28). Consequently, bacteria have a sizeable arsenal 
of resistance mechanisms which can be broken down into five categories (Figure 
1.2): mutation of the target site of the antibiotic, development of new metabolic 
pathways that are un-affected by the antibiotic, enzymatic modification or 
destruction of the antibiotic, efflux of the antibiotic from the cytoplasm using 
active transport proteins, and reducing the permeability of the cell membrane to 
the antibiotic (29).  
Mutation of the target site of the antibiotic can render the target insensitive to the 
antibiotic, reducing bacterial susceptibility (30). Furthermore, alternative steps in 
metabolic pathways can be generated to circumvent the process affected by the 
antibiotic (29, 31). However, because these enzymes and pathways are generally 
critical to cell survival, mutation may reduce bacterial fitness, and other 
adaptations arise to ensure normal metabolism (30, 32, 33).  
Some bacteria produce transferase and kinase enzymes specific for certain 
antibiotics, which modify their structure to prevent them from binding to their 
target (34). Other resistance enzymes such as β-lactamase, macrolide esterase, 
and epoxidase, chemically cleave the antibiotic and neutralise its activity (34). 
Bacteria have also been shown to inhibit antibiotics using enzymes that catalyse 
the oxidation of active sites of the antibiotics (34). For example, the TetX 
monooxygenase produced by some Bacteroide species catalyses the 
hydroxylation of the Mg+ binding site of tetracyclines. This hydroxylation inhibits 
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tetracycline activity because chelation between tetracycline and divalent cations 
is required for the antibiotic to target and disrupt ribosome activity (35).  As with 
most antibiotic resistance proteins, these transferases, hydrolases and redox 
enzymes share similarity to bacterial proteins with functions that are not related 
to antimicrobial resistance. Therefore, it has been suggested that antibiotic 
resistance enzymes originated from metabolic enzymes and increased exposure 
of microbes to antibiotics recently has led to the preservation of alterations that 
has allowed them to function as resistance proteins (34).   
Efflux pumps are protein-based transport systems which can expel toxic and non-
toxic substances from the cytoplasm of a cell (36, 37). Antibiotic efflux pumps can 
be specific to one class of antibiotic or to a broad range of antimicrobial agents, 
allowing  multiple drug resistance to be developed through mutations in the gene 
of a single protein (36, 37). These pumps are innate to both Gram-positive and 
Gram-negative bacteria and antibiotic resistance through the action of efflux 
pumps results from over-expression of the pump mechanism, rather than 
acquisition of new genetic material (36, 37). Although efflux pumps are generally 
not associated with high levels of resistance to antibiotics, it has been suggested 
that this intrinsic method allows bacteria to survive in low levels of a broad 
spectrum of antimicrobial agents, creating the potential to generate more 
effective resistance mechanisms (36).  
The outer membrane of Gram-negative bacteria can be modified to reduce its 
permeability to antibiotics: restricting access of the drug to intracellular targets 
(38). An outer membrane densely packed with hydrophilic lipopolysaccharides 
has been shown to increase resistance to large hydrophobic antibiotics such as 
aminoglycosides and macrolides (38, 39). Small hydrophilic antibiotics gain entry 
to the cell by passively diffusing through the membrane gateway proteins: porins 
(38, 39). Loss of the porin proteins, modification of their structure, or closure of 
the porin channel can increase resistance of the bacteria to hydrophilic antibiotics 
such as β-lactams (38, 39).      
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Figure 1.2 Antibiotic resistance mechanisms of bacteria 
 
1.2.2. Dissemination of Antibiotic Resistance 
The success of many medical procedures such as open surgery, organ 
transplantation and cancer chemotherapy would be severely compromised 
without antibiotics. However, resistance to antibiotics and their related 
compounds is not a new phenomenon (40). Sequencing of ancient bacterial DNA 
revealed that as far back as 30,000 years, bacterial genomes contained 
sequences which appear to confer resistance to β-lactams, tetracyclines and 
glycopeptide antibiotics (41). The introduction of antibiotics into medical practice 
and the agricultural industry and their subsequent misuse has conferred a 
selective advantage on those bacterial populations already resistant to antibiotic 
compounds. This evolutionary pressure, combined with the development of 
global markets, increased international travel and migration has caused antibiotic 
resistance to spread rapidly throughout hospitals and the general communities 
within the past 50 years (42).   
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1.2.2.1. Healthcare Industry 
The effectiveness of antibiotic treatment against pathogens has led to their 
overuse in the healthcare industry. The threat of litigation from patients 
demanding relief from illness may cause clinicians to disregard their better 
judgement and prescribe antibiotics inappropriately.(43, 44). In China, 50% of the 
revenue of hospitals comes from drug sales and Chinese physicians can receive 
upward of 20% commission on drug prescriptions. This has undoubtedly 
contributed to China having one of the highest consumption rates of antibiotics by 
inpatients in the world (45). To compound the problem, medical professionals 
who may be inexperienced or inappropriately trained are prescribing broad 
spectrum antibiotics for viral infections such as the common cold world-wide (45, 
46). The over-prescription of antibiotics through negligence or corruption exposes 
potential pathogens to antibiotics: encouraging resistance development in 
microbial communities whilst having no effect on the causative agent (46). The 
emergence of the HIV pandemic has also greatly contributed to the development 
and spread of antibiotic resistant pathogens. The impaired host defence system 
in immunocompromised patients makes them more susceptible to infection from 
pathogenic organisms (47, 48). Constant prophylactic treatment with antibiotics 
to prevent these infections can replace  the patient’s normal antibiotic-sensitive 
flora with more difficult to treat antibiotic resistant bacteria (49). In addition, the 
complimentary antimicrobial activity of antibiotics and the immune system may 
not be as effective in patients with impaired immunity. Therefore, bacteria 
infecting these patients may be more likely to survive antibiotic treatment than in 
healthy patients, which may compromise future use of the antibiotic.    
 
1.2.2.2. Pharmaceutical Industry 
Investment from private companies and public funds into medical research has 
created therapeutic agents and strategies to address the problems created by 
antibiotic resistant pathogens (50). However, the competitive nature of the global 
economy and strict policies controlling the approval of therapeutic agents for use 
in humans and animals have caused a significant reduction in funding from 
pharmaceutical companies, leading to a decline in antimicrobial agent research 
and development (51, 52). The development of antibiotic resistance by 
pathogenic organisms reduces the therapeutic effectiveness of the antibiotic 
which limits its applications in medicine and ultimately decreases its potential as 
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a profitable investment within a relatively short time. Additionally, a course of 
antibiotics is prescribed to eliminate an infection, rather than treating the 
symptoms, and once the infection is eliminated the patient stops purchasing the 
antibiotics. Therefore, it appears more lucrative for a company to invest in a 
therapeutic agent that treats a chronic illness, for example: insulin or insulin 
mimics for diabetics, or statins for patients with high LDL levels. Conversely, 
investment in pharmaceutical research may be a double edged sword as it may 
encourage some companies to report misleading or erroneous results if it is in 
the company’s interest (49).  
 
1.2.2.3. Agricultural Industry 
In North America it is estimated that approximately 80% of available antibiotics 
are given to livestock (53). The majority of these are administered in the feed to 
promote growth in cattle, poultry and swine (54) and as a prophylaxis to prevent 
disease transmission in unsanitary farms (53, 54). Both practises expose 
microorganisms to low doses of broad-spectrum antibiotics which can encourage 
resistance development in native and exogenous gastrointestinal flora and leave 
the livestock susceptible to colonisation by antibiotic tolerant pathogens (54). In 
2013 the U.S Food and Drug Administration (FDA) released two documents 
recommending that food animal production groups and pharmaceutical 
companies stop the use of antibiotic growth promotants (AGP:55). Since these 
were only recommendations, the FDA is not playing a regulatory role in phasing 
out AGP and is instead relying on these groups to act voluntarily. Additionally, the 
report encourages farms to continue to use antibiotics as prophylactics if a 
veterinarian considers the animals at risk of infection (55). Prophylactic 
medication does not fix the underlying problem of unsanitary, overcrowded farms. 
Perhaps a more prudent move would be to provide incentives for farms to rely on 
good animal husbandry practice, to avoid AGP and only used them as a last 
resort. In 1999 Denmark banned the use of AGP and now regulates antibiotic use 
in animal food production (56). Since then, the incidence of antibiotic resistant 
Enterococci has declined significantly in Danish livestock without any serious 
deterioration in animal health or farmers’ profit (56).   
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1.2.3 Global Strategies to Counteract Antibiotic Resistance 
In 1940, a follow-on study from Alexander Fleming’s original work was released 
which described bacteria that could tolerate penicillin by producing an enzyme 
which inhibited the antibiotic (21).  Consequently, in his acceptance speech for 
the 1945 Nobel Prize, Alexander Fleming warned that ―an ignorant man may 
easily underdose himself and, by exposing his microbes to non-lethal doses of 
the drug, make them resistant‖ (57). Despite the early observations of resistance 
development in pathogens (21, 22, 58), only recently have strategies been put in 
place to address the problem. Antimicrobial stewardship programs (ASPs) have 
been developed and implemented in many countries to audit the use of 
antibiotics in the clinic and community and ensure appropriate treatment is given 
to patients (59). Originally, ASPs were designed to ensure that infections were 
properly managed based on treatment effectiveness, toxicity to the patient and 
cost (60).  Many countries also structure ASPs to maximise the longevity and 
effectiveness of available antibiotics by monitoring antibiotic prescriptions, 
rotating the use of effective antibiotics, educating clinicians in antibiotic 
resistance and using specialised equipment and techniques to rapidly identify the 
disease-causing organism (60-62). To address the problem of diminishing stocks 
of effective antibiotics the U.S FDA has established the Antibacterial Drug 
Development Task Force (63). This group encourages research and 
development of antibacterial compounds by working with entrepreneurs in 
biotechnology to design clinically relevant trials for their product, thereby 
replacing the daunting and expensive clinical trials currently applied to antibiotics 
(63). Whether this new scheme is an effective strategy to promote drug 
development or simply a revision of old FDA policies remains to be seen.  
 
1.3 Antimicrobial Gauze 
An open wound, resulting from cutaneous-burn or impact trauma, is a breach of 
the epithelial barrier that prevents microbes from invading the body and causing 
systemic infections. Burn wounds account for the highest fatality rate in all injury 
related deaths (64). Depending on the area of the body affected, the trauma of 
the burn may be sufficient to cause death. However, in most cases the principal 
complicating factor potentially leading to patient mortality is colonisation of the 
avascular necrotic tissue at the centre of the burn, or the burn eschar, by 
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pathogenic organisms and subsequent transmission of the infection systemically 
(64).  
The burn eschar is at high risk of infection for a number of reasons. In the innate 
immune system, burn injury represses the activation and biocidal activity of 
macrophages and natural killer cells, disrupts neutrophil chemotaxis, oxidative 
burst and phagocytic capabilities, and inhibits complement cascade-initiation of 
the membrane attack complex (64-66). Thermal injury also significantly impairs 
the adaptive immune system by decreasing T-lymphocyte proliferation, 
increasing spontaneous apoptosis, and inhibiting the T-cell activation of 
immunoglobulin synthesis (67, 68). Although immunodeficiency of the burn 
patient is systemic, the eschar is at particular risk of infection because the wound 
exudate provides an ideal microbial growth medium and the extracellular matrix 
proteins secreted by the wound healing response of the body enables microbial 
attachment and biofilm formation (64). It has therefore become common practice 
to surgically excise the eschar and surrounding tissue from the patient, following 
serious burn trauma, to reduce the risk of systemic infection and to decrease 
scarring (64, 69).  
Generally, the excision is performed within the first few days following trauma, 
although surgery is sometimes delayed for a week or more (70). Burn patients 
are generally kept in the hospital prior to surgery, so the risk of an infection in the 
burn wound by an antibiotic resistant pathogen is high. Antibiotics are sometimes 
administered to the patient systemically and may be an effective prophylactic for 
invasive infections. However, it is unlikely that these antimicrobial agents will be 
able to penetrate the damaged eschar tissue and reduce bacterial load if the 
wound is already infected (64). Therefore, to prevent infection and long term 
discomfort to the patient, the burns are wrapped in antimicrobial bandages which 
may or may not be co-administered with additional microbicidal compounds such 
as antibiotics (64, 71-73). 
 
1.3.1 Silver Nanoparticle-Loaded Wound Dressings 
Wound dressings have been used for centuries to absorb exudate, decrease 
blood loss and allow normal wound healing to proceed (74). Advances in 
nanotechnology and materials science has allowed the development of gauzes 
with bioactive compounds incorporated into polymer networks, which have been 
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optimised to be absorptive, insulate the wound while still allowing gas exchange, 
and provide a scaffold to augment wound healing (74). The dressing with the 
embedded bioactive compounds can be used for debridement of the wound, 
elimination of odorous gases, microbial clearance, initiation and maintenance of 
wound healing or, more commonly, a combination of all four (64, 74). The use of 
silver nanoparticle-loaded bandages has now become commonplace for the 
prevention of infections in burn patients and those with open wounds (72, 73, 75). 
The disease-fighting effects of silver have been known for millennia and, as such, 
silver has been used in many different items such as drinking vessels, eating 
utensils, and surgical equipment, to preserve the health of the owner or patient 
(76).  
 
1.3.2 Antibacterial Properties of Silver 
Although the mechanism of action of silver against microbes has not yet been 
fully elucidated it seems that the metal ions have multiple toxic effects both 
intracellularly and extracellularly. It seems the main property of silver that confers 
antibacterial activity is its ability to bind weak bases such as sulphur and 
phosphate (77). The intramolecular disulphide bonds between the cysteine 
residues of proteins are generally critical for their stability and secondary 
structure formation (78). Silver has been shown to disrupt disulphide bonds, 
which is likely to result from its binding of sulphur molecules, resulting in protein 
misfolding (79). Many proteins, especially those with β-sheet structures that are 
secreted extracellularly, require disulphide bonds to maintain their structural 
integrity. This means silver can have multiple disruptive effects on bacteria such 
as membrane integrity and metabolic processes (77, 79).  
The aerobic respiratory system of bacteria generates reactive oxygen species by 
enzymatic reduction in the oxidative state of oxygen (80). Reactive oxygen 
species are extremely damaging to cells, as they can cause lipid peroxidation 
resulting in increased membrane permeability, sever the phosphate-sugar 
backbone of DNA and RNA, and denature proteins. Therefore, prokaryotic and 
eukaryotic cells have developed defence mechanisms such as antioxidant 
synthesis pathways, oxidative-damage repair mechanisms, and dismutase 
enzymes that convert reactive oxygen back into its benign (O2) state (80). Silver 
therapy is believed to exploit the sensitivity of the cells to reactive oxygen species 
by disabling superoxide dismutase and similar catalase enzymes, which 
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increases the concentration of reactive oxygen species in the cell (77, 81). Silver 
has also been shown to bind DNA and, depending on the concentration of silver, 
cause a structural transition to one of three denatured, bio-inactive states (82). 
Silver can bind to nucleotide bases, although it was originally believed that the 
metal interacted with the phosphate backbone of DNA. Detailed investigations 
have shown that, at low concentrations, silver will only bind guanine nucleotides. 
In contrast, high concentrations will cause the ions to bind between pyrimidine 
and purine base-pairs (82). In both cases it is likely that in these condensed 
states, normal DNA replication and protein synthesis may be impeded. 
 
1.3.3 Wound Healing Properties of Silver   
Topical silver therapy has, for the most part, centred on clearing an infected 
wound of the infecting organisms and not about improving the healing rate. In an 
international consensus report detailing the positive effects and proper use of 
medicinal silver, it was suggested that silver has no influence on wound healing 
(72). However, multiple in vitro and in vivo studies contradict this notion and 
instead suggest that the bioactivity of silver extends to injury recovery (83-86).  
For example, excessive matrix-metalloproteinase activity, resulting from 
inflammation or from bacterial secretion, can degrade the extracellular matrix in 
the wound bed and delay healing (83). Silver has been shown to inactivate 
metalloproteinases through an, as yet, unknown mechanism (83). However, it is 
possible that silver ions could displace the zinc ion in the catalytic domain of the 
metalloproteinase: leading to unfavourable energetics between the nucleophile-
water complex which is critical for hydrolysis (83, 87).  
The initial inflammation response to wounding is an important phase of wound 
repair, as it allows closure of the wound and begins the process of sterilising the 
vulnerable tissue (88). However, continued inflammation of the wound is 
detrimental to wound healing, as this encourages the release of tissue degrading 
matrix-metalloproteinases and toxic reactive oxygen species (88). Additionally, 
the increased permeability of the vascular network around the wound exposes 
the body to increased risk of systemic infection (88, 89). In rodent and in vitro 
model wounds, silver treatment was shown to suppress the release of the 
proinflammatory cytokines: interleukin 6 and tumour necrosis factor-α (85, 90). 
Furthermore, in mice, silver treatment increased the production of the angiogenic 
cytokine: vascular endothelial growth factor. Collectively, these observations 
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correlated with reduced inflammation and improved wound healing in mice (85). 
The antibacterial effect of silver also provides dual benefits to the patient in that it 
protects against invasive infection and clears the wound of pathogenic organisms 
which stimulate proinflammatory cytokine production, cause further tissue 
damage and prolong the wound healing process (86). The wound healing ability 
of silver nanoparticle gauzes seems to be related to the antibacterial activity of 
silver as well as its modulation of inflammatory response and inhibition of metal-
associated proteolytic enzymes.      
       
1.4 Antimicrobial Peptides 
Antimicrobial peptides (AMP) are a structurally diverse class of proteins which 
are integral to the innate defence systems of a wide array of organisms (91, 92). 
Most AMPs are multifunctional and generally perform roles linked to immunity 
such as chemo-attraction of immune cells and wound healing (91). As a host 
defence molecule, AMPs can protect against bacterial, fungal and viral 
pathogens (91-93).  It has also been reported that some AMPs are selectively 
cytotoxic to cancerous cells and may be able to inhibit the growth of tumours that 
have become resistant to chemotherapy (94). Although the exact mechanisms 
behind the mode of action of AMPs have not yet been verified, it appears that 
cationic peptides are attracted to anionic residues on the target membrane. Once 
bound, the peptides form transmembrane pores which can kill or inhibit the 
metabolic processes of the cell, either by lysing the membrane or by disrupting 
intracellular processes after gaining access to cytoplasmic organelles (93, 95). 
This rapid, broad spectrum and non-specific targeting of cells has led 
researchers to hypothesise that bacterial resistance to AMPs is unlikely to occur 
(93, 96). Development of resistance to new antibiotics is of serious concern to 
healthcare workers and pharmaceutical companies, as increased use could 
desensitize the target organism and render the product ineffective as a 
marketable therapeutic. As a result of this, plus an urgent need for effective 
therapeutic agents against multidrug resistant organisms, extensive research and 
developmental studies have been conducted into the therapeutic potential of 
AMPs (93, 97).    
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1.4.1 Structure-Function Relationship in Antimicrobial Peptides 
Antimicrobial peptides are produced by nearly every known organism and have 
multiple roles including protecting the host against a broad spectrum of 
pathogens (92, 93, 97, 98). Antimicrobial peptides are of various sizes, tertiary 
structures, and physicochemical properties (92, 95, 99). However, certain 
characteristics are common to most AMPs. These include a length of less than 
100 amino acids, a net cationic charge, and a high proportion of hydrophobic 
amino acids (92, 95, 99). Antimicrobial peptides have a disordered or incomplete 
folded structure in solution but generally fold to form amphiphilic secondary 
structures when bound to the cell membrane (98, 99). The amphiphilic 
configuration of amino acids segregates charged residues and hydrophobic 
residues to separate regions of the peptide (99). Once bound to the membrane, 
most AMPs form an α-helical conformation, while some cyclic AMPs form β-sheet 
conformations and others may remain as unfolded linear or loop peptides (98). 
The amphipathic secondary structures of AMPs allow the peptides to insert into 
the cell membrane, form pores and kill or inhibit the growth of the cell through 
one or more proposed mechanisms (95, 98, 99). At present there are multiple 
models which describe the pore-forming mechanisms of AMPs. However, details 
of the exact mechanisms involved remain unclear and, although some studies 
have provided evidence as to how a specific peptide may function to create 
transmembrane pores, no unifying theory has been developed to link the 
structure of AMPs with their pore forming mechanism (92, 99-101).  
 
1.4.1.1 Nett Electrostatic Charge of Antimicrobial peptides 
Bacterial membranes are composed of phospholipids arranged in an amphipathic 
bilayer. In contrast to eukaryotic cell membranes, bacterial membranes contain 
hydroxylated phospholipids: phosphatidylglycerol, phosphatidylserine and 
cardiolipin (Figure 1.3: 102). The phosphate group of phosphatidylglycerol and 
phosphatidylserine each give the molecules a charge of -1 (103, 104). 
Phosphatidylserine also has a carboxylate anion group but it is electrostatically 
balanced by an ammonium group (104). Cardiolipin is formed from two 
phosphatidylglycerol molecules and, therefore, has a charge of -2 (103). The high 
proportion of these three phospholipids in bacterial membranes gives the cells a 
net anionic surface charge (105). Most AMPs contain a higher proportion of basic 
amino acids than acidic amino acids, which gives the peptides a net positive 
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charge at physiological pH (99, 105). It is theorised that the anionic teichoic acids 
in the cell wall of Gram-positive bacteria and lipopolysaccharides in the outer 
membrane of Gram-negative cells may draw the cationic peptides towards the 
surface of bacterial cells (102, 106-109). The peptides are then drawn to regions 
of anionic phospholipids on the bacterial membrane through electrostatic 
interaction (105). This may partly explain the selective toxicity of the peptides to 
prokaryotes, as the cationic peptides are electrostatically attracted to anionic 
membranes and have little electrostatic affinity to zwitterionic, eukaryotic cell 
membranes (105).  
Although the cationic charge appears important for the initial attraction and 
binding between peptides and bacterial membranes, it has been shown that this 
relationship is not linear. Increasing the ratio of basic residues in AMPs above a 
critical threshold can reduce the selectivity and antibacterial activity of the 
peptides (110). An increased positive charge of the peptides may increase the 
affinity of the peptides for the anionic phosphate groups on phospholipids, which 
may increase the cytolytic effects of the peptides on eukaryotic cells. 
Interestingly, this may also cause the peptides to bind to the membrane of 
bacteria with greater force, which could reduce the propensity of the peptide to 
translocate into the membrane interior which is required for the formation of 
transmembrane pores (105). Despite the predominant focus on cationic AMPs, 
recent studies into anionic AMPs have shown that this class of peptides is an 
important component of innate immunity in eukaryotes and may show promise for 
antibacterial therapy (111). For example, the anionic peptide, dermcidin from 
human sweat has been shown to have antibacterial activity against a broad 
spectrum of topical pathogens in acidic environments with high  salt 
concentrations (112). Generally, anionic AMPs require divalent cations or other 
cationic AMPs to function effectively (111, 113). Negatively charged molecules 
will naturally be repelled by anionic groups on bacterial membranes. However, it 
is believed that divalent cations may mask the charge of the anionic 
phospholipids, or form salt-bridges between the peptides and phospholipids, 
which allow the anionic AMPs to insert into the phospholipid bilayer through 
hydrophobic interactions (111, 113). The peptides are then able to diffuse 
through the membrane and interfere with intracellular processes (111, 113-116). 
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Figure 1.3 Anionic phospholipids of bacterial membranes 
 
1.4.1.2 Hydrophobicity and Amphipathicity 
Antimicrobial peptides generally have a higher proportion of hydrophobic than 
hydrophilic residues. When the peptides have folded into their secondary 
structures, hydrophobic regions are separated on separate faces to hydrophilic 
regions. This structural asymmetry of the peptide, with hydrophobic and 
hydrophilic residues polarised on opposite faces, is referred to as amphiphilicity 
(110, 111). With this amphiphilic configuration, the cationic residues attract the 
peptides to anionic regions of the bacterial membrane. When in close proximity to 
the bacterial membrane, the hydrophobic face of the peptides overcomes the 
electrostatic affinity of the cationic face for the anionic components of the 
membrane, causing insertion of the peptide into the membrane and disruption of 
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the phospholipid bilayer (117). It could be assumed that increasing the 
hydrophobicity of a peptide would increase its antimicrobial and haemolytic 
activity because an increased number of hydrophobic residues should intensify 
the hydrophobic interactions between the peptide and the hydrophobic interfacial 
membrane. This may be true for zwitterionic, cholesterol stabilised eukaryotic 
membranes since the main interaction between the peptide and the membrane is 
hydrophobic (118). However, it appears that peptides with greater amphiphilicity 
have a higher affinity for interfacial binding and insertion into membranes than do 
peptides with higher hydrophobicity (110, 113). This observation may aid in 
peptide drug design because increasing the amphiphilicity of a peptide without 
increasing the number of hydrophobic residues could create peptides with 
greater antimicrobial activity and lower eukaryotic cytotoxicity. 
 
1.4.1.3 Alpha-helical Peptides 
Alpha-helical peptides are the most extensively studied class of AMPs because 
they are abundant in nature, easy to synthesise and simple to characterise using 
spectroscopy techniques such as circular dichroism and attenuated total 
reflectance infrared spectroscopy (119). In solution, α-helical peptides have a 
linear structure. Once bound to a membrane, the hydrophobic nature of the lipid 
bilayer induces a conformational change in the peptide causing it to adopt an α-
helical conformation with a hydrophobic face and a polar cationic face 
segregated along a perpendicular plane (99). If the hydrophobic regions of a  
peptide lie outside the hydrophobic core of the bacterial membrane, 
intermolecular forces cause a change in the conformation of the peptide and the 
phospholipid structure of the membrane, to shield these regions from the 
aqueous environment. Hydrophobic interactions force the helices of the peptides 
to tilt towards the hydrophobic acyl-core, causing the peptides to insert deeper 
into the membrane. In addition, the acyl chains of membrane lipids stretch, 
compress or tilt to align with the hydrophobic regions of the peptides (120). 
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1.4.1.4 β-Sheet Peptides 
Unlike α-helical AMPs, most β-sheet peptides have a cyclic structure with a 
partially folded β-hairpin or β-sheet conformation in solution and form stabilised 
secondary structures in membranous environments (99). The cyclic structure 
increases the tendency for β-sheet structures to form by reducing the entropy 
and the number of possible conformations of the peptide (116). Generally, the β-
structure is secured by intramolecular disulphide bridges between cysteine 
residues. For some peptides, such as porcine protegrins, the disulphide bridges 
are essential for antimicrobial activity (121). However, multiple studies have 
shown that disulphide bridges are not necessary for some peptides to form β-
sheets when in contact with the membrane (121, 122). Furthermore, removal of 
the cysteine residues also reduced the haemolytic potential of some peptides 
while retaining antimicrobial activity (122).    
 
1.4.1.5 Extended and Loop Structured Antimicrobial Peptides 
Peptides that do not form secondary structures are referred to as extended 
peptides. Generally, these contain a high proportion of one type of amino acid. 
An example is the bovine neutrophil peptide indolicidin, which contains 40% 
tryptophan residues (99). Unlike other antimicrobial peptides, for most extended 
peptides transmembrane pore formation does not appear to be the functional 
mechanism. Instead, many of the smaller extended peptides diffuse through the 
membrane, accumulate in the cytoplasm and interact with intracellular machinery 
(99). However, the neutrophil-derived peptides indolicidin and tritrpticin are the 
exception to this phenomenon, as they are highly membrane active and can form 
transmembrane pores in a variety of organisms (99, 123, 124). Loop peptides are 
linear peptides which form one or more loops stabilised by a single cysteine-
cysteine disulphide bridge when in a membranous environment (93). Some loop 
AMPs, such as the gramicidins, have proved excellent model peptides for ion-
channel investigations as they form well-defined selective transmembrane 
channels and can be easily modified to test various parameters of defective 
channels (125).    
 
18 
 
1.4.2 Mechanisms of Action of Antimicrobial Peptides 
Antimicrobial peptides, like antibiotics, have many different methods by which to 
stop the growth and replication of their target organisms, or kill the cell directly 
(92, 99, 105). Model membrane studies have shown that most AMPs interact with 
the cell membrane to form transmembrane pores (95). It has been proposed that 
these pores are multifunctional, in that they induce non-selective leakage of 
cytoplasmic components and allow free AMPs access to intracellular targets 
(126). The majority of studies into AMP-induced pore formation have used in vitro 
assembled lipid membranes (127). The disadvantage of this is that such studies 
can overlook secondary effects of the peptides on live bacteria. For example, 
Patrzyk et al. (128) demonstrated that a hybrid peptide of pleurocidin and 
dermaseptin (P-Der) could diffuse across the cell membrane and inhibit 
macromolecular synthesis at the minimal inhibitory concentration (MIC) without 
forming transmembrane pores. However, at ten times the MIC, P-Der was able to 
form transmembrane pores and cause cell death (128). In addition to this, studies 
from other groups have shown that the antimicrobial activity of AMPs is more 
complex than pore formation and may include disruption of other cellular 
processes such as the synthesis of peptidoglycan, nucleic acids and proteins 
(105, 126). Therefore, some AMPs are able to target multiple organelles, in 
addition to the cell membrane, potentially reducing the chance of resistance 
developing in microorganisms by increasing the complexity of change required to 
make the organism resistant to the peptide. Although pore formation may not be 
the exclusive mechanism of action, it still appears a critical step in the peptide-
induced pathway to cell death: especially at high peptide to membrane lipid ratios 
(105, 114, 128, 129). Exactly how AMPs form transmembrane pores is still 
unclear. However,  techniques such as nuclear magnetic resonance imaging of 
the peptides and analysis of artificial lipid membranes has allowed the proposal 
of multiple models of pore formation, such as the barrel-stave, toroidal pore and 
carpet method to explain the peptide-lipid interactions (99, 105, 130). 
 
1.4.2.1 Models of Pore Formation: Barrel-Stave 
The barrel-stave model depicts pores as transmembrane channels of aggregated 
AMP oligomers arranged in a cylindrical or ―beer barrel‖ structure (99, 105). This 
model proposes localised binding of multiple peptides to the membrane surface 
with the hydrophobic surfaces of the peptides facing towards the hydrophobic 
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core of the interfacial membrane. Once bound, the hydrophobic residues insert 
into the membrane: repelling the phosphate head-groups of the phospholipids. 
As more peptides bind and embed, the membrane surface area expands and the 
void between the extracellular and intracellular lipid layers is filled by the acyl 
chains of phospholipids surrounding the peptide. The induced negative-curvature  
on the membrane surface thins the interfacial space of the lipid bilayer and allows 
the hydrophobic face of the peptides to insert further into the hydrophobic core 
(Figure 1.4a: 131).  
 
 
Figure 1.4a Membrane thinning from antimicrobial peptide hydrophobic 
interactions 
 
If the number of peptides bound to the same area reaches a threshold 
concentration, the peptides will aggregate and translocate perpendicularly across 
the membrane to form a transmembrane pore. The translocated AMPs position 
their hydrophilic faces away from the hydrophobic membrane core which creates 
a pore lumen and allows indiscriminate leakage of the cell content. The pore is 
expanded by unbound peptides inserting themselves into the transmembrane 
complex in a manner resembling staves in a barrel (Figure 1.4b: 105). Despite 
earlier studies regularly using the barrel-stave model to describe AMP pore 
formation, only one naturally occurring peptide has been shown to use this 
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mechanism (132). More recent studies have shown that a majority of AMPs use a 
variant of the barrel-stave mechanism which has been described as the toroidal 
or wormhole pore model (105, 133, 134). 
 
 
Figure 1.4b Illustration of a barrel-stave pore in a phospholipid membrane 
in top-down and profile view 
  
1.4.2.2 Models of Pore Formation: Toroidal Pore   
The configuration of a toroidal pore differs from the barrel-stave pore in that the 
peptide residues intercalate with phospholipid head-groups to form a peptide-
membrane supramolecule (Figure 1.4c). As in the barrel-stave model, toroidal 
pores are formed by peptides binding to bacterial membranes and displacing the 
phospholipid head-groups by inserting their hydrophobic faces into the 
membrane (105). Monomer peptides aggregate on the bacterial membrane 
through binding of their hydrophobic N-terminal regions. These peptide 
aggregates can then saturate areas of the cell membrane, increasing the tensile 
forces between peptide hydrophobic residues and membrane phospholipids 
(135). At a critical peptide to membrane lipid ratio, the curvature-strain induced 
on the membrane is great enough to force phospholipids apart and allow the 
peptides to insert perpendicularly into the membrane (105, 135). Once inside the 
membrane, hydrophobic forces and electrostatic interactions between the anionic 
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phospholipid heads and the basic peptide residues cause the peptides to embed 
within the outer leaflet of the bilayer, creating a peptide-phospholipid complex 
(135). This forms a torus shaped transmembrane pore lined with the hydrophilic 
AMP regions and phospholipid head groups (105, 135). An alternative model of 
the toroidal pore proposes that only one or two peptides insert deep into the 
membrane while other peptides bind to the opening of the pore and stabilise the 
channel (136). Toroidal pores may have much shorter half lives than barrel-stave 
pores. Electrostatic repulsion of the positively charged side-chains of the AMPs 
can cause the pores to collapse in on themselves and release embedded 
peptides into the cytoplasm (105). This has been suggested as a method of AMP 
translocation across cellular membranes (105, 135).    
 
Figure 1.4c Illustration of a toroidal pore in a phospholipid membrane in 
top-down and profile view 
 
1.4.2.3 Models of Pore Formation: Carpet Model 
The carpet model does not rely on cells inserting into the membrane or the 
formation of peptide-stabilised transmembrane channels (137). Instead, this 
model proposes that localised sections of the membrane become saturated with 
AMPs, leading to membrane disaggregation and the formation of large holes 
(Figure 1.4d). This is achieved by large numbers of peptides binding parallel to 
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the membrane surface which increases the surface area covered and enhances 
the electrostatic forces between peptide and phospholipid layers (105, 138). 
Once a high enough concentration of peptides has bound to a region, the 
electrostatic forces between phospholipid head groups and the basic residues of 
the AMPs cause the packed configuration of the lipid bilayer to become 
disrupted. This causes a loss of surface tension between phospholipids resulting 
in segments of the lipid bilayer dispersing as micelle particles and the formation 
of holes in the membrane (99, 105, 138). It has been suggested that the carpet 
model may be applicable to most AMPs as long as the concentration of peptides 
is high enough (137). However, as the carpet model requires a very high peptide 
to membrane lipid ratio to form transmembrane holes, it appears unlikely that this 
mechanism occurs naturally in vivo.    
 
Figure 1.4d Carpet model of pore formation in bacterial membranes 
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1.4.2.4 Extracytoplasmic Targets of Antimicrobial Peptides 
As described above, the lipid membrane is not the only target of AMPs. A study 
by Bierbaum and Sahl (139) has shown that the AMPs nisin and Pep5 can 
associate with lipoteichoic acids and activate autolysins, which hydrolyse 
peptidoglycans resulting in cell lysis. In addition, nisin and other lantibiotics 
contain a set of lanthionine rings which form a glove like structure known as the 
pyrophosphate cage. The pyrophosphate cage is able to bind the lipid II 
transferase, which is essential for transmembrane transport of cell wall subunits, 
and to inhibit cell wall assembly (140). Understanding the multiple bactericidal 
mechanisms of AMPs can help to improve drug design by removing or replacing 
residues that could influence patient cytotoxicity. For example, protegrin-1 is a 
peptide with broad spectrum antimicrobial activity and a high potential for 
haemolysis of human erythrocytes (141). Srinivas et al. (142) have shown that an 
analogue of protegrin-1 can kill Pseudomonas aeruginosa by binding to the 
lipopolysaccharide membrane protein D and impair correct outer membrane 
formation, without forming transmembrane channels. The peptide was also more 
effective against P. aeruginosa at lower concentrations and had a reduced 
haemolytic capability compared to full length protegrin-1 (142).  
 
1.4.2.5 Intracellular Targets of Antimicrobial Peptides 
Multiple studies have shown that AMPs can diffuse across cell membranes or 
enter through transmembrane pores to disrupt intracellular metabolite synthesis 
and other crucial bacterial processes (105, 143). Linear peptides rich in proline 
and arginine generally follow this process (144). The high proportion of proline 
residues inhibits the formation of amphipathic α-helices and β-sheet structures in 
the peptides. This is due to a lack of free amine groups on proline residues, 
which prevents hydrogen bonding between amino acids and the formation of an 
α-helical or β-sheet backbone. The folding of β-sheets is also inhibited by the 
limited spectrum of available phi angles on this cyclic amino acid (145). The lack 
of an amphipathic structure may explain why these peptides have little tendency 
to produce transmembrane pores and instead rely on the membrane transport 
system of the bacteria to enter the cell and attack intracellular targets (144, 146). 
So far, the mechanisms by which proline/arginine rich peptides affect the cell are 
still unclear. It has been proposed that once inside the cell, these peptides may 
inhibit the growth of the microorganism by disabling chaperone proteins, 
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inhibiting protein synthesis or directly binding to nucleic acids (147). Otvos et al. 
(148) have shown that pyrrhocoricin, apidaecin, and drocosin specifically bind to 
the chaperone protein DnaK and inhibit its ability to assist in protein folding. 
Further studies have shown that mutants lacking DnaK are also susceptible to 
pyrrhocoricin and similar peptides, which suggests that these AMPs may have 
multiple internal targets (144). Some peptides such as indolicidin and the 
neutrophil AMP PR-39 can inhibit the cell from dividing and cause filamentation 
of the bacteria (146, 149). The mechanism behind this has not yet been 
elucidated but is believed to be a result of the peptides either blocking DNA 
replication or inhibiting the membrane proteins required for the division septum to 
form (149).  
The diversity of AMPs with intracellular functions extends beyond proline rich 
linear peptides. Buforin-2 is a histone-derived alpha helical peptide with two 
helices separated by a proline residue (150). It is a non-lytic peptide that 
penetrates the cell membrane and binds to DNA and RNA (150, 151). It appears 
that buforin-2 binds to nucleic acid by non-specific interactions of the basic 
residues of the peptides and the anionic phosphate backbone of DNA and RNA 
(150). However, there is some evidence that the peptide may also have a specific 
nucleic acid sequence to which it strongly associates (151). Although it is not 
known how binding DNA or RNA kills the cell, the link between the antimicrobial 
activity of the peptides and their affinity for nucleic acids has been established 
(151). It can therefore be theorised that aggregation of buforin-2 with DNA or 
RNA could broadly inhibit protein synthesis and retard cellular metabolism. 
Understanding the multiple mechanisms of microbial inhibition or destruction by 
AMPs is of great interest to researchers, as it may provide insight into new 
techniques that could substantially improve our arsenal of antimicrobial agents, 
drug delivery vectors, wound healing drugs, and anti-cancer cell therapeutics. 
 
1.4.2.6 Immunomodulatory Activity of Antimicrobial Peptides  
 In vivo AMPs are believed to be critical to the nonspecific clearing of pathogens. 
However, physiological factors inside the body such as high ionic concentrations, 
exogenous peptides, peptidases and acidic environments can inhibit the 
bactericidal action of the peptides (152, 153). Additionally, in a healthy host the 
concentrations of peptides are far lower than those required to achieve effective 
inhibition of the microorganisms in vitro (154). Therefore, AMPs in nature may 
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need to work in conjunction with additional host defence mechanisms, such as 
extracellular enzymes, leukocytes or other AMPs, to inhibit invading pathogens. 
Direct targeting and lysis of bacteria may not be the principal role of these 
peptides in host defence (155). In fact, numerous immunomodulatory roles have 
already been identified in two broad families of mammalian AMPs: the defensins 
and cathelicidins.   
Defensins are a class of AMP, segregated into groups α, β and, in old world 
primates, θ which show broad spectrum antimicrobial activity (156, 157). In 
addition to the direct antibiotic action of these peptides, it has been demonstrated 
that defensins are also regulatory molecules of the immune system (154, 158). 
Human defensins have multiple roles in the direct, non-specific clearing of 
localised epidermal and systemic infections. These molecules also serve the 
innate and adaptive immune systems by recruiting T-lymphocytes, macrophages, 
dendritic cells and mast cells.  
The α-defensin subfamily recruits T-lymphocytes by acting as chemotaxins in 
areas of infection and inflammation (159-161). Alpha-defensins have also been 
shown to enhance the efficiency of leukocyte phagocytosis by stimulating the 
release of tumour necrosis factor-α and interferon-γ molecules from 
macrophages (162). The AMP LL-37 is derived from the cathelicidin polypeptide 
hCAP18. To date, it is the only functional cathelicidin AMP identified in humans 
(163, 164). In addition to its pore forming activity, LL-37 induces the release of 
chemotactic cytokines from cells at areas of infection. The peptide can also act 
as a pro-inflammatory molecule by degranulating mast cells, resulting in the 
release of histamine and prostaglandin (155). Conversely, LL-37 can act as an 
anti-inflammatory molecule by neutralising inflammation-inducing endotoxins 
such as lipoteichoic acids and lipopolysaccharides released by dead bacteria 
(165). Furthermore, LL-37 can enhance phagocytosis in neutrophils by 
interacting with extracellular kinase receptors to stimulate interleukin-8 production 
(166).     
 
1.4.3 Mechanisms of Resistance against Antimicrobial Peptides  
The jawless ancestors of modern vertebrates lacked an adaptive immune 
system. Instead they relied on innate defences such as physical barriers, non-
adaptive phagocytes, natural killer cells and cytotoxic molecules (167). A study 
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by Uzzel et al. (167) found that hagfish contain peptides strongly related to 
mammalian cathelicidin AMPs. This suggests that AMPs are an ancient defence 
mechanism that has protected organisms for hundreds of millions of years (168). 
Given the amount of time pathogens have been exposed to these molecules and 
their abundance in nature, it seems likely that resistance mechanisms have 
already been developed. Multiple reports have shown that bacteria can become 
resistant to the peptides in vitro and in some cases quite rapidly (169-171). It may 
be possible that some populations of bacteria have already developed resistance 
mechanisms that are either activated on exposure, or that intrinsically resistant 
bacteria grow to dominate the population when it is exposed to the peptides. 
Other studies report that bacteria only have a limited ability to become resistant 
to AMPs, which supports the idea that the non-specific targeting of fundamental 
organelles restricts the development of resistance (172, 173). The reasons 
behind these contradictory results have not yet been fully explored. However, it 
may be that mechanisms of resistance against AMPs are not universal and some 
bacteria are better equipped to develop, or may have already developed, these 
survival methods.   
 
1.4.3.1 Modification of Cell Membrane Molecules 
Regardless of the site of bactericidal activity of an AMP, in most cases the cell 
membrane is the initial site of interaction. Bacteria which are exposed to 
sublethal concentrations of a peptide can subsequently survive higher 
concentrations than their wild-type counterparts. This tolerance can be achieved 
by adding, altering or removing different membrane molecules (173-176). 
Lipopolysaccharides are major constituents of the Gram-negative bacterial outer 
membrane. They consist of three major components: a distal anionic 
polysaccharide referred to as the O-antigen, a zwitterionic oligosaccharide at the 
core of the molecule, and the hydrophobic, negatively charged lipid A endotoxin 
which anchors the lipopolysacharide to the outer membrane (177). In the 
presence of AMPs, the PhoPQ-PmrD systems in E.coli and Salmonella 
typhimurium increase the expression of the membrane bound enzymes ArnT and 
EptA (178, 179). These transferases modify the core and lipid A moieties of 
lipopolysaccharides with ethanolamine and aminoarabinose to mask their anionic 
charge (180, 181). A reduction in the negative surface charge probably reduces 
the electrostatic affinity of cationic peptides for the membrane. Similar 
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modifications of lipid A by the addition of cationic residues are observed in 
Bordetella pertussis, E.coli and Neisseria meningitidis (182-185).  
PhoPQ-PmrD activation is also initiated by temperature fluctuations. Studies 
have shown that Yersinia species are more sensitive to AMPs at higher 
temperatures (186, 187). The many arms of the innate immune system of 
vertebrates includes the initiation of fever, an increase in body temperature 
above that of homeostatic levels, in response to pathogenic invasion (188). 
Besides strengthening many aspects of the immune system, increasing the core 
body temperature may make some Gram-negative bacteria more susceptible to 
AMPs because it has been suggested that the PhoPQ-PmrD regulatory system is 
inhibited at higher temperatures (186). However, suppressing lipopolysaccharide 
modifications also helps the cell evade recognition by the immune system.  
Some Gram-negative bacteria may increase their tolerance to AMPs and reduce 
the immune response of the host by inhibiting the action of their inner membrane 
phosphotransferase: LpxT (179, 189). This enzyme catalyses the transfer of a 
phosphate residue to the 1’ position of the glucosamine backbone of lipid A 
(190). This creates a pyrophosphate anion on lipid A which increases the 
negative charge and the immunogenicity of the bacterial membrane. Therefore, 
inhibiting the action of LpxT increases resistance to AMPs and assists the cells in 
evading the immune system (179, 189).  
The lipoteichoic acids (LTA) are a major anionic constituent of Gram-positive cell 
walls. These phosphate rich molecules give the cells an overall negative charge. 
In addition, LTA are believed to be important structural molecules because 
mutants lacking LTA show morphological defects and sensitivity to temperature 
fluctuations (191). Gram-positive bacteria such as S. aureus, Enterococcus 
faecalis and Streptococcus species can become resistant to cationic 
antimicrobial peptides by adding cationic D-alanyl residues to LTA. This is 
mediated by the dlt operon and is believed to confer resistance by reducing the 
net negative charge of the cell surface, thereby diminishing the electrostatic 
attraction of the peptides (174, 176, 192). However, Saar-Dover et al. (174) have 
shown that there is no difference in the amount of peptide bound to 
Streptococcus agalactiae mutants that lack the dlt operon and to wild-type 
bacteria (174). Instead, they propose that D-alanylation of LTA masks their 
anionic charges and allows the polysaccharides to pack more closely together 
and increase the density of the cell wall (174).  
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A similar resistance pathway involving the masking of anionic membrane charges 
in both Gram-negative and Gram-positive bacteria is mediated by the multiple 
peptide resistance factor protein (mprF: 126, 174, 193, 194). 
Phosphatidylglycerol is an anionic phospholipid that constitutes the bulk of 
bacterial membranes and contributes significantly to the net negative charge of 
the membrane (195). In the inner leaflet of the cytoplasmic membrane, the mprF 
protein switches the anionic charge of phosphatidylglycerol molecules to a 
cationic charge by attaching L-lysine residues using a synthase domain located 
in its hydrophilic C-terminus (193, 194). A translocase domain, located at the N-
terminus of the mprF protein, flips the cationic lysyl-phosphatidylglycerol 
molecules to the outer leaflet of the membrane, thereby repelling cationic AMPs 
(193). The mprF enzyme is found in a broad range of both Gram-negative and 
Gram-positive bacteria and can also confer resistance to the antibiotic 
daptomycin (193, 196, 197). Strategies to inhibit or counteract the activity of 
mprF may therefore increase the sensitivity of pathogens to a large array of 
antimicrobial agents.  
 
1.4.3.2 Direct Inhibition of Antimicrobial Peptide Action 
Membrane modifications can improve the effectiveness of the barrier between 
the extracellular environment and cytoplasmic constituents in keeping out AMPs. 
However, a concentrated dose of AMPs may overcome these resistance 
mechanisms. Therefore, bacteria have evolved extracellular resistance strategies 
to inhibit the action of the peptides before they damage the membrane (102, 
198). A range of bacterial extracellular proteases have been identified which 
cleave AMPs before they can interact with the cell membrane (199-201). To date, 
peptidases which degrade AMPs have been identified in the three major classes 
of bacterial proteases: metalloproteases, cysteine proteases and serine 
proteases (200, 202, 203). Elastase is a zinc-dependent metalloprotease that has 
been shown to contribute to the virulence of Pseudomonas aeruginosa by 
degrading the extracellular matrix of host tissue, as well as immune molecules 
such as cytokines, antibodies and lysozyme (204). Elastase from these cells has 
been shown to rapidly hydrolyse the human cathelin-like peptide hCAP18 and its 
C-terminal AMP, LL-37,  specifically at hydrophobic residues (200).  Peptidases 
with similar structures from Enterococcus faecalis and Proteus mirabilis were also 
shown to cleave LL-37 at its hydrophobic amino acids (200). Interestingly, 
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neutrophil-derived elastases have been shown to be essential for releasing the 
LL-37 peptide in its active form from the hCAP18 propeptide  (205). Furthermore 
Zaiou et al. (206) have shown that the N-terminal domain of hCAP18, which also 
has antibacterial activity, is capable of inhibiting extracellular cysteine proteases 
from E.coli after it is cleaved from HCAP18. This may protect AMPs in the vicinity 
from degradation while at the same time inhibiting peptidase-mediated tissue 
damage in the area. It seems then, that in infected wounds, a proportionate 
balance between the cytotoxicity of neutrophil-elastases and their AMP-
modulatory roles, exists to clear the area of infection while still allowing the 
wound to heal.  
Oligopeptidase B is a serine peptidase, identified in Gram-negative bacteria, 
spirochaetes and some protozoan species which have been shown to have 
hydrolytic activity that appears specific to short cationic peptides. This enzymes 
activity appears to be restricted to hydrolysing the carboxyl side of basic residues 
in short peptides (around 40 amino acids in length), which suggests its main 
function could be to deactivate AMPs (203). Additionally, oligopeptidase B has 
been shown to play other roles in the virulence of Leishmania and Trypanosomal 
protozoa by regulating entry into host cells and stimulating the formation of 
lesions in the circulatory system (207). A mammalian orthologue of 
oligopeptidase B has not yet been discovered, which  means that treatment with 
a peptidase inhibitor specific for this enzyme may selectively decrease the 
invasive capacity and haemorrhagic activity of protozoa from the Leishmania and 
Trypanosoma genus (208). Furthermore, peptidase inhibitor treatment may 
increase the effectiveness of the patients’ innate antibacterial peptides. 
Another mechanism that bacteria employ to inhibit the action of AMPs is the 
extracellular secretion or membrane surface attachment of peptide binding 
molecules. Sequestration and aggregation of AMPs mediated by these binding 
molecules reduces their concentration around the cell’s surface, which limits 
peptide clustering on the membrane and pore formation (198, 209, 210). The 
concept appears simple, but a range of different mechanisms of peptide 
sequestering have been identified in a variety of different bacteria (211-214). For 
example, the staphylokinase enzyme is an important virulence protein that 
activates the plasma-protein cleaving enzyme plasmin. In a healing wound, the 
fibrin clot prevents entry of pathogens into the circulatory system, so plasmin 
activation and subsequent degradation of fibrin allows S. aureus access into the 
body (215). Staphylokinase has also been shown to bind and inactivate α-
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defensins (211). The presence of multiple α-defensin binding sites on the enzyme 
allows a low concentration of staphylokinase to inactivate a large quantity of 
defensins (215). It seems then, that this virulence protein not only increases the 
invasive potential of the bacteria, it also allows them to evade immune cell 
molecules.  
 
Another potent secreted inhibitor of AMPs is the Streptococcal inhibitor of 
complement (SIC) protein (216). As the name suggests, SIC was first discovered 
in Streptococcus pyogenes as a mechanism employed to prevent the formation 
of the membrane attack complex by the complement pathway of the immune 
system (216). However, more recent studies have shown that SIC is far more 
effective at binding and inhibiting the action of other immune molecules, such as 
lysozyme and leukocyte proteinase inhibitor (217, 218). It also has a high binding 
affinity for a range of cationic AMPs which is probably due to its anionic surface 
charge and its hydrophobic nature (218, 219).  
Streptococcal M1 protein has also been shown to sequester and inhibit AMPs 
(212). The M1 protein is one of a family of surface-associated virulence factors 
which contribute to the invasive capacity and pathogenicity of group A 
Streptococcal species (212, 220). Lauth et al. (212) have also demonstrated that 
this protein inhibits the action of LL-37 by binding the peptide to its hypervariable 
N-terminal region. In a separate study, bacterial pilli of Streptococcus and 
Lactococcus lactis were shown to trap LL-37 before it reached its target organelle 
(213). In the presence of bactericidal molecules, using cell surface entrapment 
molecules such as those described in the previous studies may be a more 
metabolically efficient means of obstructing AMP activity, instead of secreting 
inhibitory molecules, although it is likely that bacteria use a combination of the  
mechanisms described. For example, Schmidtchen et al. (214) have shown that 
the elastases, gelatinases and cysteine proteases of various bacteria are able to 
release dermatan sulphate from decorin: a human proteoglycan that constitutes 
the major portion of collagenous connective tissue. Dermatan sulphate 
sequesters α-defensins which protect the bacteria from AMP activity (214). 
Therefore, bacterial extracellular enzymes may play multiple roles in inhibiting the 
action of AMPs.  
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1.4.3.3 Intracellular export of antimicrobial peptides 
The majority of studies investigating AMP resistance have focused on 
extracellular or membrane-associated modifications. This is understandable 
because the initial target of AMPs appears to be the bacterial membrane. 
However, the identification of internal resistance mechanisms specific to AMPs 
provides evidence that some peptides may be effective intracellular 
bacteriocides. Antimicrobial efflux pumps are membrane bound transporter 
proteins which can be activated to expel toxic molecules from the cytoplasm (36). 
These ancient resistance proteins can be specific to one compound, such as a 
particular antibiotic or peptides of a specific sequence, or can have broad 
substrate selectivity so that a single class of efflux pump can provide resistance 
to multiple antibiotics, disinfectants or other toxic molecules (36).  
 
So far five different families of efflux pumps have been identified in bacteria:  
1. major facilitator super family (MFS) 
2. resistance nodulation division superfamily (RND) 
3. small multidrug resistance family (SMR) 
4. multidrug and toxic compound extrusion transporter (MATE).  
5. ATP-binding cassette superfamily (ABC) 
 
The MFS is the largest transporter group dependent on the cells proton motive 
force to drive antimicrobial efflux. In Gram-positive and some Gram-negative 
bacteria these pumps are single protein antiporters with twelve transmembrane 
α-helical domains that use a ―rocker-switch‖ mechanism to bind toxins in the 
cytoplasm and expel them by switching their orientation so their substrate binding 
site opens to the extracellular environment (Figure 1.5a: 221). These efflux 
pumps are described as antiporters as, generally, the movement of the toxic 
molecule out of the cytoplasm is coupled with the influx of hydrogen ions (222, 
223). In Gram-negative bacteria, most MFS have been shown to use a trimeric 
system where the drugs are transported into the periplasm by the MFS protein 
and are then removed by membrane fusion proteins (224, 225).  
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Figure 1.5a Illustration of the proposed “rocker-switch” mechanism used 
by the major facilitator super family efflux pumps 
 
In contrast to the narrow spectrum of drugs transported by the MFS, the RND 
super family, which is also dependent on ion gradients, can confer resistance to a 
broad range of antimicrobial compounds (226). Similar to some MFS systems, 
RND transporters comprise three separate components: a trimeric RND-drug 
efflux protein complex, membrane fusion proteins and an outer membrane 
channel to export antibacterial agents from the cytoplasm (224, 225). In this 
system, the periplasmic substrate-binding site of the RND protein is protonated, 
which induces a structural change in the protein, allowing AMPs and other drugs 
to diffuse across the plasma membrane bound region of the RND protein and 
bind to the substrate binding site. The RND-protein is then de-protonated which 
causes the toxic molecule to lose affinity with the binding site and diffuse across 
the cell wall, through a linked outer membrane channel, and into the extracellular 
environment (Figure 1.5b: 227). Although the RND-systems are generally found 
in Gram-negative bacteria, these systems have been found in many other 
species including Gram-positive bacteria, plants, animals and humans (224, 
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227). A study by Lee et al. (228) has also shown that RND transporters can work 
synergistically with MFS to remove antibiotics from the cell (228).  
 
 
Figure 1.5b Illustration of resistance nodulation pumps of Gram-negative 
bacteria. The acronyms RNP, PSBS, MFP and OMF stand for resistance 
nodulation protein, periplasmic substrate binding site, membrane fusion protein 
and outer membrane factor, respectively.  
  
Members of the SMR family consist of four α-helical protein domains, which span 
the inner membrane of bacteria (229). However, the SMR pumps function as a 
homodimer with two proteins, each made up of four α-helices, bound together in 
an antiparrell configuration. The mechanism behind SMR efflux is still not clear. 
However, multiple studies describe models in which a lipophillic toxic compound 
is taken into a protonated hydrophobic pocket of the protein. This de-protonates 
the binding site, causing the protein to alter its configuration so that the inner 
pocket is exposed to the external environment. The toxic compound is 
exchanged for proton ions in the extracellular environment and the SMR protein 
returns to its active intracellular state with its hydrophobic pocket facing the 
cytoplasm (230, 231).  
The last proton motive force-dependent family, the MATE family, confers 
resistance to multiple cationic toxic compounds and can be found in both 
prokaryotic and eukaryotic species (224, 232). The MATE complex consists of an 
internal cation binding site which is open to the external environment. When a 
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cation, such as hydrogen or sodium ion, binds to the protein, it flips its 
configuration so that the binding site and cation is open to the cytoplasm. The 
cation is then exchanged for a cationic molecule, such as an AMP, the protein 
flips again, and the toxic molecule is expelled from the cell (Figure 1.5c:233) . In 
human renal cells, the MATE transporters have been shown to exchange sodium 
and hydrogen cations for harmful cationic molecules which are then expelled in 
the urine (234). Likewise, bacterial MATE proteins confer resistance to cationic 
compounds, such as fluoroquinolones and ethidium bromide, by exchanging 
these molecules with extracellular sodium ions (224, 235).  
 
 
Figure 1.5c Illustration of the MATE efflux pump mechanism 
 
ATP-binding cassette transporters differ from the other four classes of 
transporters because these transporters use the direct hydrolysis of ATP to drive 
efflux. Typically, ABC transporters are found in Gram-positive bacteria, where 
they remove endogenously produced toxic compounds (224). Their structures 
consist of two hydrophobic membrane-integrated domains and two hydrophilic 
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nucleotide binding domains which are situated in the cytoplasm (236). When a 
target substrate binds to the hydrophobic transmembrane domains, the 
nucleotide binding domains switch to an ATPase-active state. ATP is bound to 
each of the two nucleotide binding regions causing dimerization of the nucleotide 
binding regions. This forces the cytoplasmic-facing region of the transporters to 
close and the externally-facing region to open. ATP is hydrolysed, releasing 
phosphate molecules and ADP which allows the structure to return to its native 
state (Figure 1.5d: 237, 238).  
 
 
Figure 1.5d Illustration of the ABC-transporter mechanism 
  
Efflux pumps provide a broad spectrum mechanism of resistance to antibacterial 
compounds in pathogens. Some of these drug exporters, such as the ABC 
transporters, which are over expressed in malignant cells and provide immunity 
to anticancer drugs, are also clinically relevant in normal human cells (239). 
Therefore, efflux pump inhibitors could have multiple roles in medicine. The multi-
faceted components of activation and mechanism of action of bacterial efflux 
pumps gives researchers a range of targets on which to base inhibitory 
molecules. Such targets include the expression of the efflux proteins, ATP for 
ABC-pump activation, proton motive force pathways and competitive binding to 
drug affinity sites of efflux transporters (240, 241). Combinational therapy with 
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efflux inhibitors and antimicrobial agents might be used effectively to treat 
bacteria which have developed broad resistance. It is possible that a novel 
mechanism might be created by covalently linking the antimicrobial agent with an 
efflux inhibitor. In the case of antimicrobial peptides, this could enable the 
inhibitor to readily enter the cell, while at the same time protecting the peptide 
from cellular efflux. However, it is unclear how the pharmacokinetics of this 
relationship would affect the pore forming ability of the peptide, or whether the 
complex would be able to separate in the cytoplasm so that each component can 
reach its target.       
 
 
1.4.3.4 Two component regulation of resistance 
The five basic senses of humans and animals make up our perception of the 
external environment and allow us to respond to changes accordingly. In most 
cases, bacterial perception of external stimuli comes from transmembrane 
regulatory proteins such as those in two-component regulatory systems (TCRS). 
Despite the name, TCRS can consist of two or more protein domains. However, 
the system generally consists of a membrane-bound histidine kinase sensor and 
a cytoplasmic phosphatase response regulator (242, 243). If the sensor domain 
of the histidine kinase is stimulated, it causes phosphylation of a histidine residue 
in the carboxyl or transmitter terminal of the protein. The phosphoryl group is 
then attached to an aspartate residue in the receiver domain of the regulatory 
phosphatase. This causes the protein to undergo a conformational change, 
allowing it to affect its target organelle or gene and induce a proportionate cellular 
response to the external stimulus (242, 243). Most of the time these systems 
serve to regulate gene expression but they can also activate cellular responses 
to variations in the external environment through enzymatic reactions (243).  
Two-component regulatory systems have been shown to regulate antimicrobial 
peptide and antibiotic-resistance pathways in multiple bacterial species, including 
S. aureus (244-246). In S. aureus the graRS, or antibiotic peptide sensor, TCRS 
has been shown to mediate resistance to a select range of AMPs and also to 
induce partial tolerance to vancomycin (247, 248). If a graS receptor is 
stimulated, graR phosphatase responds by inducing increased expression of the 
vraFG, mprF and dlt genes (244). As discussed above mprF and dlt mediate 
resistance to AMPs by decreasing the net anionic surface charge of the cells. 
This was acheived by modifying various constituents of the plasma membrane 
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(174, 192, 193, 249). The vraFG locus encodes an ABC transporter protein 
composed of an extracellular transmembrane domain (vraG) and an intracellular 
ATP-binding domain (vraF: 250). Falord et al. (250) have shown that vraFG 
permease responds to the presence of AMPs by signalling the graS histidine 
kinase to initiate resistance. As graS is an intracellular transferase, it is likely that 
vraFG stimulation induces graRS-mediated resistance rather than direct 
interactions of the AMP with the graS sensor domain (250). As a result, vraFG 
expression creates a positive feedback loop for itself in the presence of 
antimicrobial peptides. A similar resistance pathway, mediated by interactions 
between a TCRS (bceRS) and the permease of an ATP-binding cassette 
transporter (bceAB) has been detected in other firmicute bacteria: Bacillus 
subtilis and Streptococcus mutans(251).  
Some Gram-negative bacteria also use multiple TCRS to resist AMPs. In 
Salmonella enterica, the phoPQ TCRS responds to the presence of AMPs by 
initiating the expression of the PmrD protein: which in-turn activates the PmrAB 
TCRS (252). The chief role of PmrAB is to increase the activity of the ArnT and 
EptA transferases and decrease the activity of the LpxT phosphotransferase. 
Collectively, this decreases the anionic charge of lipopolysaccharides and 
reduces the affinity of cationic AMPs for the bacteria (179). Although PmrAB-
mediated resistance is observed in various bacteria, phoPQ activation may not 
be a necessary cofactor in every species (179, 245).      
  
1.4.5 Limitations of Antimicrobial Peptides 
Despite the intrinsic and developed AMP-resistance mechanisms of bacteria, in 
many cases AMPs remain an effective protective barrier against invasion by 
microorganisms. Despite this, the limitations of AMPs in their native forms 
suggest that it is unlikely that the peptides can be used therapeutically without 
physicochemical modifications. For example, AMPs are susceptible to enzymatic 
degradation and environmental conditions such as alkaline pH, salt and 
temperature extremes (93, 253).  Peptide toxicity, antigenicity and the potential 
for cross-resistance against host peptides is also of concern to drug developers 
and therapeutic regulatory agencies. Consequently, only three out of the 2531 
discovered AMPs, all of which come from the polymyxin group, have been 
approved for clinical use so far (254, 255). However, structure-function 
38 
 
relationship studies and research into hybrid synthetic peptides is providing 
strategies to overcome these limitations. 
 
1.4.5.1 In vivo Stability of Antimicrobial Peptides 
Antimicrobial peptides can either be constitutively released or secreted in 
response to infection (256, 257). Generally, high concentrations of AMPs are 
stored in the vesicles of granulocytes (257) presumably to protect the peptides 
from digestive enzymes and inhibitory molecules present in biological fluids. As 
discussed above, bacteria already have a host of proteolytic enzymes to evade 
AMPs. In addition, the half-life of peptides in the body is substantially reduced by 
host trypsin-like enzymes which cleave proteins adjacent to basic residues (258). 
To improve the resistance of cationic AMPs to enzymes that cleave at basic 
residues, Rozek et al. (258) added a cysteine residue to both ends of an 
indolocidin analogue. This circularized the peptide by disulphide bridge formation 
between the cysteine residues and protected the cationic arginine residues from 
enzymatic cleavage. Other strategies to reduce the affinity of enzymes for AMPs 
include using shorter peptide fragments or modified peptides with fewer potential 
enzyme binding sites, using d-enantiomers to limit interactions with proteases, 
and acetylation of the N-terminal and amidation of the carboxy terminals of the 
peptide (259, 260).  
In the presence of salts and cationic organic molecules the activity of most AMPs 
is also greatly reduced (261, 262). It is believed that positively charged ions may 
compete with the peptides for anionic binding sites on the bacteria. Furthermore, 
monovalent ions such as sodium have been shown to bind deep within the lipid 
bilayers, near the lipid ester oxygens. This causes the lipids to cluster closer 
together, which increases membrane organisation and reduces lipid head group 
displacement by the peptides (262). Most AMPs have reduced activity at 
physiological salt levels. Consequently, diseases that disrupt salt homeostasis, 
such as cystic fibrosis, can inhibit peptide activity entirely (263, 264). Salt 
sensitivity appears to be dependent on two physiochemical characteristics of the 
peptides: structural stability, and cationic charge cluster density (264). The ability 
for peptides to form stable secondary structures when in the presence of a 
bacterial membrane is critical for their bactericidal activity. Multiple studies have 
shown that increasing the structural stability of the peptides by adding cysteine 
pairs, or by end capping α-helices with stabilizing motifs, increases the 
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antibacterial activity of the peptides under high salt conditions (264, 265). 
Although it is not clear how salts and cations affect the structure of the peptides, 
it appears that excess positively charged ions can change the conformation of 
some peptides which reduces their bactericidal activity (115, 265). Incorporating 
cationic motifs into an AMP sequence also increases the antibacterial activity of 
the peptides in high salt environments (264, 266). The higher density of cationic 
residues on the peptides may displace sodium ions that are shielding anionic 
regions of the membranes phospholipids (266). In a similar manner, overcoming 
the negative effects of salts on the binding efficiency of the peptides could be 
achieved by adding hydrophobic amino acids to the ends of the peptides. It is 
suggested that this increases the tendency for the peptides to bind and insert into 
the hydrophobic lipid bilayer, regardless of anion shielding by salts and other 
cations (267). Replacing smaller aromatic residues with bulky amino acids, such 
as substituting alanine with phenylalanine, L-(4,4’-phenyl)alanine or β-
napthylalanine, increases the antibacterial activity of the peptides in media with 
high salinity but also slightly increases their haemolytic activity (268). The bulky 
amino acid variants of alanine (Figure 1.6) are extremely hydrophobic and, 
therefore counteract the inhibitory effects of salt in the same manner as adding 
hydrophobic motifs to the ends of the peptides.  
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Figure 1.6 Bulky amino acid derivatives of alanine 
 
The acid disassociation constant (Ka) measures the tendency of hydrogen atoms 
to disassociate from a molecule at different pH values (269). Multiple studies 
have shown that the bactericidal activity of AMPs, with varying pKa values, is 
influenced by pH (270, 271). Antimicrobial peptides rich in histidine residues 
(pka≈6) such as the histatins and clavanins may be ineffective for therapeutic use 
in humans because physiological pH (≈7.4) reduces the overall cationic charge of 
the peptide (270). On the other hand, clavanins have been shown to have 
increased antimicrobial activity in acidic media (270). Therefore, to increase the 
antibacterial efficacy of peptides in vivo, it may be best to select those which 
have pKa values one, or preferably two, units above that of the environmental pH 
in which they will be used. For example, in more alkaline environments such as 
the pancreas, AMPs which have a large proportion of amino acids with side 
chains that have high pKa values, such as arginine (12.48), lysine (10.53), and 
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tyrosine (10.07), may be more likely to retain their cationic charge and therefore 
be more effective at targeting bacteria than peptides with low pKa values.   
 
1.4.5.2 Antagonistic potential of in vivo antimicrobial peptide treatment 
Antimicrobial peptides seem to be semi-selective in that they do not interact with 
specific receptors but are structured to interact with the anionic charge and 
hydrophobic environment of cell membranes to bind to their target (272). The 
zwitterionic and cholesterol stabilised nature of mammalian cell membranes  
protects them from peptide attack (273). However, some AMPs can form lethal 
membrane pores in human cells and disable mitochondrial function if used at 
high concentrations (274). The cytotoxicity of AMPs comes mainly from their 
hydrophobicity, amphiphilicity and α-helical structures (118, 275, 276). Therefore, 
artificial peptides which are optimised to balance these characteristics, for 
optimum effect against bacterial membranes, could reduce the injurious side-
effects of AMPs in vivo. Polyanski et al. (277) have shown that reducing the 
hydrophobicity of the N-terminal region of α-helical peptides, by adding cationic 
or polar amino acids, substantially reduces the toxicity of the peptides to 
erythrocytes and leukocytes (277). These modifications did not affect the 
antibacterial activity of the peptides against wild-type E.coli and B. subtilis. 
However, the modified peptides had reduced antibacterial activity against S. 
aureus. It was suggested that the S. aureus strain used in their study had a 
greater tendency than the other bacteria to reduce its outer surface negative 
charge so that its membrane charge more closely resembled a zwitterionic 
eukaryotic membrane than the other bacteria, which allowed the strain to evade 
the modified peptides (277).  
Leucine zipper motifs are sequences of leucine and isoleucine residues that are 
spaced seven amino acids apart. As one α-helix has approximately 3.5 residues 
per turn, two leucine residues spaced seven amino acids apart will be located on 
approximately the same sides of the helix (278). It is believed that these motifs 
promote dimerization between peptides through the hydrophobic interactions of 
the leucines and isoleucines between peptides (Figure 1.7: 279). In a study by 
Asthana et al. (280) the leucine zipper motif of melittin was disrupted by 
substituting the sixth and thirteenth leucine residue with an alanine residue. This 
did not affect its antibacterial activity. However, on zwitterionic membranes, the 
modified melittin failed to form α-helices which resulted in reduced haemolytic 
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activity (280). It could be that the dimerization of melittin by leucine zippers 
influences secondary structure formation, membrane clustering and subsequent 
pore formation. On a zwitterionic membrane, the lack of electrostatic attraction 
and peptide dimerization mediated by leucine zippers could reduce clustering of 
these modified AMPs on the membrane and explain the absence of pore-forming 
activity.  
 
 
Figure 1.7 Leucine zipper dimerization between two LL37 peptides. Two 
LL37 peptides are shown in a potential dimer caused by leucine zipper motifs. 
Leucine (L) and isoleucine (I) which are coloured red indicate residues that likely 
participate in the zipper dimerization. Although the secondary structure of LL37 is 
α-helical, only the regions affected by the leucine zipper are shown as a yellow 
helix. 
 
The multiple roles AMPs perform in the immune system illustrate the importance 
of these molecules to the host. Most AMPs target the bacterial membrane, which 
allows them to attack a broad variety of pathogens (99, 102). However, having a 
mode of action which is shared among the majority of AMPs also enhances the 
risks of developing widespread cross-resistance. This has already been 
demonstrated in S. aureus species which developed point mutations in their 
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mprF domain for daptomycin resistance and, in turn, became resistant to a 
variety of structurally distinct AMPs (281). In addition, resistance to pexiganan 
conferred intermediate levels of resistance to α-defensin: a human defence 
peptide with contrasting structure and mechanism of action (282). Pathogens that 
have invaded a multicellular organism have probably developed means to evade 
AMPs. If AMP-based therapeutics encourages wide-spread development of 
resistance, this could result in the weakening of a critical part of the immune 
system, resulting in an increased incidence of recalcitrant systemic infections.  
The antigenicity of foreign or synthetic AMPs could also complicate clinical 
treatment by activating the immune system. However, it appears that some AMPs 
have little or no antigenic potential, which may be due to their small size (283-
285). Surprisingly, this is not the case when the peptides are used as an adjuvant 
for an antigenic molecule for vaccine therapy. Co-administration of an AMP with 
a subunit antigen has been shown to increase the production of antibodies by the 
humoral immune system as well as augmenting the activity of cytotoxic T cells 
(286-288). The risks of AMP use in vivo are serious and some consequences, 
like cross resistance to other peptides, will be difficult to mitigate as they relate 
directly to the mode of action of the peptides. However, in the context of an 
almost inevitable epidemic of total drug resistant pathogens (24, 25, 289), the 
availability and effectiveness of AMPs is too valuable to dismiss without trying to 
offset their negative characteristics.      
 
1.4.6 Antimicrobial Peptides used in this Study 
In this study, various aspects of three antibacterial peptides: melittin (280, 290), 
bac8c (291), and the anionic peptide, AP1 (292), were investigated. Melittin is a 
highly lytic peptide that has similar primary and secondary structure to many 
other peptides (132, 290, 293, 294). Two truncated analogues of melittin, which 
are claimed to retain bactericidal activity, but to have reduced haemolytic activity, 
were also investigated (295, 296). Bac8c is a truncated variant of bactenecin and 
is one of the shortest AMPs with potent, broad-spectrum activity (297). Peptide 
AP1 is an anionic synthetic peptide that was designed to form oblique α-helical 
secondary structures (292). In this study a variety of different parameters that 
have relevance in the design and implementation of AMPs in clinical therapy 
were investigated using peptides with different physicochemical and functional 
characteristics.  
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1.4.6.1 Melittin 
Melittin is a 26 amino acid peptide, which constitutes the main component of 
honey bee venom (290). It has a cationic charge of +5 with four of its five basic 
residues situated at positions 21-24 in a lysine-arginine repeat. The N-terminal 
region of the peptide has a high proportion of hydrophobic residues with the first 
six amino acids being hydrophobic and the remainder scattered through the 
central region of residues 7-20. This pattern of a hydrophobic N-terminal and a 
cationic C-terminal is common among pore-forming α-helical peptides and 
appears to be an important factor in maintaining the amphiphilic α-helical 
configuration adopted when bound to lipid bilayers (132, 290). The amphiphilic α-
helices allow melittin to insert into and lyse eukaryotic and prokaryotic 
membranes (110). Many groups have attempted to improve the specificity of 
melittin for bacterial membranes by hybridisation with other AMPs, truncating the 
peptide, and/or inserting or substituting amino acids at critical sequence points 
(295, 296, 298). A hybrid peptide composed of the first eight amino acids from 
the N-terminal of cecropin A, which has four basic and four hydrophobic residues, 
and the twelve amino acid hydrophobic N-terminal of melittin, was shown to have 
greater antimicrobial activity, a broader spectrum of prokaryotic targets than 
either of the wild-type AMPs, and reduced haemolytic activity (299). Cecropin A 
does not adopt a secondary structure in the presence of zwitterionic membranes. 
Similarly, the melittin-cecropin A hybrids show only a slight tendency to adopt α-
helical configuration on neutral membranes (300). This may explain why the 
hybrid peptide shows reduced lytic activity on erythrocyte membranes. However, 
Schlamadinger et al. (300) have shown that the partially folded structure of the 
hybrids can still insert into zwitterionic lipid vesicles, which suggests that the 
peptide may still be toxic to some eukaryotic cells at high concentrations. Sun et 
al. (296) have reported that deleting eleven residues from the hydrophobic N-
terminus of melittin eliminated its haemolytic activity but did not affect its 
bactericidal activity. In the same study, removal of the two glutamate residues 
from the carboxyl terminal did not affect the haemolytic or bactericidal activity of 
the truncated peptide (296). Collectively, these studies concluded that 
optimisation of melittin sequences can generate analogues that have a better 
therapeutic index than wild-type peptides and the same principals could be 
applied to other peptides to produce effective therapeutics.    
45 
 
 
1.4.6.2 Bac8c 
The benefits of developing derivatives of natural peptides are demonstrated by 
the truncated and modified bactenecin peptide, bac8c. Bactenecin is a cyclic 
AMP, found in the granules of bovine neutrophils (301). Bac8c consists of 
residues 4-11 of bactenecin, with multiple substitutions, including replacement of 
the carboxyl terminal cysteine with an alanine residue (291). Removal of the N-
terminal and carboxyl terminal cysteine residues from bactenecin linearises the 
peptide in solution and on bacterial membranes. This change in secondary 
structure is believed to be the reason for the increased antimicrobial activity of 
the peptides against Gram-positive bacteria and reduced haemolytic activity 
(302). The main mechanism by which bac8c damages bacterial cells is by 
membrane destabilisation and permeation. At concentrations below its minimal 
lethal concentration (MLC) it has also been shown to arrest cell growth by 
disrupting the proton motive force across the membrane and reducing the 
synthesis of ATP, NAD/NADH and proteins (297). Bac8c has also been shown to 
effectively inhibit the growth of cells in biofilm. Additionally, in Streptococcus 
mutans, bac8c represses the gtfBC genes, that encode glycosyltransferase 
which metabolizes sucrose for biofilm formation. It also represses expression of 
LuxS and ComDE genes, which allow interspecies and intraspecies interactions 
in biofilms respectively (302). This suggests that the peptide can inhibit the 
growth of cells in the protective biofilm environment and can also suppress the 
development of biofilm by gene repression.  
 
1.4.6.3 AP1 
The abundance of cationic AMPs in nature appears to have selected for 
resistance mechanisms in pathogens that seem specifically evolved to counteract 
the positive charge of the peptides. In response, organisms susceptible to 
pathogenic infection have developed anionic antimicrobial agents that 
complement the action of cationic peptides which have become ineffective 
against bacteria with zwitterionic membranes (292, 303). In humans, anionic 
AMPs are used by the innate immune system to protect the brain, respiratory 
tract, skin and gastro intestinal tract from a narrow spectrum of pathogens (303). 
Compared to research focused on cationic AMPs, research into the mechanisms 
46 
 
of action of anionic AMPs has been limited. However, it has been documented 
that some anionic AMPs have membranolytic activity as well as antibacterial 
mechanisms that operate inside the bacterial cell (106, 303). The peptide AP1 
was chosen as a model anionic AMP for investigations of antibacterial function. 
AP1 is a synthetic α-helical peptide with a glutamic acid residue at each terminal 
and a predominantly hydrophobic carboxyl terminal region, which gives the 
peptide a nett charge of -2. Apart from the negative charge, AP1 is similar to 
other α-helical peptides and appears to rely on its uneven distribution of 
hydrophobic residues to form amphiphilic secondary structures on bacterial 
membranes. This asymmetrical hydrophobic gradient of the helices allows the 
peptide to insert into the membrane and form lethal transmembrane pores (292). 
AP1 has been shown to be bactericidal to S. aureus and E. coli only at relatively 
high concentrations (4.2 mg/ml: 292). However, to effectively target the anionic 
bacterial membrane most anionic AMPs require divalent cationic cofactors, such 
as zinc or magnesium, to form cationic salt bridges between the peptide and 
negatively charged membrane components (114, 115, 303). This may explain 
why a concentration of 4.2 mg/ml of AP1 was required to kill S. aureus and E.coli 
in the study conducted by Dennison et al (292). In addition, bacteria which mask 
their anionic membrane charge to evade cationic AMPs could become more 
susceptible to anionic peptides even without functional cofactors. Therefore a 
combinational, but separately administered, treatment of anionic and cationic 
AMPs might effectively eliminate an infection and reduce the likelihood of 
developing resistance.  
 
1.5 Aims and Significance of Project 
Antibiotic resistance is not an emerging threat but rather a current impedance to 
medical treatment (26). Global strategies to counteract antibiotic resistance by 
reducing usage and promoting novel drug development are steps in the right 
direction. However, the continued exposure of pathogens to antimicrobial drugs, 
as a consequence of continued abuse in medicine and agriculture, is 
perpetuating the development and dissemination of more efficient resistance 
strategies, against a broader range of antimicrobials (26). The broad spectrum 
and rapid killing mechanism of action of AMPs could turn around this current 
dearth in the production of effective antimicrobial agents. However, there are 
conflicting reports on whether resistance to peptides could develop in the same 
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way that antibiotic resistance in pathogens developed. In this study the aim was 
to investigate important features that could govern the therapeutic potential of a 
variety of model peptides against MRSA and, if possible, to identify antibacterial 
peptides in a variety of plant and invertebrate species. A primary interest was to 
examine the potential for S. aureus to develop resistance to AMPs, identify 
changes that mediated resistance, and to investigate how this resistance might 
be counteracted. In addition, this project also examined the possibility that 
current bactericidal strategies such as antibiotic therapy and silver bandage 
treatment of wounds might be augmented with AMPs. From these experiments, 
new strategies were developed and explored to enhance the bactericidal potency 
of the peptides by themselves and as adjuncts with other antimicrobial agents 
and devices against wild-type and AMP resistant MRSA. The results from this 
study will hopefully assist in identifying potential limitations and risks of using 
AMPs as therapeutic agents, and whether these peptides may become a potent 
tool against pathogens in the post-antibiotic era.  
  
2. Materials  
 
2.1 Chemicals, Reagents and Equipment 
Table 2.1 Chemicals and suppliers 
Chemical/Reagent Supplier 
Agarose (Molecular Grade) Electran 
Attune Focusing Fluid Life Technologies 
Bacteriological Grade Agar VWR Chemicals 
Bactopeptone Oxoid 
Bacterisense 645 Molecular Probes Perkin Elmar 
Brain Heart Infusion Media Oxoid 
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Briji 58® Sigma-Aldrich 
Bromophenol Blue Sigma-Aldrich 
Boric Acid Sigma-Aldrich 
Chloroform  Chem-Supply 
Chromosomal Grade Agarose Bio-Rad 
Dimethyl Sulphoxide (DMSO) Fischer Bioreagents 
DNA Marker (100bp-Ladder) New England Biolabs 
Eosin Y Sigma-Aldrich 
Ethidium Bromide Sigma-Aldrich 
Ethylenediaminetetraacetic acid (EDTA) Ajax Chemicals 
Gel Green Biotium 
Glutaraldehyde Asia Pacific Specialty Chemicals 
Glycerol Ajax 
HCl Sigma-Aldrich 
KCl VWR Chemicals 
KH2PO4  Sigma-Aldrich 
Lysine Sigma-Aldrich 
MgCl2 VWR 
MyTaq Polymerase Bioline 
MyTaq Reaction Buffer Bioline 
NaCl Amresco 
NaH2PO4 Sigma-Aldrich 
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NaOH Sigma-Aldrich 
Pierce BCA Protein Assay Thermo Scientific 
Trypan Blue Astral Scientific 
Pulse-Field Certified Agarose Bio-Rad 
Sodium deoxycholate Merck Millipore 
Sodium dodecyl sulphate (SDS) MP Biomedicals 
Sodium lauroyl sarcosinate Sigma-Aldrich 
Triton X-100 Ajax 
Trizma® (Tris Base) Sigma-Aldrich 
Tryptone Oxoid 
Tween-20 Ajax 
Undenatured ethanol Scharlau 
Xylene Cyanol FF Sigma-Aldrich 
Yeast Extract Oxoid 
 
Table 2.2 Enzymes 
Enzyme Supplier 
Lysostaphin  Sigma-Aldrich 
Lysozyme Sigma-Aldrich 
Protease OB Omega Bio-Tek 
Proteinase K Roche 
Restriction Endonuclease Sma1 Promega 
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Trypsin  VWR 
All enzymes were supplied in solution and stored at -20°C prior to use 
 
Table 2.3 Equipment and manufacturer 
Equipment Model Manufacturer 
Biopsy punch BP-30F Kai Medical 
Blood collection vessel 
Vacutainer Rapid Serum 
Tube 
BD 
Cell disrupter HAIVA Constant Systems 
Cell homogeniser FastPrep FP120 Thermo Scientific 
Centrifuge Allegra X-12R Beckman Coulter 
Cellulose membrane filter 
(0.2µm) 
GSWP29325 MF-
Millipore 
Merck Millipore 
Electrophoresis 
apparatus 
PowerPac 3000 Bio-Rad 
Electroporation cuvettes 
(0.1cm gap) 
Gene Pulser Bio-Rad 
Electroporation system 
Micropulser 
Electroporation 
Apparatus 
Bio-Rad 
Flow cytometer 
Acoustic Focusing Flow 
Cytometer 
Life Technologies 
Freeze dryer Scanvac Coolsafe Labogene 
Haemocytometer 
Bright-Line 
Haemocytometer 
Hausser Scientific 
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pH meter Ultrabasic-10 Denver Instruments 
Pulse field 
electrophoresis system 
CHEF-DR Variable Angle 
pulse-field 
electrophoresis system 
Bio-Rad 
Scanning electron 
microscope 
40ESB Crossbeam Zeiss 
Spectrophotometer Nanodrop 1000 Thermo Scientific 
Spectrophotometric plate 
reader 
Victor 3V Multilabel Plate 
Reader 
Perkin Elmar 
Thermo cycler Veriti 96-well Applied Bioscience 
UV transiluminator Gel Doc XR+ Bio-Rad 
Water purification system 
Alpha Water Purification 
System 
Ibis 
 
 
2.2 Bacterial Strains 
All S. aureus strains were obtained from Dr Frances O’Brien and Professor 
Warren Grubb, Australian Collaborating Centre for Enterococcus and 
Staphylococcus species Typing and Research (ACCESS), Faculty of Health 
Sciences, School of Biomedical Sciences, Curtin University, Perth Western 
Australia. A summary of the strains used, their origins and resistance profiles is 
presented in Table 2.4 
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Table 2.4 Characteristics of S. aureus strains  
Strain Epidemiology 
Antimicrobial 
Resistance 
Phenotype 
Reference 
Aus3 
Mercuric acetate and mercuric 
chloride resistant clone of ST239-
MRSA-III: a multidrug resistant 
epidemic-MRSA (EMRSA) 
predominantly found in central and 
eastern Australia. Aus3 is the most 
prevalent EMRSA isolated from 
Victorian and Tasmanian patients. It 
has a low frequency of identification 
(≈1%) in Western Australia.   
ERY,TCN, 
TMP, GEN, 
CIPX, HgOAc2, 
HgCl2,PMA 
304, 305 
Bengal 
Bay (BB) 
ST772-MRSA-V origin. Originally a 
community associated (CA-MRSA) 
strain isolated in India in 2004. 
Bengal bay has spread globally and 
accounted for ≈1% of CA-MRSA 
infections in Australian in 2011. 
Produces the Panton-Valentine 
leukocidin (PVL) cytotoxin.  
OXA, GEN, 
ERY, COT 
306 
WBG 
8287 
Genetic lineage ST1-MRSA-Iva. The 
prefix WBG indicates the strains 
were obtained from Professor 
Warren Grubbs group. Ancestral 
clones of this group were identified 
in Aboriginal communities in the 
Kimberley region in the 1980s. First 
isolated from a diabetic foot ulcer in 
1996, WBG 8287 became infamous 
as the first CA-MRSA to cause a 
nosocomial epidemic. It is now the 
most prevalent CA-MRSA in 
OXA, ERY, 
CIPX, FA, 
RFP,GEN, 
TCN,MUP 
304 
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Western Australia. Contains 
pWBG750 plasmid which encodes β-
lactamase, cadmium resistance and 
bacteriocin production.     
W17S 
ST93-MSSA lineage: most prevalent 
methicillin susceptible S. aureus 
(MSSA)-group identified in West 
Australian aboriginal communities. 
First isolated from the epidermal 
layers of a patients hand in 1995, 
W17S has now displaced most other 
CA-MSSA. Produces the PVL toxin.   
NRa 307 
Antibacterial Resistance: ERY: Eythromicin, TCN: Tetracycline, TMP: 
Trimethoprim, GEN: Gentamicin, CIPX: Ciprofloxacin, HgOAc2: Mercury acetate, 
HgCl2: Mercury chloride, PMA: Phenylmercuric acetate, OXA: Oxacillin, COT: 
Cotrimoxazole, FA: Fusidic acid, RFP: Rifampicin, MUP: Mupirocin 
aNone reported 
 
2.3 Highly Purified Water 
Water used in this study was purified using an Ibis Alpha water purification 
system which produces high purity water (HpH2O) with resistivity readings around 
15 MOhm/cm.   
 
2.4 Buffers 
Phosphate Buffered Saline (PBS) 
NaCl      8.01 g/l    
KCl       0.20 g/l 
NaH2PO4      1.78 g/l 
KH2PO4      0.27 g/l 
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Reagents were dissolved in 800 ml of HpH2O, adjusted to pH 7.4 with HCl and 
then made up to 1 litre with HpH2O. The PBS solution was sterilized by 
autoclaving at 121°C for 15 minutes.  
 
Phosphate Buffer (PB) 
KCl      0.20 g/l 
NaH2PO4     1.78 g/l 
KH2PO4     0.27 g/l 
Reagents were dissolved in 800 ml of HpH2O, adjusted to pH 7.4 with HCl and 
then made up to 1 litre with 200 ml of HpH2O. The PB solution was sterilized by 
autoclaving at 121°C for 15 minutes. 
 
Extraction Buffer JEB1 
NaCl        5.85 g/l 
Glycerol        25% v/v  
DMSO         1% v/v 
 
Extraction Buffer JEB2 
NaCl        5.85 g/l 
Glycerol       25% v/v 
DMSO        1% v/v 
EDTA        29.2 g/l  
All extraction buffer reagents except DMSO were dissolved in 500 ml HpH2O and 
autoclaved for 15 minutes at 121°C. After sterilization, DMSO was added and the 
extraction buffers were stored at room temperature prior to use.  
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20x SB Buffer 
Boric acid        48 g/l 
NaOH        8 g/l 
Reagents were dissolved in 1 litre HpH2O. When used in electrophoresis 
experiments, 50 ml of the stock solution was added to 750 ml of HpH2O adjusted 
to pH8. The solution was then made up to 1 litre with HpH2O. 
 
EC Buffer  
Tris Base        0.73 g/l 
NaCl        58.44 g/l 
EDTA        29.22 g/l 
Briji 58        0.5% wt/v 
Sodium deoxycholate      0.2% wt/v 
Sodium lauroyl sarcosinate      0.5% v/v 
Sodium lauroyl sarcosinate, Briji and sodium deoxycholate were dissolved in 800 
ml warm (≈60°C) HpH2O. The rest of the reagents were added and the pH was 
adjusted to 7.5. HpH2O was added to a final volume of 1 litre and the buffer was 
stored at room temperature. 
 
EST Buffer 
Tris Base        0.61 g/l 
EDTA        146.12 g/l 
Sodium lauroyl sarcosinate     1% v/v 
Sodium lauroyl sarcosinate was dissolved in 800 ml warm HpH2O after which, 
Tris and EDTA were added to the solution. The pH was adjusted to 7.5 and the 
solution was made up to 1 litre.  
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20x TBE Buffer 
Tris Base       121.14 g/l 
Boric Acid        61.83 g/l 
EDTA        5.85 g/l 
When used in contour clamped homogeneous field electrophoresis (CHEF) 
experiments, 50 ml of the stock solution was added to 1950 ml of HpH2O.  
 
Cell Lysis Buffer 
Tris Base        1.214 g/l 
EDTA        0.29 g/l 
SDS        1% w/v 
Triton X-100       2% v/v 
Tris, EDTA and SDS were added to 800 ml HpH2O and the solution was 
sterilised by autoclaving at 121°C for 15 minutes. Triton X-100 was added, the 
buffer was made up to 1 litre with HpH2O and then filter sterilised through a 0.2 
µm cellulose membrane filter (Merck Millipore).  
 
DNA Loading Buffer (6x) 
Glycerol       30% v/v 
Bromophenol Blue      2.5 mg/ml 
Xylene Cyanol FF      2.5 mg/ml 
The reagents were dissolved in 7 ml HpH2O. When the reagents had dissolved 
the volume was adjusted to 10 ml and stored at room temperature.  
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2.5 Growth Media 
Lysogeny broth (LB) was made using 10 g/l tryptone, 5 g/l yeast extract and 10 
g/l NaCl. The LB media components were mixed with 800 ml of HpH2O, adjusted 
to pH 7.4 using an Ultrbasic-10 pH meter (Denver Instruments) and NaOH and 
then made up to 1 litre by adding 200 ml of HpH2O. The agar growth medium 
used in these experiments was 25 g/l of bactopeptone in HpH2O, supplemented 
with 1.5% w/v bacteriological agar (VWR). Twenty millilitres of molten agar was 
poured into each 94 mm petri dish to form the solid bacteriological peptone agar 
plates. All growth media were autoclaved at 121°C for 15 min and stored at 4°C 
prior to use.  
 
2.6 Antibiotics  
 All antibiotic discs were purchased from Oxoid. The antibiotics used and their 
concentrations are presented in table 2.5. Fusidic acid was supplied as sodium 
fucidin powder from (CSL Biotherapies). Once solubilised in HpH2O, the stock 
and working solutions were stored at -20°C.  
 
Table 2.5 Antibiotic discs 
Antibiotic 
Conc. 
(µg/disc) 
Antibiotic 
Conc. 
(µg/disc) 
Ampicillin 10 Nitrofurantoin 5 
Amoxicillin 30 Norfloxacin 10 
Augmentin 60 Oxacillin 1 
Cefaclor 30 Penicillin 9.91 
Cefoxitin 10 Polymyxin B 35.7 
Cephalexin 100 Rifampicin 1 
Ciprofloxacin 2.5 Streptomycin 10 
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Chloramphenicol 10 Sulfamethoxazole 25 
Erythromycin 15 Tetracycline 10 
Fusidic Acid 10 Ticarcillin 75 
Gentamicin 10 Tobramycin 10 
Imipenem 10 Trimethoprim 5 
Kanamycin 30 Vancomycin 5 
Nalidixic acid 30   
  
2.7 Biological Tissue Tested for Antimicrobial Activity 
Table 2.6 lists of all the plant, fungal and invertebrate tissue tested for 
antimicrobial activity. Also included is the location from where the sample was 
obtained, and the weight of the sample per ml of buffer used in the extraction. 
 
Table 2.6 Plant, fungal and invertebrate samples 
Species 
Common 
Name 
Tissue Origin 
Concentration 
(mg/ml) 
Agaricus 
xanthoderma 
Yellow-staining 
mushroom 
Head 
Curtin 
university 
grounds 
667 
Agaricus 
xanthoderma 
Yellow-staining 
mushroom 
Stem 
Curtin 
university 
grounds 
667 
Aloe vera Aloe vera plant Leaf Local Market 200 
Amanita 
xanthocephala 
Vermillion 
amanita 
Head 
Curtin 
university 
grounds 
279 
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Amanita 
xanthocephala 
Vermillion 
amanita 
Stem 
Curtin 
university 
grounds 
222 
Armillaria 
luteobubalina 
Australian 
honey fungus 
Head 
Curtin 
university 
grounds 
446 
Armillaria 
luteobubalina 
Australian 
honey fungus 
Stem 
Curtin 
university 
grounds 
535 
Brassica 
oleracea 
Cabbage Leaf 
Curtin 
university 
grounds 
667 
Capscium 
chinese 
Bhut jolokia 
chilli 
Seeds Wild Fire 106 
Capscium 
chinese 
Bhut jolokia 
chilli 
Fruit Wild Fire 403 
Citrus latifolia Persian Lime Fruit Local Market 300 
Cucumis sativus Cucumber Fruit Local Market 667 
Elettaria 
cardamomum 
Green 
cardamom 
Seeds Local Market 300 
Humulus 
lupulus 
Hop plant 
(Cascade) 
Flower 
Gage Roads 
Brewery 
250 
Humulus 
lupulus 
Hop plant 
(Citra) 
Flower 
Gage Roads 
Brewery 
250 
Humulus 
lupulus 
Hop plant 
(Chinook) 
Flower 
Gage Roads 
Brewery 
250 
Humulus 
lupulus 
Hop plant 
(Summer) 
Flower 
Gage Roads 
Brewery 
250 
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Humulus 
lupulus 
Hop plant 
(Topaz 
Flower 
Gage Roads 
Brewery 
250 
Juniperus 
comminus 
Juniper berry Berry Local Market 300 
Lucilia sericata Green bottle fly Larva 
Pathology 
West 
100 
Mentha spicata Spearmint Leaf Local Market 200 
Musa acuminata 
Cultivated 
banana 
Skin Local Market 667 
Musa acuminata 
Cultivated 
banana 
Fruit Local Market 667 
Persea 
americana 
Avocado Fruit Local Market 1136 
Pisolithus 
tinctorius 
Horse dung 
fungus 
Head 
Curtin 
university 
grounds 
667 
Pisolithus 
tinctorius 
Horse dung 
fungus 
Stem 
Curtin 
university 
grounds 
667 
Pycnoporus 
coccineus 
Scarlet bracket Head 
Curtin 
university 
grounds 
323 
Solanum 
lycopersium 
Common truss 
tomato 
Fruit Local Market 300 
Tulbaghia 
violacea 
Society garlic Leaf Local Market 200 
Tulbaghia 
violacea 
Society garlic Bulb Local Market 200 
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Zingiber 
officinale 
Ginger Root Local Market 667 
 
2.8 Synthetic Antimicrobial Peptides 
Table 2.7 shows the AMPs used in this study, their amino-acid sequence and 
electrostatic charge. All peptides were synthesised and purchased from 
Mimotopes in powder form. Peptides were dissolved in HpH2O and absorbance 
at 280nm was measured using a Nanodrop spectrophotometer (Thermo 
Scientific). The concentration of the peptide in solution was then calculated using 
the following formula: X=(A280÷MWp)÷[(nwx5500)+(nyx1490)] were (X) is the 
concentration of the peptide, (A280) is the measured absorbance of the peptide 
solution at 280nm, (MWp) is the molecular weight of the peptide, (nw) is the 
number of tryptophan residues in the peptide sequence and (ny) is the number of 
tyrosine residues in the sequence. Using this formula, it was possible to 
accurately predict the concentration of the peptide in solution by accounting for 
the absorption bias of the aromatic rings of tryptophan and tyrosine. Peptide 
stock solutions were kept at -20°C prior to use. 
 
Table 2.7 Antimicrobial peptides 
Peptide Sequence  Charge 
AP1 GEQGALAQFGEWL-OH -2 
Bac8c RIWVIWRR-OH +3 
Melittin GIGAVLKVLTTGLPALISWIKRKRQQ-OH +5 
Melfrag12-24 GLPALISWIKRKR-OH +4 
Melfrag12-26 GLPALISWIKRKRQQ-OH +4 
Melfrag12-26-L1 LLPALISWIKRKRQQ-OH +4 
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2.9 Primers 
Primers for fusB and fusC genes were obtained from Geneworks and were 
diluted to 100µM in HpH2O
 before use. Table 2.8 shows the sequence of the 
primers as well as the Genbank accession number of their corresponding 
sequence and their location in the sequence. Forward primers were designed to 
match the sequence of the sense-strand, whereas the reverse primers were 
designed to be complimentary to the sense strand of the DNA.  
 
Table 2.8 Primer sequences  
 
2.10 Pig Skin Preparation 
Pig skin, which included the epidermis, dermis and sub-dermal fat layer was 
purchased from a local abattoir. The fat layer was removed from the dermis and 
the skin was cut into 2cm x 2cm squares. The skin was sterilised in 70% 
undenatured ethanol for 1h, washed with HpH2O and allowed to dry under UV 
bactericidal lights of a biological safety cabinet. The skin was placed in molten 
bactopeptone agar 2mm deep to immobilise and rehydrate the sterilised skin. 
The plates were stored at 4°C until needed.  
Primer Sequence (5’->3’) Accession 
Number 
Location 
(nt #) 
FusB-F CGATATGAATTCCCATAAAACACA CP003193.1  1414  
1437 
FusB-R GAGTGAGGTACAAAATATAACAACCC CP003193.1 2011
2036 
FusC-F GATAAATCTTGATTCGGATGCTG KF527883.1 22073  
22095 
FusC-R CTAAAGATCAGGGCTGTTTGG KF527883.1 22990  
23011 
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2.11 Acticoat 
Acticoat™ (Smith and Nephew) was generously donated by Dr Fiona Wood and 
the burns department of Fiona Stanley Hospital, Perth, Western Australia.   
 
2.12 Details of suppliers 
Table 2.9 Suppliers details 
Name of Supplier Suppliers Address 
Ajax Chemicals Supplied By: Rowe Scientific Pty Ltd 
11 Challenge Boulevard 
Wangara, Perth, W.A, 6065 
Australia 
Amresco Amresco LLC 
6681 Cochran Road 
Solon, Ohio, 44139  
USA 
Applied Bioscience Supplied By Life Technologies Australia Pty Ltd 
30-32 Compact Circuit  
Mulgrave, Melbourne, VIC, 3170 
Australia   
Asia Pacific 
Specialty Chemicals 
Asia Pacific Specialty Chemical Ltd 
9 Short Street 
Auburn, Sydney, NSW, 2144 
Australia 
Astral Scientific Astral Scientific Pty Ltd 
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29 Mangrove Lane 
Taren Point, Sydney, NSW, 2229 
Australia 
Bioline  Bioline (Aust) Pty Ltd 
PO Box 122 
Alexandria, Sydney, NSW, 2015 
Australia 
Bio-Rad Bio-Rad Laboratories Pty Ltd 
Level 5, 446 Victoria Road 
Gladesville, Sydney, NSW, 2111 
Australia 
Bright-Line  Supplied by Sigma Aldrich 
PO Box 970 
Castle Hill, Sydney, NSW 1765 
Australia 
Chem-Supply Chem-Supply Pty Ltd 
PO Box 201 
38-50 Bedford Street 
Gill Man, Port Adelaide, S.A, 5013 
Australia 
Constant Systems Constant Systems LTD 
Low March Daventry 
Northants, NN11 4SD 
UK 
CSL Biotherapies CSL Corporate Registered Head Office 
45 Poplar Rd 
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Parkville, Victoria, NSW, 3052 
Australia 
Denver Instruments Denver Instrument 
5 Orville Dr 
Bohemia, New York, 11716 
U.S.A 
Electran Supplied By: VWR International Pty Ltd 
Unit 1/31Archimedes Place 
Murarrie, Brisbane, QLD, 4172   
Australia 
Fischer Bioreagents Thermo Fischer Scientific Australia Pty Ltd 
5 Carribean Drive 
Scoresby, Melbourne, VIC, 3179 
Australia 
Gage Roads Gage Roads Brewing Corporate 
14 Absolon Street  
Palmyra, Perth, W.A, 6157 
Australia 
Geneworks Geneworks Pty Ltd 
28 Dalgleish St 
Thebarton, Adelaide, SA, 5031 
Australia  
Hausser Scientific  Hausser Scientific Company 
935 Horsham Road: Suite C 
Horsham, Pennsylvania,19044 
U.S.A 
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Ibis Technology Ibis Technology  
24/70 Roberts Street  
Osborne Park, Perth, WA, 6017 
Australia 
Kai Medical Kai Europe GmbH 
Kottendorfer Str 5 
Solingen 42697 
Germany 
Labogene Supplied by Bio-Strategy Pty Ltd 
Unit 3, 21 Lakeside Drive 
Broad Meadows, Newcastle, NSW, 3047 
Australia 
New England 
Biolabs 
New England Biolabs 
240 Country Road 
Ipswitch, Massachusetts, 1938-2723 
USA  
Omega Bio-Tek Omega Bio-Tek Inc 
400 Pinnacle Way, Suite 450 
Norcross, Georgia, 30071 
USA  
Pathology West A division of: Westmead Hospital 
Dept of Medical Entomology 
PO Box 533 
Level 3, ICPMR, Westmead Hospital 
Wentworthville, Sydney, NSW,2145 
Australia 
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Perkin Elmar Perkin Elmar 
Level 2, Building 5, Brandon Office Park 
530-540 Springvale Road Glen Waverley, Melbourne, 
VIC, 3150 
Australia 
Promega Promega Corporation 
Suite W3A, Level 3, Westside Building 
South Sydney Corporate Park 
75-85 O’Riordan St 
Alexandria, Sydney, NSW, 2015 
PRO Scientific PRO Scientific 
99 Willenbrock Road 
Oxford, Connecticut, 06478 
USA 
Roche  Roche Products Pty Ltd 
4-10 Inman Road 
Dee Why, Sydney, NSW, 2099 
Australia 
Sigma-Aldrich  Sigma-Aldrich 
PO Box 970 
Castle Hill, Sydney, NSW, 1765 
Australia 
Smith and Nephew Smith and Nephew Pty Ltd 
Suite 7, 567 Newcastle Street 
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West Perth, W.A, 6005 
Australia 
VWR Chemicals VWR International, Pty Ltd 
Unit 1/31 Archimedes Place  
Murarrie, Brisbane, QLD, 4172 
Australia  
Wildfire Chilli Wildfire Chilli Pty Ltd 
http://www.wildfirechilli.com.au/ 
Zeiss Carl Zeiss Pty 
Microscopy 
Tenancy Office 4 Level 1, 40-52 
Talavera Road 
North Ryde, Sydney, NSW, 2113 
Australia 
 
3. Methods  
3.1 Selection of Plant, Fungal and Invertebrate Samples for Anti-
MRSA Screening 
Sample selection was based off ease of acquisition, exposure of the samples to 
microorganisms in nature and ethical considerations. Initial experiments focused 
on fruits, seeds, leaves and other material from commonly available plants. From 
these results, material from plants with more aromatic attributes, such as chilli 
seeds and hop flowers, more frequently showed antibacterial activity than other 
samples. Subsequently, samples were sourced from plants which displayed 
these characteristics. The natural habitats of fungi among damp and decaying 
material could be predicted to expose them to a wide variety of benign and 
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pathogenic microorganisms. Therefore it may be predicted that most fungi would 
synthesise broad spectrum antibacterial compounds as part of their innate 
immunity. Similarly, scavenging invertebrates which both feed and lay their eggs 
in carrion tissue would be expected to produce antibacterial compounds to 
prevent infection from pathogens growing in necrotic wounds. Consequently, 
multiple fungal samples commonly found in Western Australia as well as medical 
debridement larva: Lucilia sericata were tested for antibacterial activity.  
 
3.1.1 Homogenisation of Biological Material 
The materials tested for antimicrobial activity, their sources and the concentration 
of tissue tested are listed in table 2.6. Two slightly different methods were used to 
homogenise the different materials. 
 
3.1.1.1 Freeze dry mortar and pestle 
Whole samples were cut into fragments roughly 1 cm in length using sterile 
forceps and scalpel blades and transferred to a mortar bowl containing a pinch of 
sterile glass powder. Liquid nitrogen (5-10 ml) was added to the mixture, the 
sample was ground into a fine powder using a pestle and added to a 15 ml 
centrifuge tube. Five millilitres of JEB1 was added per 2 g of sample  and the 
samples were centrifuged at 3000 x g for 15 minutes using a Beckman Coulter 
Allegra X-12R centrifuge. The supernatant was collected and stored at -20°C. 
The L. sericata, M. spicata, S. lycopersium, T. violacea and Z. officinale samples 
were homogenised using this method. All other samples were homogenised 
using the bladed homogeniser and cell disrupter method described below. 
 
3.1.1.2 Homogeniser and Cell Disruptor 
Samples were cut into fragments as described above and transferred to a 250 ml 
beaker containing 20 ml of JEB1. The samples were then homogenised using a 
20 mm generator probe at 30,000 RPM. The homogenised extract was then 
passed through a HAIVA cell disrupter (Constant Systems) at 40 KPSI at a flow 
rate of 100 ml/minute. The extract was centrifuged at 3000 x g for 15 minutes. 
The supernatant was collected and stored at -20°C.  
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3.2 Antibacterial Analysis of Biological Extracts 
The toxicity of the extraction buffers on MRSA was analysed by growth curve 
analysis. An overnight culture of WBG 8287 was counted and 105 CFU/ml were 
added to separate wells containing 0-50% v/v extraction buffers in 8 g/l. The 
plates were incubated for 16h in a plate reader at 37°C with 150 rpm orbital 
shaking for 30 seconds every 15 minutes. The absorbance of each well was 
measured at 600nm every hour over the 16 hour period. Each sample was tested 
in triplicate and the experiment was performed twice. 
The effect of the biological extracts on MRSA was measured using a modified 
version of the calibrated dichotomous sensitivity (CDS) method developed by 
Sydney M. Bell (308). Follow-on experiments were conducted by measuring 
colony survival after treatment with increasing concentrations of the extracts.  
 
3.2.1 Extract Sensitivity Testing Using CDS Method 
Plate inoculation followed the method as described by Bell et al. (308).A single 
colony of WBG 8287, which had previously been streaked on a bactopeptone 
agar plate for single colonies, was transferred to 2.5 ml of PBS using a sterile 
wire loop. The inoculated saline was spread evenly on a fresh agar plate by 
rocking. Excess media was removed and the surface was allowed to dry for 10-
15 minutes. Holes, 3 mm2 in diameter, were punched into the inoculated agar 
plates using a sterile tissue biopsy punch (Kai Medical) connected to a 1 ml 
automatic pipette (Figure 3.1). The agar inside the biopsy punch was aspirated 
off the petri disc using the pipette and discarded. Fifteen microlitres of sample 
extract was loaded into each well and the plates were incubated at 37°C for 24h. 
The annular radius from the edge of the well to the edge of the zone that begins 
to show bacterial growth, i.e. the zone of inhibition was measured for each 
sample.Extracts which showed antibacterial activity using the CDS method were 
tested another 2-3 times. The extracts which did not show activity were not tested 
again.    
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Figure 3.1 The hole punching apparatus used to create sample wells in agar 
plates 
 
3.2.2 Colony Survival 
WBG 8287, cultured in 8 g/l bactopeptone medium for 24h, was diluted 1/50 in 
PBS. Twenty microlitres of cell suspension was added to 20 µl of 0.4% trypan 
blue and the mixture was transferred to a haemocytometer chamber (Brightline), 
with graduations corresponding to 1/400 mm2, for cell counting. One million cells 
were treated with 10, 50 and 90% solutions of A. luteobubalina, C. chinese, C. 
latifolia, E. cardamomum and J. communis in 1 ml of 8 g/l bactopeptone for 1 
hour at 37°C with 150 rpm orbital shaking. Mock-treated controls were prepared 
in parallel with the test samples. After 1h the samples were diluted 1/1, 1/10, and 
1/50 with PBS and 100 µl of each suspension was spread on separate 
bactopeptone agar plates using a sterile plate spreading rod. After 24h 
incubation, the number of surviving colonies was counted and the percentage of 
viable colonies relative to the untreated controls was calculated.  
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3.3 Testing of Digested Extracts for Antibacterial Properties 
Aqueous extracts from A. luteobubalina, C. chinese, C. latifolia, E. cardamomum 
and J. communis were treated with 0.25 mg/ml trypsin and 1 mg/ml OB protease 
for 30 minutes at 37°C with 150 rpm orbital shaking. Mock enzyme-treated 
samples were prepared in parallel with the test samples. Following incubation, 
180 µl of sample extract solution was added to 20 µl of a 107 CFU/ml inoculum of 
WBG 8287 in 8 g/l bactopeptone. Bacteria were also treated in the same way 
with mock-digested aqueous extracts. Survival of treated bacteria was tested by 
plating on agar and calculating the percentage colonies formed relative to mock-
treated bacteria. Hop flower extracts were treated in triplicate with OB protease 
and Trypsin enzymes as described above. However, the sensitivity of MRSA to 
these extracts was tested using the CDS method (section 3.2.1).  
 
3.4 Analysis of Protein Content and Peptide Precipitation in Growth 
Media  
3.4.1 Quantitation of Media Protein Concentration 
The concentration of proteins in the various media used in this study was 
measured using the Pierce BCA Protein Assay. This method relies on the 
peptide-peptide bonds catalysing the reduction of copper (Cu2 =>Cu+) which 
interacts with two BCA molecules to form a purple compound that can be 
measured spectrophotometrically. The absorbance is proportional to the 
concentration of proteins in solution and, is calibrated against protein standards 
of known concentrations. Absorbance was measured at 660nm using a Victor 3V 
multilabel spectrophotometric plate reader.  
 
3.4.2 Analysis of Peptide Precipitation in Different Media 
Increasing concentrations of melittin and melfrag12-26 were added to 8 g/l 
bactopeptone, PBS and PB (Table 3.1). Media without antibacterial peptides 
served as blank controls. Two microlitres of each solution was analysed at 
630nm using a Nanodrop spectrophotometer. All samples were tested in 
triplicate.  
 
73 
 
Table 3.1 Concentration of melittin and melfrag12-26 in growth media and 
phosphate buffer 
Melittin Conc. In Media 
(µg/ml) 
Melfrag12-26 Conc. In Media 
(µg/ml) 
50 50 
75 100 
100 150 
200 200 
500 250 
 500 
 
3.5 Minimal Inhibitory and Minimal Lethal Concentration Testing  
3.5.1 Minimal Inhibitory Concentration: Growth Curve Analysis 
An overnight culture of WBG 8287 was counted and diluted in 200 µl of 8 g/l 
bactopeptone medium to 105 CFU/ml. Serial dilutions of AP1, melittin, melfrag12-
24 and melfrag12-26-L1 ranging from 1-200 µg/ml were added to separate 
inoculated wells. The plates were incubated for 16h in a plate reader at 37°C with 
150 rpm orbital shaking for 30 seconds every 15 minutes. The absorbance of 
each well was measured at 600nm every hour over the 16 hour period. The 
minimal inhibitory concentration (MIC) of the peptides was defined as the lowest 
concentration in which the absorbance of the wells did not increase over that of 
the mock inoculated negative control. Unless otherwise stated, each sample was 
tested in triplicate and the experiment was performed twice. 
 
3.5.2 Minimal Lethal Concentration: Colony Survival on Agar Plates 
S. aureus was grown overnight at 37°C in 8 g/l bactopeptone and cell numbers 
were counted the next day. The minimal lethal concentration (MLC) of synthetic 
AMPs was determined by treating 106 CFU/ml inoculum in 200 µl of medium with 
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a range of concentrations of the test samples for 1h at 37°C with 150 rpm orbital 
shaking. After incubation, 100 µl from triplicate samples were plated on individual 
bactopeptone agar plates. The mock-treated control samples were diluted 1/50 
with PBS prior to plating. The inoculated plates were incubated at 37°C for 24h 
after which the surviving colonies were counted. The MLC was defined as the 
lowest concentration of peptide or compound that reduced the amount of 
surviving colonies by at least 99.99% compared to the mock-treated control. The 
same methodology was used to test the MLC concentration of melittin, 
melfrag12-26 and bac8c in 8 g/l bactopeptone with 0.005% and 0.1% v/v Triton 
X100. Unless otherwise stated, experiments were performed twice with triplicate 
samples for each peptide tested.  
 
3.5.2 Antibacterial Activity of AP1 in media Supplemented with MgCl2 
WBG 8287 cells were suspended at 106 CFU/ml in 200 µl of 8 g/l bactopeptone 
medium supplemented with 10, 15 or 20 mM MgCl2. The cells were then treated 
in triplicate with 50 or 100 µg/ml of AP1. Growth was measured over ten hours 
using a spectrophotometric plate reader (section 3.51).  
 
3.6 Antibacterial Activity of Melittin at Different Incubation 
Temperatures     
Cultures of MRSA strain WBG 8287 (106 CFU/ml) were treated with 0.1 µg/ml or 
0.5 µg/ml of melittin in 200 µl of PBS. The cells were incubated at 5°, 25°, 37° 
and 45°C for 1h with 150 rpm orbital shaking and then plated on bactopeptone 
agar plates. The mock treated controls were diluted 1/50 prior to plating. After 
24h incubation, the resulting colonies were counted and expressed as a 
percentage of untreated controls. Each sample was tested in triplicate and the 
experiment was performed twice. 
 
3.7 MRSA Growth in Sub-inhibitory Doses of Antimicrobial Peptides 
In the initial experiments, strain WBG 8287 was inoculated at 106 CFU/ml into 
200 µl of 8 g/l bactopeptone medium containing 1 g/ml of melittin and incubated 
overnight at 37°C with 150 rpm orbital shaking. This population was subcultured 
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for a further six days, with the melittin concentration increased by 2 g/ml each 
day to a final concentration of 13 g/ml. These cells were designated ―melittin-
resistant‖ bacteria and untreated controls, subcultured in parallel, were 
designated ―melittin-naive‖ bacteria. After the six days of exposure to melittin, the 
MLC and MIC of melittin was tested as described above. WBG 8287 bacteria 
from these experiments were used to test the stability of melittin resistance in a 
population and were photographed using scanning electron microscopy (SEM). 
In all other resistance-based investigations, overnight cultures of strains WBG 
8287, W17S, Aus3 and BB were counted (section 3.2.2) and resuspended at 107 
CFU/ml in 200 µl of 8 g/l bactopeptone. The medium was supplemented with 2.5 
µg/ml of melittin and the samples were incubated for 12h at 37°C with 150 rpm 
orbital shaking. After 12h the cells were counted and resuspended at 107 CFU/ml 
in 200 µl of 8 g/l bactopeptone medium supplemented with 5 µg/ml melittin. The 
cells were then re-incubated for an additional 12h. This was repeated with 
melittin concentrations in the medium increasing to 8, 10, 15, 20, 40 and 60 µg/ml 
for the first three days followed by subculture every 12h in medium supplemented 
with 80 µg/ml of melittin for the next three days. Parallel experiments were 
performed with increasing concentrations of bac8c in cultures of WBG 8287, 
W17S and Aus3.     
 
3.8 Scanning Electron Microscopy 
3.8.1 Desiccator Method 
Bacteria were suspended in 200 µl PBS at 106 CFU/ml and centrifuged at 12,000 
x g for five minutes. The supernatant was removed and the bacteria resuspended 
in 1 ml PBS. The samples were then recentrifuged and the bacteria suspended in 
100 µl PBS containing 10 g/ml of melittin for 1h at 37°C. Control samples were 
prepared by the same process, without melittin. Aliquots of each sample (15 µl) 
were dispensed onto separate aluminium stubs. The stubs were covered and 
incubated for thirty minutes at 37°C. The cells were fixed by overlaying with 25 µl 
of a PBS solution containing 2.5% glutaraldehyde (Asia Pacific Specialty 
Chemicals) for 3 h at 4°C. The stubs were washed by gently applying HpH2O to 
the tilted surface of the stubs, followed by a series of thirty minute incubations at 
37°C in 70%, 90% and 100% ethanol respectively. The samples were transferred 
to a desiccator and dried for 24h at 37°C over silica gel. The stubs were 
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evaporatively coated with a 3 nm layer of platinum and viewed using a Neon 
40ESB Crossbeam SEM. The desiccator method was used to obtain close-up 
images of melittin naive and melittin resistant WBG 8287 cells after melittin 
treatment. 
  
3.8.2 Freeze Dry Method 
WBG 8287 cells were seeded on bactopeptone agar plates (section 3.2.1). 
Acticoat strips, cut to 1 cm2 were carefully placed on the inoculated agar. The 
plates were then incubated at 37°C for 24h. After 24h the strips were removed 
from the agar and washed with PBS. The Acticoat strips were transferred to a 5 
ml tube containing 2.5% glutaraldehyde supplemented with 75 mM lysine at 37°C 
for 10 minutes. Lysine fixation solution was washed off the Acticoat with HpH2O 
and the cells attached to the Acticoat were fixed for a further 24h in 3% 
glutaraldehyde at room temperature. After fixing, the strips were washed with 
HpH2O and then transferred to a tube containing 50% undenatured ethanol for 5 
minutes. The ethanol was aspirated from the tube and the Acticoat strips were 
immersed for another 5 minutes in 70% ethanol. This step was repeated with 
80% and 90% ethanol and then repeated twice with 100% ethanol for 10 
minutes. After ethanol dehydration the Acticoat strips were frozen in liquid 
nitrogen and then transferred to a petri dish with a perforated lid. The petri dish 
was placed in a Scanvac Coolsafe freeze dryer and the cells were freeze dried at 
-55°C overnight. After the freeze drying process was completed the Acticoat was 
immobilised on the surface of aluminium stubs using conductive carbon glue 
(Figure 3.2). The stubs were then coated with platinum and viewed using the 
scanning electron microscope as described above (section 3.8.1). This process 
was repeated for WBG 8287 cells that were exposed to Acticoat on bactopeptone 
agar plates for 48h and 72h.  
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Figure 3.2 Acticoat, prepared for SEM using the freeze drying method, 
adhered to an aluminium stub 
 
3.9 Qualitative Analysis of the Electrostatic Potential of the surface of 
Naive and Resistant Cells   
3.9.1 Eosin Staining and Spectrophotometric Analysis of Cells 
WBG 8287 cells were counted and resuspended at 108 CFU/ml in 1 ml HpH2O. 
The cells were centrifuged at 8,000 x g for 10 minutes, the supernatant was 
removed and the cells were resuspended in 1 ml HpH2O at concentrations of 2.5 
x 107, 1.5 x 107, and 5 x 106 CFU/ml. The cells were recentrifuged and 
resuspended in 1 ml HpH2O with 0.01% v/v eosin Y. The cells were incubated at 
37°C with 150 rpm orbital shaking for 30 minutes. The cells were then 
recentrifuged, the supernatant was removed and the pellet was resuspended in 
250 µl of HpH2O and the absorbance of the cell suspension was measured 
spectrophotometrically at 490nm. Each test was performed in triplicate and the 
experiment was repeated three times.  
 
3.9.2 Flow Cytometry Analysis of a Cationic Fluorophore 
Binding of the cationic fluorescent probe Bacterisense 645 (Perkin Elmer) to the 
cell surface was compared between parental strain WBG 8287 and melittin 
resistant WBG 8287. Two hundred microlitre suspensions of both populations 
(107 CFU/ml) were washed twice in 1 ml PB with centrifugation at 8,000 × g for 
five minutes and resuspended in 1 ml of PB. A 100 µl aliquot (107 CFU/ml) was 
transferred to 400 µl of HpH2O containing 2.08 picomoles of Bacterisense 645. 
The bacteria were washed three times for ten minutes each in PB, with shaking 
at room temperature, to remove unbound or weakly bound probe. Dye-binding to 
bacteria was measured using an Attune Acoustic Focusing Cytometer using 
Attune focusing fluid. All solutions including growth media used for flow cytometry 
were filtered through 0.2 µm membrane filters.  
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3.10 Removal and Return of Antimicrobial Peptide Selection Media 
Melittin resistant bacteria (WBG 8287) and bac8c resistant bacteria (WBG 8287, 
W17S and Aus3) were subcultured daily for seven days in 8g/l bactopeptone 
medium without AMPs. These were designated the ―reversion‖ populations. After 
seven daily subcultures, the MLC of the peptides for the reversion bacteria was 
measured as described in section 3.5.2. The MIC of melittin against the reversion 
bacteria was also measured as before (section 3.5.1). Melittin reversion bacteria 
were returned to medium containing 12 g/ml melittin for 24h and the MLC of 
melittin was measured. 
 
3. 11 Internalisation of Antimicrobial Peptides by Electroporation 
3.11.1 Preparation of Electro-competent MRSA 
A 1 ml overnight culture of WBG 8287 (approximately 109 cells) was centrifuged 
at 8,000 x g for ten minutes and the cells were washed with 500 mM sucrose. 
The cells were recentrifuged and the pellet was resuspended in 500 µl of 500 mM 
sucrose. The cells were chilled on ice for thirty minutes and then recentrifuged 
and resuspended in 500 µl of 500 mM sucrose. The bacteria were then used in 
electroporation experiments or stored in 15% glycerol at -80°C.  
 
3.11.2 Electroporation-Transfection of MRSA with Antimicrobial Peptides   
Electro-competent WBG 8287 were counted and resuspended at 106 CFU/ml in 
50 µl of 500 mM sucrose, in five separate Gene pulse™ electroporation cuvettes 
with a 0.1cm electrode gap. In two cuvettes, melittin was added at a 
concentration of 2.5 µg/ml and all cuvettes were chilled on ice for one minute. 
One cuvette containing cells with melittin and two cuvettes with cells but without 
melittin were pulsed using a Micropulser electroporator set at 25 µF, 2.5 kV and 
100 Ω, which gave a pulse time of 2.5 ms. After electroporation, 2.5 µg/ml of 
melittin was added to a control, untreated electroporated sample and 450 µl of 
sucrose was added to each cuvette. The samples were placed on ice for fifteen 
minutes then spread on bactopeptone agar plates (Figure 3.2). The untreated 
samples were diluted 1/50 prior to plating. The plates were incubated for 24h at 
37°C. Colony survival was measured after incubation and expressed as a 
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percentage of an untreated, un-electroporated control. This method was also 
used to measure the effectiveness of transferring 50 µg/ml melfrag12-26 and 2 
µg/ml bac8c into MRSA. All electroporation experiments were repeated twice with 
three replicates for each sample.   
 
 
Figure 3.3 Flow diagram of cells exposed to antimicrobial peptides with and 
without electroporation. Some samples were electroporated before being 
plated on agar plates, while others were plated without being electroporated 
(lightning bolt with cross). One sample group which had been electroporated 
without the AMP, was exposed to the peptide before being spread on the agar 
plates.   
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3.12 Haemolysis Assays 
3.12.1 Preparation of Erythrocytes 
Fifteen millilitres of whole blood was drawn from the vein of a 26 year old male 
volunteer (ethical approval not required) and stored in an EDTA-coated 
Vacutainer. Erythrocytes were separated from whole blood by centrifuging at 500 
x g for five minutes at 4°C. The supernatant was removed and 10 ml of ice-cold 
PBS was added. The cells were recentrifuged, the supernatant was removed and 
the pellet was resuspended in 10 ml PBS. 
 
3.12.2 Haemolysis Assay  
Red blood cells were counted and resuspended in PBS at 106 cells/ml. To 
measure haemolysis, melittin, melfrag12-26 or bac8c was added to each medium 
at different concentrations (Table 3.2). The erythrocyte suspension was 
incubated at 37°C for thirty minutes with 150 rpm orbital shaking and then 
centrifuged at 500 x g. The absorbance of the supernatant at 405nm was 
measured using a Victor Multilabel plate reader spectrophotometer. The 
haemolytic potential of the peptides was also measured in PBS supplemented 
with various combinations and concentrations of Triton X-100, glycerol and 
lysozyme (Table 3.2).   
 
Table 3.2 Concentrations of the antimicrobial peptides, and other 
compounds, in PBS medium used to assess haemolysis  
Sample 
Peptide Conc. 
(µg/ml) 
TX100 Conc. 
(v/v%) 
Blank 
0 0 
0 0.005 
0 0 
Bac8c 6 0 
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4 0.005 
80 0 
Melittin 
5 0 
2.5 0.005 
Melfrag12-
26 
130 0 
80 0.005 
100 0 
 
3.13 Antibiotic Sensitivity of Antimicrobial Peptide Naive and 
Resistant MRSA 
3.13.1 Disc Diffusion 
Antibiotic sensitivity of wild-type and melittin or bac8c resistant MRSA was tested 
using the calibrated dichotomous sensitivity method described by Bell et al. 
(308). Single bacterial colonies, grown overnight, were suspended in PBS and 
used to lawn inoculate bactopeptone agar plates. Antibiotic discs were placed on 
the plates and incubated for 24h at 37°C, before measuring zones of inhibition as 
previously described (section 3.2.1). The antibiotic resistance profile of AMP-
resistant bacteria was compared against wild-type populations to identify any 
change in sensitivity. The experiment was repeated 2-6 times for each antibiotic.  
 
3.13.2 Growth of MRSA on Media containing Sub-inhibitory Concentrations 
of Fusidic Acid 
 Overnight-colonies of wild-type WBG 8287, W17S, Aus3 and BB were streaked 
on bactopeptone agar plates containing 0.5 µg/ml fusidic acid. After 24h 
incubation a single colony was picked from each plate and streaked on agar 
containing 1 µg/ml fusidic acid and the plates were incubated for another 24h. 
This process was continued for a further five days with the concentration of 
fusidic acid increased by 2 µg/ml each day. A population of each MRSA strain 
exposed in this way to fusidic acid was made resistant to melittin and bac8c as 
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described above (section 3.7). The MLC concentration of fusidic acid to AMP-
naïve and AMP-resistant populations was tested as described above (section 
3.5.2).  
 
3.14 PCR of FusB and FusC Genes 
3.14.1 DNA Isolation   
Two millilitres of MRSA culture, grown for 24h in 24 g/l bactopeptone medium 
was centrifuged at 16000 x g for five minutes and the pellet was resuspended in 
200 µl of lysis buffer. The cells were snap frozen in liquid nitrogen and then 
immediately thawed at 95°C for one minute. This process was repeated twice. A 
pinch of sterile glass beads (approximately 1/4 the volume of the cell suspension) 
and 200 µl of chloroform was added to the tubes. The tube lids were secured with 
parafilm and the samples were homogenised using a FastPrep FP120 cell 
homogeniser for 30s at 6.5 m/s. Two hundred microlitres of HpH2O was added 
and the samples were mixed by inversion for 30s. The samples were centrifuged 
at 5000 x g for five minutes and the aqueous phase was collected in a fresh tube. 
An equal volume of chloroform was added to the extracts which were then mixed 
by inversion for two minutes and recentrifuged. The aqueous phase was 
collected and the chloroform extraction was repeated. A 1/10 volume of 1M NaCl 
and a 3 x volume of ice cold 70% undenatured ethanol was added to the 
aqueous phase. The tubes were placed on ice for 45 minutes. The extracts were 
then centrifuged at 16000 x g for ten minutes and the supernatant was removed. 
One millilitre of 70% ethanol was added and the tubes were centrifuged again. 
The supernatant was removed and the pellet was allowed to dry for 
approximately 5-10 minutes until no ethanolic aroma was detected from the 
tubes. The pellet was resuspended in 50 µl HpH2O and the DNA concentration 
and purity was tested spectrophotometrically using a Nanodrop 
spectrophotometer.  
 
3.14.2 PCR Amplification Primer Design 
Primers were designed to match a partial sequence submitted to NCBI (S.  
aureus, fusB: Genbank accession number CP003193.1 and fusC: KF527883.1) 
using Primer3 software  (309). The fusB gene begins at nucleotide 1336 of the 
83 
 
CP003193.1 sequence and continues for another 640 nucleotides (i.e. the gene 
is comprised of 641 nucleotides). The fusB forward primer was designed to 
match a 24 base-pair sequence on the sense-strand, beginning at nucleotide 
1414 of the CP003193.1 sequence and ending at nucleotide 1437. The reverse 
primer was designed to compliment a sequence 34 bases downstream of the 
stop codon of the sense-strand (nucleotides 2011-2036) to reduce the proportion 
of AT repeats and the potential for mispriming. Likewise, the fusC gene contains 
many repeat sequences which limited the choice in the forward and reverse 
primer sequences. The fusC forward primer sequence was designed to match a 
sequence of the sense-strand of KF527883.1 that began at nucleotide 22073 and 
ended at 22095. The fusC reverse primer sequence was complimentary to the 
nucleotide sequence ranging from 22990 to 23011 of the sense-strand. The fusB 
primers produced an amplicon of 624 nucleotides and the fusC primers produced 
an amplicon of 939 nucleotides.  
 
3.14.3 PCR Amplification  
Table 3.3 shows the concentrations of the reagents used in each 20 µl PCR 
reaction. PCR reactions included the MyTaq DNA polymerase and reaction 
buffer. The reaction buffer has dNTPs and MgCl2 at concentrations that are 
considered optimal for most PCR reactions. Template DNA was added at 5 
ng/reaction and each primer was used at 2 µM. The reagents and reaction 
mixtures were kept on ice throughout the dispensing procedure.  
 Amplification was performed using a Veriti 96-well Thermal cycler. A gradient of 
annealing temperatures was conducted to optimise the PCR reactions (See 
Appendix). Cycling conditions used for amplification of fusB/C are shown in table 
3.4. 
 
Table 3.3 PCR reagents 
Reagent Volume/20µl Reaction Concentration  
5xMyTaq Reaction Buffer 4µl 1x 
Forward Primer 0.4µl 2 µM 
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Table 3.4 Thermal cycler protocol 
 
3.14.4 Visualisation of Amplified PCR Products 
Amplification products were visualised on 1.5% agarose gels, with 0.6 g of 
molecular biology grade agarose in 40 ml SB buffer heated in a microwave oven. 
When the mixture had cooled to around 60°C, 5 µl of a 1000X concentration of 
Gel Green nucleic acid stain was added and the gel was cast in a plastic mould. 
The sample wells were loaded with 5 µl of amplified DNA, premixed with 4 µl of 
6X loading buffer. A 100 base-pair DNA ladder ranging from 100-1500 base 
pairs, was added to the first and last well to allow calculation of the length of the 
amplicons. Electrophoresis used a PowerPac 3000 power supply, operating at 
60V for ninety minutes. Following electrophoresis, the DNA was visualised using 
a Gel Doc XR+ UV transiluminator.   
 
Reverse Primer 0.4µl 2 µM 
Template 1µl 5 ng/reaction 
Polymerase  (5U/µl) 0.1µl 0.025 U/µl 
HpH2O 14.1µl 70.5% 
Step Temperature (°C) Time (Seconds) Cycles 
Initial Denaturation 95 60 1 
Annealing 59 15 
30 Extension 72 15 
Denaturation 95 15 
Final Extension 72 60 1 
Hold 4 ∞ 1 
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3.15 Assessment of Acticoat as a Antibacterial Dressing 
3.15.1 CDS Analysis of Acticoat on Agar Medium 
Acticoat layers were separated from the inner absorbent lining and cut into 1 cm 
x 0.5 cm rectangles using a scalpel blade and forceps (Figure 3.3). Bactopeptone 
agar plates were inoculated with wild-type WBG 8287 cells as described above 
(section 3.2.1). The Acticoat strips were aseptically placed on the agar and the 
plates were incubated for 24h at 37°C. Filter paper cut to the same size as the 
Acticoat strips was used as a negative control for growth inhibition. The zone of 
inhibition around the strips was measured after incubation. In subsequent 
experiments, the molten agar was textured using sterile moulds to create striated, 
blistered and creased textured surfaces. Each test and control sample was tested 
in a series of 9 replicates. 
 
 
Figure 3.4 Preparation of Acticoat Strips. The silver nanoparticle loaded mesh 
was separated from the inner absorbent layer and then cut into 1cm x 0.5cm 
rectangles.  
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3.15.2 Measuring Bacterial Survival on Acticoat 
WBG 8287 was overlain with Acticoat and filter paper on flat and textured 
bactopeptone agar plates, which were incubated for 24, 48 and 72h as described 
above (section 3.15.1). After incubation, the strips were carefully removed and 
placed on fresh bactopeptone agar for 5 minutes. The strips were then removed 
and the plates were incubated for 24h. The ability of MRSA to survive and 
transfer on Acticoat was assessed by observing growth within the regions 
exposed to Acticoat and the locations on which Acticoat was ―blotted‖.  
Similar experiments were conducted with cells inoculated onto 2cm x 2cm 
squares of sterile pig skin immobilised in agar (section 2.11). WBG 8287 bacteria 
were counted and resuspended at 107 CFU/ml in PBS. Two microlitres of the 
suspension was placed in the middle of each square of pig skin and the plates 
were incubated at 37°C for 30 minutes. Acticoat strips were then applied to the 
middle of each inoculated square of skin and the survival of bacteria on the 
gauze was measured after 24, 48 and 72h as described above.  
 
3.15.3 Measuring Bacterial Survival on Acticoat Encased in Antimicrobial 
Gels 
A 200 µl mixture of 1% molten agarose or bacteriological agar and 0.1% Triton X-
100 in HpH2O was cast in a 1.9 cm
2 well of a 24-well plate. An Acticoat strip was 
placed on the surface on the gel along with 20 µl of 1 mg/ml fusidic acid or bac8c. 
A further 200 µl of agarose or agar and Triton X-100 was added to the well and 
the gel was allowed to set. A 10 ml pipette with a tip that had been cut to create 
an opening with a diameter of approximately 1.9 cm2 was used to aspirate the 
Acticoat gels from the wells and place them on inoculated pig skin (Figure 3.5). 
Bacterial survival and transference on the antimicrobial gels after 24h was 
measured as described above (section 3.15.2).  
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Figure 3.5 Diagram of the process of casting Acticoat in agar or agarose 
gels with Triton X-100 and antibacterial agents. Once the gels were set, the 
negative and positive pressure created by a semi-automatic pipette was used to 
transfer the gels to inoculated pig skin.  
 
3.15.4 Measurement of Survival after Acticoat Treatment by Colony Survival  
Using methods described in section 3.15.2, Acticoat was overlain on sterile pig 
skin inoculated with 2 µl of WBG 8287 cells at 105 CFU/ml. Immediately after the 
Acticoat was placed on pig skin, it was removed and placed in a 5 ml tube 
containing 1 ml of PBS. The skin was also transferred from the plate to a tube 
containing 1 ml of PBS. The tubes were mixed by vortexing for 30s and the PBS 
was spread on bactopeptone agar plates (section 3.5.2). The plates were 
incubated for 24h and colonies were counted. Survival was expressed as a 
percentage of viable colonies on an untreated skin control. This was repeated for 
skin samples that were treated at 37°C for 30 minutes, 1h, 4h, 8h and 24h.  
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Matching experiments were performed with Acticoat that had been coated in 
wetting agents or antimicrobial agents. Pig skin was inoculated with 2 µl of WBG 
8287 cells at 108 CFU/ml as described above. Acticoat strips were coated with 
10% glycerol with and without 50 µg/ml melfrag12-26 or bac8c. The coatings 
were applied using a sterile brush and survival was measured after 24h 
incubation at 37°C as described above. The same experiment was repeated 
using a coating of 1000 µg/ml of lysozyme with and without the AMPs, and a 
combination of glycerol and lysozyme with and without the peptides (Figure 3.6).  
 
 
Figure 3.6 Flow diagram of the method to measure colony survival, after 
exposure to Acticoat, on pig skin and Acticoat strips 
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3.16 Contour Clamped Homogenous Field Electrophoresis  
Contour clamped homogeneous field electrophoresis was performed using the 
protocol described by O’Brien et al. (310). A single colony from each strain was 
resuspended in 5 ml of 5 mM EDTA and centrifuged for 10 minutes at 1000 x g. 
This step was repeated and the cells were resuspended in EC buffer at 1.8 x 106 
CFU/ml. Fifty microlitres of the cell suspension was mixed with 50 µl of 400 µg/ml 
lysostaphin and 100 µl of 1.2% chromosomal grade agarose in TBE buffer, the 
solution was mixed by pipetting, and then dispensed into a 0.5 cm x 1 cm plug 
mould. When set, the blocks were transferred to 1.5 ml tubes, each containing 
500 µl EC buffer. The tubes were incubated at 37°C for 4h. The EC buffer was 
removed and replaced with 300 µl of EST buffer and 30 µl of 20 mg/ml proteinase 
K and was incubated overnight at 50°C.  
The buffer and proteinase K was removed and the blocks were washed with 1 ml 
EDTA for thirty minutes at room temperature with gentle shaking. The EDTA 
solution was removed and the wash step was repeated three more times. The 
blocks were sliced in half using a glass cover slip to allow easy fit in the agarose 
wells. The half-blocks were washed with HpH2O for thirty minutes. After washing, 
the water was replaced with 20 µl enzyme buffer J, 40 units of SmaI restriction 
endonuclease and 180 µl of HpH2O and the tubes were chilled on ice for 30 
minutes. The blocks were then incubated at 25°C for 3h.  
After restriction enzyme digestion the blocks were removed from the tubes and 
placed in the wells of a 1% pulse-field-certified agarose gel in TBE, using a sterile 
wire loop. The gel was electrophoresed in TBE buffer at 14°C and 200V for 20h, 
with pulsing times of 40s using a CHEF-DR Variable Angle pulse-field 
electrophoresis system. After electrophoresis, the gel was stained with 0.5 µg/ml 
ethidium bromide for twenty minutes and de-stained in HpH2O for ten minutes. 
The gel was visualised and photographed using a UV transiluminator. A NCTC 
8325 control block was added to the end well of each row to act as a molecular 
weight marker.  
 
3.17 Statistics  
Data compared across control and test bacterial populations were analysed using 
the T-test calculated using Microsoft Excel software. 
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4. Results 
4.1 Effects of Extraction Buffer on S. aureus  
The effects of the extraction buffers on MRSA are shown in figure 4.1. Buffer 
JEB1showed no toxic effect against MRSA at any of the concentrations tested. 
Addition of 5 and 25% of JEB1 to growth media appears to increase the growth 
rate of cells over that of unsupplemented growth media. In contrast, buffer JEB2 
inhibited the growth of cells at and above 25%, which could be attributed to the 
inclusion of 1mM EDTA in the buffer.  From these results, JEB1 was selected as 
the most suitable buffer for the extraction of bio-active compounds from biological 
material.  
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Figure 4.1 Growth curves of MRSA in media supplemented with extraction 
buffer. The growth rate of WBG 8287 cells in (a) 8 g/l bactopeptone 
supplemented with  5% (open triangles), 25% (closed triangles) and 50% (open 
circles) PBS, (b) JEB1 and (c) JEB2 was measured spectrophotometrically over 
15h. Data represents mock inoculated (open squares) and inoculated medium 
(closed squares) respectively. Error bars represent standard deviation of triplicate 
samples.    
 
4.1.2 Antibacterial Activity of Crude Extracts from Plant, Fungal and 
Invertebrate Samples 
Table 4.1 shows the zone of inhibition around the well containing each extract. 
Most of the extracts from fruit, vegetable and fungal material as well as those 
from aloe vera and the green bottle fly larvae showed no inhibitory effect against 
MRSA. Excluding the mint leaf and aloe vera extracts, plant samples with a 
strong aromatic smell such as the bhut jolokia chillies, ginger root, hop flowers 
and garlic bulbs appeared to have a moderately strong inhibitory activity against 
WBG 8287 bacteria. Of the fungal samples, only the Australian honey and scarlet 
bracken fungus showed antibacterial activity. Extracts from the stem and cap of 
the fungus showed similar inhibitory activity.      
 
Table 4.1 Antibacterial activity of biological extracts  
Species Common Name Tissue ZOIa (mm) 
Agaricus 
xanthoderma 
Yellow-staining 
mushroom 
Head 0 
Agaricus 
xanthoderma 
Yellow-staining 
mushroom 
Stem 0 
Aloe vera Aloe vera plant Leaf 0 
Amanita 
xanthocephala 
Vermillion amanita Head 0 
Amanita Vermillion amanita Stem 0 
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xanthocephala 
Armillaria 
luteobubalina 
Australian honey 
fungus 
Head 5 
Armillaria 
luteobubalina 
Australian honey 
fungus 
Stem 4 
Brassica oleracea Cabbage Leaf 0 
Capscium chinese Bhut jolokia chilli Seeds 2 
Capscium chinese Bhut jolokia chilli Fruit 2 
Cucumis sativus Cucumber Fruit 0 
Humulus lupulus Hop plant (Cascade) Hop flower 3 
Humulus lupulus Hop plant (Citra) Hop flower 2 
Humulus lupulus Hop plant (Chinook) Hop flower 3 
Humulus lupulus Hop plant (Summer) Hop flower 3 
Humulus lupulus Hop plant (Topaz Hop flower 3 
Lucilia sericata Green bottle fly Larva 0 
Mentha spicata Spearmint Leaf 0 
Musa acuminata Cultivated banana Skin 0 
Musa acuminata Cultivated banana Fruit 0 
Persea americana Avocado Fruit 0 
Pisolithus 
tinctorius 
Horse dung fungus Head 0 
Pisolithus 
tinctorius 
Horse dung fungus Stem 0 
Pycnoporus Scarlet bracken Head 4 
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coccineus 
Solanum 
lycopersium 
Common truss 
tomato 
Fruit 0 
Tulbaghia 
violacea 
Society garlic Leaf 0 
Tulbaghia 
violacea 
Society garlic Bulb 1 
Zingiber officinale Ginger Root 2 
 aZone of inhibition 
 
In subsequent experiments the antibacterial activity of the extracts towards 
MRSA were analysed by treating WBG 8287 for 1h in growth medium with 
increasing concentrations of extract, after which colony survival was measured 
(Figure 4.2).  Honey fungus and cardamom pod extracts reduced colony survival 
by 95% or more when cells were treated with a 1:1 mixture of extract and growth 
medium. At a ratio of 9:1, honey fungus, cardamom pods and juniper berries 
eradicated all surviving colonies. Extraction buffer controls showed that this was 
due to the toxicity of the extract and not the extraction buffer itself (Figure 4.1). 
Bhut jolokia chilli seeds and Persian lime fruit showed 75.04% and 61.36% 
reduction in surviving colonies respectively when used at a 9:1 ratio 
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Figure 4.2 Survival of MRSA with increasing concentrations of plant and 
fungal extracts. S. aureus WBG8287 treated for 1h in bactopeptone medium 
containing 10% (open column), 50% (closed column) and 90% (striated column) 
of the five most bactericidal tissue extracts. Data represent the percentage 
survival relative to an untreated control. Data represent the mean of triplicate 
tests. Error bars represent standard deviation of triplicate samples.  
 
4.1.4 Proteinase Digest of Plant and Fungal Samples 
Survival of WBG 8287 cells after treatment with proteinase digested extracts and 
mock digested control samples is shown in figure 4.3. Proteinase digestion of 
honey fungus extract had no effect on its activity. Surprisingly, proteinase 
digestion of Persian lime extract appeared to increase its antibacterial activity. 
Juniper berries digested with either proteinase showed a slight loss of inhibitory 
activity. Trypsin and proteinase OB digestion of the bhut jolokia chilli extract 
reduced its antibacterial activity by 59.5% and 34.5% respectively. Cardamom 
pod extracts digested with either proteinase showed complete loss of 
antibacterial activity. 
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Figure 4.3 Survival of MRSA treated with protease digested plant and fungal 
extracts. Survival of S. aureus WBG 8287 treated for 1h with plant and fungal 
extracts (open columns). Extracts digested with trypsin (closed columns) or 
protease OB (striated columns). Open columns represent mock digested 
controls. Survival was measured as a percentage of inoculated bactopeptone 
controls. Data represent the mean of triplicate samples. Error bars represent the 
standard deviation.  
 
Table 4.2 shows the zone of inhibition of the protease digested and mock 
digested hop flowers on WBG 8287 inoculated plates. Most hop flowers treated 
with trypsin or proteinase OB showed no difference in the radius of zone of 
inhibition compared to the mock digested controls. Citra hop flowers showed an 
increase in the inhibition radius by 0.5 mm and summer hops showed an 
increase in radius of 1 mm when treated with trypsin and proteinase OB 
respectively.     
 
Table 4.2 Zone of inhibition around proteinase treated hop extracts 
Humulus 
lupulus Variety 
Undigested  
(mm) 
Trypsin 
(mm) 
Proteinase 
OB (mm) 
Cascade 3-4 3 3-3 
Citra 2-4 2.5-3 3 
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Chinook 3-4 3 3 
Summer 3-4 3 4 
Topaz 3-4 3 3 
 
4.2.1 Minimal Inhibitory and Minimal Lethal Concentrations of Synthetic 
Antimicrobial Peptides  
Table 4.3 shows the MIC and MLC of antibacterial peptides against S. aureus. In 
bactopeptone medium, the MIC of melittin against WBG 8287 was 3 µg/ml. The 
MIC and MLC of the truncated analogues of melittin could not be determined 
because these peptides were not soluble in bactopeptone medium at 
concentrations above 50 µg/ml (Figure 4.4a). In phosphate buffer and PBS 
melfrag12-26 appeared soluble at all concentrations up to 500 µg/ml. Melittin 
precipitated out of bactopeptone medium at concentrations above 75 µg/ml 
(Figure 4.4b). However, the peptide appears soluble in phosphate buffer and 
PBS at concentrations up to 500 µg/ml. Melittin showed a greater tendency to 
precipitate out of bactopeptone medium than its truncated analogue at 
concentrations below 200 µg/ml. However, at concentrations above 200 µg/ml, 
melfrag12-26 showed much higher absorbance in bactopeptone medium 
compared to melittin. The minimum lethal concentration of bac8c against WBG 
8287 was 7 µg/ml. But against strain W17S and Aus3 it was 80µg/ml. Peptide 
AP1 did not inhibit growth of WBG 8287 at 200 µg/ml. Therefore, the MIC and 
MLC could not be measured for this peptide.     
 
Table 4.3 Minimal inhibitory and minimal lethal concentrations of 
antimicrobial peptides against MRSA     
Peptide MRSA Strain MIC (µg/ml) MLC (µg/ml) 
Melittin 
WBG 8287 3 5 
W17S  NDa 5 
Aus3 ND 5 
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BB ND 5 
Melfrag12-24 WBG 8287 >100b >100 
Melfrag12-
26-L1 
WBG 8287 >50 >300 
Melfrag12-26 WBG 8287 ND >130 
Bac8c 
WBG 8287 ND 7 
W17S ND 80 
Aus3 ND 80 
AP1 WBG 8287 >200 ND 
a Not determined b Minimal inhibitory or minimal lethal concentration exceeded 
highest concentration tested  
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Figure 4.4 Absorbance of melittin and melfrag12-26 in different media. 
Figure 4.4a shows the absorbance of increasing concentrations of melfrag12-26 
in PBS (open squares) phosphate buffer (closed squares) and 8 g/l bactopeptone 
(open triangles). Figure 4.4b shows data from an identical experiment performed 
with melittin. Each point is the mean of triplicate tests with error bars representing 
the standard deviation.    
 
4.2.2 Minimal Lethal and Minimal Inhibitory Concentrations of Melittin, 
Melfrag12-26 and AP1 in Different Media 
The MLC and MIC of melittin against WBG 8287, in different growth media and 
phosphate buffer containing increasing concentrations of NaCl, is presented in 
Table 4.4. Exposure to melittin in PBS showed significantly lower MLC than that 
measured in culture media. Tests in phosphate buffer containing different NaCl 
concentrations confirmed that sensitivity to melittin was inversely proportional to 
salt concentration. The MLC of melittin differed in the three different media and 
the protein concentrations of the three media correlated directly with the 
corresponding MLC (Table 4.4). Salt content was below 1% in all three media. In 
phosphate buffer, melfrag12-26 was lethal to all cells at 35 µg/ml. Figure 4.5 
shows the growth curves of WBG 8287 in the presence of AP1 in bactopeptone 
medium supplemented with MgCl2. Addition of MgCl2 to the medium did not 
increase the inhibitory activity of AP1 against WBG 8287. Cells grown in the 
presence of AP1 had increased growth rates over those grown without AP1. In 
particular, treatment with AP1 in media supplemented with MgCl2 at 15mM 
b) 
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(Figure 4.5c) and 20 mM (Figure 4.5d) greatly increased the growth rate of the 
cells.  
 
Table 4.4 Minimal lethal and minimal inhibitory concentrations of melittin 
peptides in different media 
Media Melittin 
MLC 
( g/ml) 
Melittin 
MIC 
( g/ml) 
Melfrag12-26 MLC 
( g/ml) 
Medium 
Protein 
Conc. 
(µg/ml) 
Bactopeptone 5 3 ND 19.7 
Lysogeny 
Broth 
4 2 ND 17.8 
Brain Heart 
Infusion 
2 1 ND 9.1 
PB 0.5 NDb 35 ND 
PBa + 8 g/L 
NaCl 
3 ND ND ND 
PB + 15 g/L 
NaCl 
5 ND ND ND 
 a Phosphate buffer  b Not determined 
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Figure 4.5 Growth curves of MRSA treated with AP1 in media supplemented 
with MgCl2. WBG 8287 cells were exposed to 0 µg/ml (closed squares) 50 µg/ml 
(open triangles) and 100 µg/ml (closed triangles) of AP1 in 8 g/l bactopeptone (a) 
and bactopeptone supplemented with 10 mM MgCl2 (b), 15 mM MgCl2 (c) and 20 
mM MgCl2 (d) for 15h. Mock inoculated samples of each medium (open squares) 
were negative controls. Each data point represents the mean of three tests. Error 
bars represent the standard deviation of triplicate samples.     
 
4.2.3 Effect of Incubation Temperature on Melittin Susceptibility.  
Survival of bacteria after exposure to melittin was inversely related to the 
temperature during exposure (Figure 4.6). At 0.1 g/ml melittin, survival was 97% 
at 5ºC, but was reduced to 35% at 45ºC. At 0.5 g/ml melittin, 66% survival at 
5ºC was reduced to 5% survival at 45ºC. 
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Figure 4.6 The effect of incubation temperature on the bactericidal activity 
of melittin. WBG 8287 exposed for 1h in 0.1 g/ml (open squares) or 0.5 g/ml 
(closed squares) of melittin in PBS, at different incubation temperatures. Colony 
survival was expressed as the percentage of surviving bacterial colonies 
compared with an untreated control. Data represent the mean of six replicates 
and error bars indicate standard deviation.   
 
4.3.1 Development of Resistance to Melittin and Bac8c 
All strains grown in sub-inhibitory concentrations of the AMPs were able to 
tolerate higher concentrations of the peptides than their wild-type counterparts. 
The four S. aureus strains sub-cultured in increasing concentrations of the 
peptide every 24h had comparable MLCs in bactopeptone to that of cells which 
were sub-cultured every 12h. In these experiments the MLC of melittin against 
WBG 8287, W17S, Aus3 and BB was increased by 34, 30, 32 and 30 fold 
respectively after fourteen subcultures (Table 4.5).  However, when melittin 
resistant WBG 8287 cells were treated with melittin in phosphate buffer the MLC 
dropped from 170 µg/ml to 3 µg/ml. The addition of NaCl at 8 and 15 g/l to 
phosphate buffer increased the MLC of melittin against resistant cells to 5 and 7 
µg/ml respectively (Table 4.5). However, even at 15 g/l NaCl, the MLC of melittin 
against resistance cells was 7 µg/ml, which is similar to the MLC of 5 µg/ml of 
melittin against wild-type cells treated in bactopeptone. After seven days sub-
culture in the presence of bac8c, WBG 8287 could survive in concentrations of 
the peptide 24-fold higher than that tolerated by the wild-type population. With the 
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same level of exposure to bac8c as WBG 8287, the MLC of bac8c against strains 
W17S and Aus3 increased to 170 µg/ml and 150 µg/ml respectively (Table 4.5). 
However, due to the high MLC of bac8c required to kill wild-type strains of W17S 
and Aus3, this only corresponded to a MLC increase of 2.1 and 1.9-fold 
respectively. The anionic peptide AP1 did not affect the growth of melittin 
resistant WBG 8287 at concentrations up to 150 µg/ml (Figure 4.7). In fact, the 
growth curves show that, over 10h, cells treated with 150 µg/ml AP1 have almost 
identical growth rates as untreated bacteria.   
 
Table 4.5 Minimum lethal concentration of melittin and bac8c against MRSA 
with induced resistance to the peptides in different media  
MRSA 
Strain 
Culture Medium 
Melittin MLC 
( g/ml) 
Bac8c MLC 
( g/ml) 
WBG 
8287 
Bactopeptone 170 160 
PB 3 NDa 
PBa + 8 g/l NaCl 5 ND 
PB + 15 g/l NaCl 7 ND 
W17S Bactopeptone 150 170 
Aus3 Bactopeptone 160 150 
BB Bactopeptone 150 ND 
a Phosphate buffer b Not determined 
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Figure 4.7 Growth of melittin resistant bacteria with AP1. Melittin resistant 
WBG 8287 was grown in 8 g/l bactopeptone with 50 µg/ml (open squares), 100 
µg/ml (closed squares) and 150 µg/ml (open triangles) of AP1.Growth was 
measured over 10h using a spectrophotometric plate reader. A mock inoculated 
(open circle) and a zero-AP1 control (closed circles) was run with the test 
samples. Each data point is the average of six replicates and error bars represent 
the standard deviation.  
 
4.3.2 Investigation of Outer Cell Surface Damage After Antimicrobial 
Peptide Treatment 
Wild-type and melittin resistant bacteria were exposed to 10 µg/ml of melittin and 
then examined by SEM. This concentration of melittin was chosen for its known 
toxicity against wild-type cells so that if melittin was causing surface damage this 
could be observed. Prior to melittin exposure wild-type cells had a ruffled surface 
with no visible signs of morphological damage (Figure 4.8a,b). The development 
of melittin resistance caused no discernable changes in the external appearance 
of resistant bacteria (Figure 4.8e,f). After exposure to 10 g/ml of melittin for 1h, 
wild-type strains showed major structural changes (Figure 4.8c,d) ranging from 
protrusions or ―blebs‖ on the cell wall to major disintegration of cellular structure. 
Under the same conditions, WBG 8287 cells made resistant to melittin showed 
occasional surface blebs but none displayed major loss of structural integrity 
(Figure 4.8g,h).     
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Figure 4.8 Scanning electron microscopy images of wild-type and melittin 
resistant MRSA. (a, b) untreated wild-type and (e, f) untreated melittin-resistant 
WBG 8287 cells in PBS, (c, d) wild-type bacteria treated with 10 g/ml melittin 
and (g, h) melittin resistant WBG 8287 cells treated with 10µg/ml melittin in PBS.   
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4.3.3 Binding Affinity of Eosin Dye and Bacterisense 641 to Wild-type and 
Melittin Resistant Cells 
Melittin resistant bacteria treated with eosin dye showed significantly higher 
absorbance at 490nm than wild-type cells (Figure 4.9: P<0.005). To test if this 
difference was due to a change in electrostatic potential, wild-type and resistant 
cells were treated with the cationic fluorescent probe, Bacterisense 645, and the 
fluorescent intensity was measured using flow cytometry (Figure 4.10). Binding of 
Bacterisense 645 to the surface of melittin-resistant MRSA was 5.3-fold lower 
than that of the parental population (P 0.001: Table 4.6). Consistent with 
previous findings (311, 312), the increased tolerance to melittin was attributable 
at least partly to a reduction in negative-charge density on the outer bacterial 
surface. 
 
Figure 4.9 Absorbance of wild-type and melittin resistant cells stained with 
eosin. WBG 8287 cells naïve (closed columns) and resistant (striated columns) 
to melittin were diluted to 2.5 x 107, 1.5 x 107, and 5 x 106 CFU/ml and stained 
with eosin. Each suspension was analysed spectrophotometrically at 490nm.  
Data represents the mean of nine tests and error bars show standard deviation. 
Statistical significance was determined using the T-test. (*) P ≤ 0.01, (**) P≤ 
0.005. 
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Figure 4.10 Flow cytometry of Bacterisense 645 bound to melittin naïve and 
resistant S. aureus WBG 8287. Closed plot:  parental strain, open plot area: 
melittin resistant strain. Data show the mean of nine measurements for each cell 
type.  
 
Table 4.6 Mean fluorescent intensity of bacterisense bound to wild-type and 
melittin resistant cells 
Strain 
WBG 8287 
Mean Fluorescent 
Intensity 
Standard 
Deviation 
P Value 
Wild-type 34099 3952 
P ≤ 0.001 
Resistant 6445 2489 
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4.3.4 Rapid Loss and Gain of Resistance in Populations of MRSA 
Melittin resistant WBG 8287 cells were cultured for seven days in bactopeptone 
medium without melittin. A control culture of the same population was grown in 
parallel with 12 µg/ml of melittin. The results are summarised in table 4.7. The 
melittin resistant population of WBG 8287 showed 100% survival when exposed 
to 3 g/ml melittin in bactopeptone medium.  However, after growth for 24h in 
bactopeptone medium without melittin, the same treatment resulted in only 46% 
survival (Figure 4.11: P 0.001).  A further six daily subcultures without melittin 
reduced the MLC to 30 g/ml and decreased the MIC to 6 g/ml (Figure 4.12).  
However, if this reversion population was cultured in media with 12 g/ml of 
melittin for 24h, the MLC of melittin against the surviving bacteria is increased to 
100 g/ml: i.e. 58.8% of the MLC of the most resistant population. In an identical 
experiment performed with bac8c resistant WBG 8287, the MLC was reduced 
from 160 µg/ml to 110 µg/ml after seven days culture without the peptide (Table 
4.7).  
 
a) 
b) 
111 
 
0.05
0.07
0.09
0.11
0.13
0.15
0.17
0 2 4 6 8 10
A
b
s
o
rb
a
n
c
e
 @
 6
0
0
 n
m
Time (h)
Figure 4.11 Survival of melittin-resistant bacteria cultured with and without 
melittin for seven days. (a) Survival of WBG 8287 cultured without melittin and 
exposed to 3 µg/ml (open circles), 6 µg/ml (closed circles) and 12 µg/ml (open 
squares) of melittin on days 0, 1, 4 and 7 respectively. Survival is expressed as a 
percentage of untreated controls. (b) Results of a similar experiment on a 
resistant population that was maintained in media containing 12 µg/ml melittin. 
Data are from two experiments with 3 replicates per experiment and Error bars 
represent the standard deviation.  
 
Figure 4.12 Growth of melittin-resistance reversion WBG 8287 in the 
presence of melittin. Growth in the presence of melittin at 3 g/ml (open 
squares), 4 g/ml (closed squares), 5 g/ml (open triangles), and 6 g/ml (closed 
triangles), control culture without melittin (closed circles) and mock inoculated 
control (open circles) over 10h. Data represent the mean of triplicate samples 
and error bars show standard deviation.  
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Table 4.7 Minimum lethal concentrations of antimicrobial peptides for 
resistant WBG 8287 and reversion/recovery populations 
Population MLC µg/ml 
Melittin Resistant 170 
Melittin Reversion 30 
Melittin Recovery 100 
Bac8c Resistant 160 
Bac8c Reversion 110 
 
4.4.1 Transmembrane Transport of Antimicrobial Peptides into MRSA  
Antimicrobial peptides were transported into MRSA strain WBG 8287 by 
electroporation to test for intracellular inhibitory activity.  All cells electroporated 
with the peptides had a significantly reduced survival rate compared to the 
controls (Figure 4.13a-c: P<0.05). Electroporation with melittin and melfrag12-26 
reduced the number of surviving colonies by 24.56% and 79.01% respectively 
compared with mock electroporated controls. The results for control populations 
electroporated with bac8c varied sufficiently that the difference between test and 
control populations reached only borderline significance (P=0.053).  
 
a) 
113 
 
0
10
20
30
40
50
60
70
80
90
100
Untreated 
Electroporated
Non-Electroporated Electroporated Treatment 
After Electroporation
P
e
rc
e
n
t 
S
u
rv
iv
a
l
 
 
Figure 4.13 Electroporation of MRSA with antimicrobial Peptides.  
(a) Electrocompetent WBG 8287 cells treated with 2.5 µg/ml melittin, (b) 50 µg/ml 
melfrag12-26 or (c) 2 µg/ml bac8c and then immediately electroporated. Colony 
survival was measured and expressed as a percentage of surviving colonies 
relative to an untreated, unelectroporated control. Data represent the mean of six 
samples and error bars represent the standard deviation. The significance of the 
difference between each sample and the control samples was calculated using 
the Pairwise t-test. (*) P ≤ 0.05. (**)P ≤ 0.001. 
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4.4.2 Effects of Triton X-100 on the Toxicity of Antimicrobial Peptides 
Six populations of WBG 8287 bacteria were treated with melfrag12-26 in 
bactopeptone medium with a range of concentrations of the detergent Triton X-
100. Cells cultured in the presence of Triton X-100 had the same survival rates 
as the controls without Triton X-100 (Figure 4.14). Most samples treated with 
melfrag12-26 and cultured with Triton X-100 showed significantly reduced 
survival, compared to the controls. Increased concentrations of Triton X-100 
correlated with decreased survival of cells exposed to the peptide (Figure 4.14). 
The exception to this trend was cells grown with melfrag12-26 plus 0.05% Triton 
X-100 which did not appear to be affected by the peptide. The MLC for cells 
treated with melittin, melfrag12-26 and bac8c in bactopeptone containing 0.1% 
and 0.005% Triton X-100 is presented in table 4.8. The MLC of melittin 
decreased by 30% and 45% when cells were treated with 0.1% and 0.005% 
Triton X-100 respectively. In bactopeptone, 130 µg/ml of melfrag12-26 reduced 
the surviving population of WBG 8287 cells to 5% of the controls. When the 
peptide was administered in bactopeptone supplemented with 0.005% or 0.1% 
Triton X-100 the MLC was 80 µg/ml and 25 µg/ml respectively. In 0.005% Triton 
X-100, the MLC of bac8c was 4.7 µg/ml and in 0.1% Triton X-100, the MLC was 
reduced to 2.6 µg/ml.   
 
Figure 4.14 Exposure of MRSA to melfrag12-26 plus Triton X-100. WBG 8287 
cells exposed for 1h to 50 µg/ml melfrag12-26 in medium supplemented with 
Triton X-100 (Closed bars) or cultured in Triton X-100 supplemented medium 
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without melfrag12-26 (open bars). Survival was calculated relative to untreated 
controls cultured in bactopeptone without Triton X-100. Data represent the mean 
of three samples and error bars show the standard deviation.  
 
Table 4.8 Minimum lethal concentration of antimicrobial peptides against 
WBG 8287 in bactopeptone supplemented with Triton X-100 
a 8g/l bactopeptone b Triton X-100 
 
4.4.3 Haemolytic Potential of Triton X-100 in Combination with 
Antimicrobial Peptides 
The pertinence of Triton X-100 on the haemolytic potential of the AMPs was 
investigated using human red blood cells. In PBS, 5 µg/ml of melittin was the only 
sample that showed any substantial increase in absorbance from erythrocyte 
lysis, compared to the untreated control (Figure 4.15a). Likewise, in PBS 
supplemented with 0.005% Triton X-100, only erythrocytes treated with melittin 
showed significant lysis compared to the untreated control (Figure 4.15b). There 
was little change in the absorbance of samples containing untreated cells or cells 
in PBS supplemented with 0.005% Triton X-100 alone.   
 
 
 
 
Peptide 
BPa 
(µg/ml) 
BP + 0.005% 
Tx100b (µg/ml) 
BP + 0.1% 
Tx100 (µg/ml) 
Melittin 5 3.5 ± 0.55 2.75 ± 0.27 
MelFrag12-26 >130 80 ± 0 25 ± 0 
Bac8c 7 4.67 ± 0.52 2.58 ± 0.49 
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Figure 4.15 Haemolysis assay of antibacterial peptides with Triton X-100.  
(a) Red blood cells were exposed to 5 µg/ml of melittin, 130 µg/ml of melfrag12-
26 or 6 µg/ml of bac8c in PBS. (b) Cells were treated with 2.5 µg/ml of melittin, 80 
µg/ml of melfrag12-26 and 4 µg/ml of bac8c in PBS supplemented with 0.005% 
Triton X-100. After incubation the samples were centrifuged and the absorbance 
of the supernatant was measured. The blank sample consisted of PBS with no 
cells. The PBS column represents absorbance of the supernatant from cells that 
were mock treated in PBS. Data represent the mean of three samples and error 
bars represent the standard deviation.      
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4.5.1 Antibiotic Sensitivity of Wild-type and Antimicrobial Peptide Resistant 
MRSA  
The sensitivity of melittin-resistant and wild-type WBG 8287 to 27 different 
antibiotics is shown in figure 4.16. The zone of inhibition radius for each antibiotic 
is presented in table 4.9. Melittin resistance did not increase the tolerance of the 
populations to any antibiotic tested. On the contrary, resistance to melittin 
appeared to sensitize the cells to many of the antibiotics tested, by varying 
degrees. The zones of inhibition created by cephalexin, fusidic acid, imipenem 
and tetracycline were greater for melittin-resistant cells than for wild-type cells, by 
5 mm or more. However, wild-type cells exposed to fusidic acid appeared to have 
a halo of partial clearing around the discs. This area was approximately the same 
size as the zone of inhibition seen for melittin-resistant cells around fusidic acid 
discs. This may indicate that the wild-type culture consists of a mixed population 
of fusidic acid sensitive and resistant cells.      
b) 
a) 
a) 
Wild-type Resistant 
Naive Resistant 
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Figure 4.16 Antibiotic sensitivity of MRSA. Melittin-naïve and resistant S. 
aureus WBG 8287 was grown on bactopeptone agar plates on which 27 different 
antibiotic discs were placed. The number on each disc corresponds to the 
antibiotic listed in table 4.9. 
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Table 4.9 Antibiotic sensitivity of melittin sensitive and resistant MRSA 
Number Antibiotic Conc.(µg) 
Wild-
type 
ZOIa 
(mm) 
Stde
v 
(mm) 
Resistan
t ZOI 
(mm) 
Stde
v 
(mm) 
2 Ampicillin 10 0 NAb 0 NA 
1 Amoxicillin 30 0 NA 0 NA 
8 Augmentin 60 2 NA 2 NA 
17 Cefaclor 30 0 0 0.3 0 
7 Cefoxitin 10 1.5 NA 3 NA 
6 Cephalexin 100 3.7 NA 9 NA 
18 Ciprofloxacin 2.5 9.3 1.21 11.2 0.7 
5 Chloramphenicol 10 2.5 NA 2 NA 
4 Erythromycin 15 0.5 NA 1 NA 
3 Fusidic Acid 10 3.1 1.75 18.6 6.36 
19 Gentamicin 10 4.7 0.6 5 0 
9 Imipenem 10 15.5 2.4 23 5.66 
16 Kanamycin 30 6.5 NA 7 NA 
20 Nalidixic acid 30 3.5 1 7.3 1.4 
21 Nitrofurantoin 5 9.3 0.6 10.3 0 
22 Norfloxacin 10 11.3 1.2 14.3 0 
13 Oxacillin 1 0 0 0 0 
15 Penicillin 9.91 1.5 0.7 1 0 
120 
 
14 Polymyxin B 35.7 3 1.4 3.4 0.7 
23 Rifampicin 1 9 0 12.3 0 
12 Streptomycin 10 4 NA 4 NA 
11 Sulfamethoxazole 25 8.5 NA 8 NA 
24 Tetracycline 10 12.3 0.5 16.3 0 
25 Ticarcillin 75 1.8 1.5 3 0 
26 Tobramycin 10 3.5 1 5.7 0 
27 Trimethoprim 5 2.3 1.5 0.7 1.4 
10 Vancomycin 5 3.5 2.12 3 0 
aZone of inhibition 
bNot applicable as samples tested in duplicate 
 
4.5.2 Fusidic Acid Resistance Loss in Antimicrobial Peptide Resistant 
MRSA 
As wild-type WBG 8287 cells already appeared sensitive to fusidic acid, before 
the MLC of fusidic acid was determined, all strains were grown with sub-lethal 
doses of fusidic acid to increase their resistance to the antibiotic. There was a 
large degree of variation in the MLC of fusidic acid between strains (Table 4.10). 
Contrary to previous findings, resistance to melittin did not affect the sensitivity of 
WBG 8287 or BB strains to fusidic acid. In contrast, strains W17S and Aus3 
showed a significant decrease in the MLC of fusidic acid as they became more 
tolerant to melittin (Table 4.10). At 250 µg/ml, the highest concentration of fusidic 
acid tested, the growth of W17S was greatly inhibited. However, the bacteria 
were still able to survive at this concentration. The MRSA strains that were made 
resistant to bac8c also appeared to be more resistant to fusidic acid (Table 4.11). 
The MLC of fusidic acid for WBG 8287 and Aus3 increased by 70.8 µg/ml and 
17.8 µg/ml respectively over that of bac8c naïve cells. Bac8c resistant W17S 
showed similar levels of survival in 250 µg/ml fusidic acid as that of its naïve 
counterpart.  
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Table 4.10 Minimal lethal concentration of fusidic acid against melittin naïve 
and resistant MRSA 
Strain Population MLC (µg/ml) Stdev (µg/ml) P-Value 
WBG 8287 
Naïve 19.22 1.72 
0.7 
Resistant 21.67 9.83 
W17S 
Naïve >250a 0 
<0.001 
Resistant 96.67 5 
Aus3 
Naïve 101.11 3.33 
<0.001 
Resistant 66.67 15.81 
BB 
Naïve 156.67 18.03 
1 
Resistant 156.67 18.03 
a Minimal lethal concentration exceeds highest concentration of fusidic acid 
tested  
    
Table 4.11 Minimal lethal concentration of fusidic acid against bac8c naïve 
and resistant MRSA 
Strain Population MLC (µg/ml) Stdev P-Value 
WBG 8287 
Naïve 19.22 1.72 
<0.001 
Resistant 90 0 
W17S 
Naïve >250a 0 
1 
Resistant >250a 0 
Aus3 Naïve 101.11 3.33 <0.001 
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Resistant 118.89 3.33 
a Minimal lethal concentration exceeds highest concentration of fusidic acid 
tested  
 
4.5.3 PCR Analysis of Fusidic Acid Resistance Genes  
Amplification of the fusidic acid resistance genes FusB and FusC was attempted 
in WBG 8287, W17S, Aus3 and BB strains that were naïve or resistant to melittin 
(Figure 4.17).  Of the four naive strains tested, only WBG 8287 yielded an 
amplification product with the FusB/FusC primers (Figure 4.17: lanes 1 and 10). 
The FusB/C genes were also able to be amplified from melittin-resistant WBG 
8287 strains (Figure 4.17 Lanes 2 and 11). Melittin naïve Aus3 appeared to carry 
both FusB and FusC genes (Figure 4.17: lanes 5 and 14). However, these genes 
could not be amplified with the primers tested, from melittin resistant Aus3 
bacteria (Figure 4.17: lanes 6 and 15). Amplification of FusB and FusC could not 
be achieved with DNA from strains W17S or BB regardless of whether they were 
naïve or resistant to melittin.  
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Figure 4.17 FusB (top row) and FusC (bottom row) gene sequences 
amplified from melittin naïve and resistant MRSA. Data-represent three 
separate experiments. 
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Lane Sample Lane Sample 
Lane L Ladder Lane 10 WBG 8287 Naïve 
Lane 1 WBG 8287 Naïve Lane 11 WBG 8287 Resistant 
Lane 2 WBG 8287 Resistant Lane 12 W17S Naïve 
Lane 3 W17S Naïve Lane 13 W17S Resistant 
Lane 4 W17S Resistant Lane 14 Aus 3 Naïve 
Lane 5 Aus 3 Naïve Lane 15 Aus 3 Resistant 
Lane 6 Aus 3 Resistant Lane 16 BB Naïve 
Lane 7 BB Naïve Lane 17 BB Resistant 
Lane 8 BB Resistant Lane 18 FusC Nega 
Lane 9 FusB Nega   
aReaction mix containing no bacterial DNA 
 
Figure 4.18 shows a representative FusB/C PCR profile from four independent 
DNA extractions from bac8c naïve and resistant S. aureus strains. Both primer 
sets were able to amplify a product from wild-type WBG 8287 DNA. Similarly, 
FusB amplification was consistently observed in resistant WBG 8287 cells. 
However, FusC amplification was observed in only three out of the four DNA 
extracts for these strains. The FusB/FusC amplification profile of bac8c-naïve 
W17S and Aus3 cells conflicted with previous findings in this study. In some 
cases, the ability to amplify the resistance genes varied between colonies of the 
same population. FusB amplification was achieved from all wild-type W17S DNA 
extracts but was only achieved from three out of the four extracts of resistant cell 
DNA. In two of the four DNA extracts from wild-type and resistant Aus3 bacteria, 
FusB amplification was observed whereas FusC amplification was not achieved 
for either population.  
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Figure 4.18 FusB (top row) and FusC (bottom row) gene sequences 
amplified from bac8c-naïve and resistant MRSA. Data represents four 
separate experiments. 
 
Lane Sample Lane Sample 
Lane L Ladder Lane 7 WBG 8287 Naïve 
Lane 1 WBG 8287 Naïve Lane 8 WBG 8287 Resistant 
Lane 2 WBG 8287 Resistant Lane 9 W17S Naïve 
Lane 3 W17S Naïve Lane 10 W17S Resistant 
L 1 2
1 
3 4 5 
10 11 12 
6 L 
10 11 12 L L 
1517 bp- 
1200 bp- 
900 bp- 
600 bp- 
100 bp- 
1517 bp- 
1200 bp- 
900 bp- 
600 bp- 
100 bp- 
L 7 8
1 
9 10 1
1 
 1
2 
L 
126 
 
Lane 4 W17S Resistant Lane 11 Aus 3 Naïve 
Lane 5 Aus 3 Naïve Lane 12 Aus 3 Resistant 
Lane 6 Aus3 Resistant   
 
4.6.1 Acticoat Treatment of MRSA  
Figure 4.19 shows that when Acticoat was placed on MRSA-inoculated agar 
plates, the silver nanoparticles were able to spread through the agar and inhibit 
growth within 1 mm of the material. In subsequent experiments, WBG 8287 was 
overlain with pieces of Acticoat or filter paper (negative controls) on textured agar 
plates (Figure 4.20: 1a-1d). On plates with striated or creased textures (Figure 
4.20: 1b, 1d) the level of inhibition from Acticoat was similar to that observed on 
agar with a flat surface (Figure 4.20: 1a). On blistered agar, significant growth of 
bacteria was observed underneath and around the Acticoat in some tests (Figure 
4.20: 1c). After exposure times of 24, 48 and 72h, the Acticoat and filter paper 
strips were lifted from the plate and placed for ten seconds on a fresh agar plate 
to measure transference of surviving bacteria (Figure 4.20: 2a-2d). Acticoat from 
all plates showed transference of viable bacteria indicating that bacteria can 
survive on the surface of the gauze. Despite the observations of bacterial growth 
under the Acticoat, samples lifted from the blistered agar were found to transfer 
fewer bacteria than those lifted from a flat surface (Figure 4.20: 2c), while 
samples from the creased agar transferred the most (Figure 4.20:2d). It appeared 
that Acticoat in contact with the inoculated plate for three days generally carried 
more bacteria than those removed at days one and two. However, the 
relationship between exposure time and the extent of transference was not 
clearly defined. 
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Figure 4.19 Acticoat Treatment of MRSA on agar plates. (a) Wild-type WBG 
8287, (b) W17S, (c) Aus3 and (d) BB strains were overlain with acticoat on agar 
plates. 
 
 
 
 
 
 
 
 
 
a) b) c) d) 
** * 
1a) 1b) 
1c) 1d) 
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Figure 4.20 Acticoat treatment of MRSA on textured agar plates. WBG 8287 
populations were spread on agar plates with (a) flat, (b) striated, (c) blistered and 
(d) creased surfaces. Strips of Acticoat (*) and sterile filter paper (**) were placed 
onto the inoculated surface for 24, 48 and 72h (columns left to right respectively: 
1a-d). After incubation the strips were lifted carefully from the plate and placed 
briefly onto fresh agar plates which were incubated for 24h (2a-d). Columns show 
triplicates of each test sample. 
 
4.6.2 Scanning Electron Microscopy Analysis of Acticoat and Attached 
Bacteria 
Wild-type WBG 8287 were over-lain with Acticoat on agar plates with either flat or 
striated surfaces for 24, 48 and 72 hours (Figure 4.21: c-d, g-h and k-l and e-f, i-j 
2a) 2b) 
2c) 2d) 
* ** 
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and m-n respectively). The Acticoat surface was seen under the microscope to 
consist of a network of raised nodes each connected to five other nodes by a 
lattice of connecting arms (Figure 4.21: a, e, g and m). When viewed under SEM, 
the Acticoat surface has a rough or grainy texture with irregular dimples spaced 
across its surface (Figure 4.21: b). Over the three days of exposure, bacterial 
clusters, 1-5 cells in height, accumulated on the arms of Acticoat that was in 
contact with the cells on agar with a flat surface (Figure 4.21: c, h and l). Acticoat 
from both flat and striated agar surfaces showed dense clusters of cells in their 
nodes (Figure 4.21: k, f and j). In some cases, these bacterial protrusions could 
be observed from a relatively low magnification (Figure 4.21: e, i and m). When 
viewed at a high magnification, cells showed little or no surface damage (Figure 
4.21: d, l and n). However, there was the occasional cell that showed severe 
disruption to its structural integrity (Figure 4.21: d). The density of cells in the 
bacterial clusters did not appear to be affected by the length of Acticoat exposure 
time. Likewise, the cells from all samples showed undamaged surfaces indicating 
that up to three days exposure did not affect the health of the cells.  
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a) b) 
c) d) 
e) f) 
g) 
h) 
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Figure 4.21 Scanning electron microscopy images of Acticoat from overlay 
experiments with MRSA. WBG 8287 on bactopeptone agar plates with a flat 
texture were treated with Acticoat strips for 24 (c, d), 48 (g, h) and 72h (k, l). In a 
parallel experiment, cells were treated on striated agar plates for 24 (e, f), 48 (i, j) 
and 72h (m, n). After incubation the strips were prepared and viewed using SEM. 
Acticoat strips that had not been exposed to bacteria were used as a negative 
control (a, b)  
 
4.6.3 Exposure of MRSA to Acticoat on Pig Skin; Transfer of Viable Bacteria 
from Acticoat Surface 
Bacteria were grown on pig skin and covered with Acticoat to measure the 
efficacy of the gauze when treating cells in situ. Figure 4.22 shows that viable 
bacteria were transferred from the surface of the gauze when the strips were 
blotted onto fresh agar. The number of S. aureus WBG 8287 cells transferred 
i) j) 
k) l) 
m) n) 
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from pig skin to culture plates by Acticoat (Figure 4.22a) was similar to that from 
filter paper controls (Figure 4.22b) Transfer from pig skin was visibly greater than 
was from agar plates. Acticoat that was encased in agar or agarose to form an 
antimicrobial disc (Figure 3.5), also showed transference of bacteria from 
inoculated pig skin to fresh agar plates (Table 4.12). However, in most of these 
samples there appeared to be a rectangular region underneath the location of the 
Acticoat that showed no transference of bacteria. It appears that the gel casings 
may improve the activity of Acticoat, but the diffusion of silver at bactericidal 
concentrations is limited to regions that are directly inferior to the gauze strips. 
Experiments in which antimicrobial agents were added to the agar or agarose 
with the Acticoat did not increase the antibacterial activity of Acticoat over those 
made with just HpH2O.   
 
 
 
 
 
 
 
 
Figure 4.22 Transference of MRSA from Acticoat after 24h on MRSA 
inoculated Pig Skin. The epidermal layer of pig skin was infected with WBG 
8287 and immediately treated with Acticoat or sterile filter paper strips. After 24 
hrs incubation, the Acticoat (a) and filter paper (b) strips were blotted onto a fresh 
agar plate to measure transference of bacteria 
 
 
 
 
 
a) 
b) 
10mm 
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Table 4.12 Transference of MRSA from Acticoat encased in gels 
 
4.6.4 Exposure of MRSA to Acticoat on Pig Skin; Bacterial Survival Beneath 
and on the Surface of Acticoat 
The percentage of bacteria surviving on pig skin and on the Acticoat was 
measured over 24h of treatment and is shown in Figure 4.23. Despite a large 
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degree of variation in the results among independent tests, it appeared that 
growth of cells was largely inhibited for the first 8h after placement of Acticoat. 
However, after 24h the cells growing underneath the Acticoat appeared to 
outnumber those growing on the pig skin controls which were inoculated but had 
no Acticoat overlay by a factor of 2.3. In contrast, the number of surviving cells on 
the Acticoat surface after 24h corresponded to 11.9% of that of the controls.  
 
 
 
 
 
 
 
 
Figure 4.23 Survival of MRSA on pig skin and Acticoat over time. Survival on 
Acticoat treated pig skin (open squares) and the Acticoat strips (closed squares) 
is expressed a percentage of cells relative to cells grown on pig skin without an 
Acticoat overlay. Each data point is the mean of twelve replicates over four 
separate experiments. Error bars show standard deviation.   
In subsequent experiments, the wetting agents glycerol (Figure 4.24a) and 
Tween-20 (Figure 4.24b) were applied to the Acticoat prior to application to 
MRSA.  Exposure of the bacteria to Acticoat plus glycerol or Tween-20 resulted 
in a 100% mortality rate of cells on the surface of the gauze. Application of 1% 
glycerol to the Acticoat strips reduced bacterial survival on the pig skin samples 
to 38.3% of the HpH2O-coated controls and increasing concentrations reduced 
survival to 0% (Figure 4.24a). In contrast, Tween-20 did not reduce the number 
of surviving bacteria on the pig skin samples when applied at concentrations of 
10% or 20% and reduced survival only to 45% when applied at 100%.  
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Figure 4.24 Survival of S. aureus WBG 8287 after exposure to Acticoat 
coated with wetting agents. Survival of WBG 8287 after 24h exposure to 
Acticoat, wet with a range of (a) glycerol or (b) Tween-20 concentrations prior to 
placing on S. aureus inoculated-pig skin. Survival of cells on the skin underneath 
the Acticoat (open columns), and on the Acticoat itself (closed columns). Data 
represent the percentage of surviving bacteria relative to those treated with 
Acticoat alone. Values are the mean of data from triplicate samples. Error bars 
show standard deviation between samples.   
Finally, the antibacterial effectiveness of applying glycerol, lysozyme and 
melfrag12-26 or bac8c to Acticoat, was tested on pig skin inoculated with 2 µl of 
WBG 8287 cells at 108 CFU/ml. Glycerol alone and in combination with AMPs 
was able to inhibit all growth on the Acticoat (Figure 4.25a). On pig skin, glycerol 
was more effective at reducing survival of bacteria when used in combination 
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with the AMPs. However, complete inhibition of growth was not observed in any 
of the tests. Lysozyme was not able to eradicate all bacteria from the Acticoat 
either alone or when used in combination with either peptide (Figure 4.25b). 
When used alone, lysozyme reduced the number of viable bacteria on the 
Acticoat surface to 62.5% of the untreated control. When used in combination 
with melfrag12-26, bacterial survival was reduced to 18.75% and when combined 
with bac8c bacterial survival was reduced to 0.03% (Figure 4.25b). Acticoat 
coated with a combination of lysozyme and bac8c or melfrag12-26 did not appear 
to be any more effective than coating Acticoat with only lysozyme at reducing 
bacterial numbers on pig skin.  
The greatest reduction in bacterial survival was observed when Acticoat was 
coated with a combination of glycerol, lysozyme and bac8c or melfrag12-26 
(Figure 4.25c). Acticoat coated with glycerol, lysozyme and melfrag12-26 was 
able to reduce bacterial survival on pig skin and Acticoat by 98.96% and 99.99% 
respectively (Figure 4.25c). No growth was observed on pig skin or Acticoat when 
the gauze was coated with glycerol, lysozyme and bac8c (Figure 4.25c).  
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Figure 4.25 Survival of MRSA on pig skin after treatment with Acticoat plus 
wetting agents and antimicrobial agents. WBG 8287 was overlain with 
Acticoat which was coated with a mixture of (a) glycerol with AMPs, (b) lysozyme 
with AMPs (b) and (c) a combination of glycerol and lysozyme with AMPs. 
Survival of cells (open columns) on the skin  and (closed columns) on the 
Acticoat  after 24 h. Data represent the mean percentage survival of triplicate 
samples relative to untreated control samples. Error bars represent the standard 
deviation.   
 
The absorbance of supernatant from erythrocytes treated with a combination of 
glycerol, lysozyme and melfrag12-26 or bac8c is shown in table 4.13. Samples 
treated with a combination of glycerol, lysozyme and melfrag12-26 had a slightly 
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higher absorbance than that of glycerol and lysozyme. Substituting melfrag12-26 
for bac8c further increased the haemolytic potential; however, this was only 23% 
higher than that of the negative control.  
 
Table 4.13 Haemolytic potential of acticoat coatings 
Test 
Absorbancea 
(405nm) 
Absorbance 
Stdev 
% 
Lysis 
Negative Control 0.042 0.001 0 
1% Triton X-100 2.71 0.21 100 
Glycerol+Lysozyme 0.197 0.114 4.7 
Glycerol+Lyszyme+Melfrag12-26 0.261 0.141 6.2 
Glycerol+Lyszyme+Bac8c 0.97 0.064 23 
aAbsorbance of supernatant after sedimenting cells and debris 
 
4.7.1 Contour Clamped Homogenous Field Electrophoresis 
The genetic profile of each strain used in these experiments was generated at 
the completion of this project by digesting chromosomal DNA with restriction 
enzyme SmaI and exposing the DNA fragments to pulsed field electrophoresis 
(Figure 4.26). WBG 8287 was the only strain that showed any genetic variation 
between populations exposed to melittin, bac8c and fusidic acid (Lanes 1-4). 
Fusidic acid resistant strains of WBG 8287 appeared to increase the size of the 
6th largest fragment from around 180 kilobases to 208 kilobases as shown by the 
arrows (Lane 2). Fusidic acid resistant strains that were exposed to melittin lost 
this apparent insertion in the 6th band while cells exposed to bac8c did not (Lanes 
3 and 4 respectively). The other samples showed no difference in fragment size. 
However, at the quantities of DNA present, the samples showed only moderate 
signal intensity. Therefore it is difficult to determine whether there may have been 
variation between the shorter bands. Lanes 4, 9 and 11 show samples with 
bands of very low signal intensity. These bands were able to be distinguished in 
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the original photo but became less clear in the imported images. The 
questionable bands have been marked with an asterisk (*).       
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Lane 1 
WBG 8287: Melittin Naive 
FDa Naive 
Lane 9 
Aus3: Melittin Naïve 
FD Naive 
Lane 2 
WBG 8287: Melittin Naive 
FD Resistant 
Lane 10 
Aus3: Melittin Naive 
FD Resistant 
Lane 3 
WBG 8287: Melittin Resistant 
FD Resistant 
Lane 11 
Aus3 Melittin Resistant 
FD Resistant 
Lane 4 
WBG 8287: Bac8c Resistant 
FD Resistant 
Lane 12 
Aus3: Bac8c Resistant 
FD Resistant 
Lane 5 
W17S: Melittin Naive 
FD Naive 
Lane 13 
BB: Melittin Naive 
FD Naive 
Lane 6 
W17S: Melittin Naive 
FD Resistant 
Lane 14 
BB: Melittin Naive 
FD Resistant 
Lane 7 
W17S: Melittin Resistant 
FD Resistant 
Lane 15 
BB: Melittin Resistant 
FD Resistant 
Lane 8 
W17S: Bac8c Resistant 
FD Resistant 
Lane C NCTC 8325 
a Fusidic acid 
 
Figure 4.26 Contour-clamped homogenous electric field electrophoresis of 
Genomic DNA from Staphylococcus aureus strains. SmaI digested DNA from 
S. aureus strains separated by pulse field electrophoresis for 21h. Numbers on 
the bottom border correspond to the size of the DNA fragment in kilobases. 
Arrows in lanes two and three indicate a band approximately 200 kilobases in 
size that is absent in the fusidic acid naive or melittin resistant variants of WBG 
8287.  Lanes 4, 9 and 11 show very faint bands marked with a white asterisk (*). 
Lane C represents the CHEF profile of an NCTC 8325 control strain which 
produces bands of well established sizes (313). 
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5. Discussion 
The adaptability of pathogens to inherent and technological defence systems of 
humans is as remarkable as it is dire. Sophisticated immune systems have 
evolved to allow plants and animals to inhabit a world populated with invasive 
microorganisms. However, it seems that for every defensive pathway identified in 
multicellular organisms there is already a resistance strategy developed in 
pathogens. This presents a problem when designing therapeutic agents based 
on antimicrobial material found in nature. If a pathogen has been exposed to an 
antimicrobial agent over a long period of time, chances are it has developed 
resistance mechanisms that allow it to tolerate that compound as well as others 
that have similar biocidal modus operandi. However, the effectiveness of some 
antimicrobial compounds suggests that they have been fine tuned by evolution to 
remain biocidal against a broad spectrum of microbial species. Misuse of these 
compounds in medicine and agriculture has allowed a rapid dissemination of 
resistance throughout the microbial community and may have even compromised 
the future development of antimicrobial drugs.   
Antimicrobial peptides have been proposed as the solution to the declining 
effectiveness of antibiotics (314). Their rapid, broad spectrum and non-specific 
mechanism of action is thought to overcome previously established antibiotic 
resistance strategies as well as limiting the risk of resistance to the peptides 
developing. In practice it is evident that some peptides are able to treat bacterial 
infections without resistance developing, while other studies show that bacteria 
can rapidly develop resistance if exposed to sub-lethal doses of the peptides 
(169-173). The therapeutic applications of AMPs are also limited by their 
potential antigenic characteristics. Immunological clearance of the peptides 
reduces their therapeutic effectiveness inside the body and may induce harmful 
reactions in the patient. In the short-term however, if the potential for resistance 
development can be restricted, it seems that AMPs may prove an effective 
alternative or adjunct to antibiotics for treating topical infections. 
This study aimed to expand our understanding of AMP resistance in MRSA and 
to examine ways the therapeutic potential of the peptides could be improved. 
Initially, the antibacterial activity of a variety of plant and invertebrate samples 
against MRSA was examined. The effectiveness of four different peptides against 
MRSA under different conditions was investigated. In addition, the potential for 
resistance against these peptides to develop in MRSA, the stability of this 
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resistance in a population over time and explanations behind these resistance 
mechanisms were explored. Subsequent experiments investigated strategies to 
counteract resistance. Finally, the effectiveness of AMPs in combination with 
topical therapeutics was explored.  
 
5.1 Screening of Biological Tissue for Anti-MRSA Activity 
The dearth of emerging antimicrobial agents could be addressed by investigating 
antimicrobial compounds and molecules present in nature and improving on 
these by synthetic modifications. These sorts of studies have the benefit of 
potentially identifying compounds with novel mechanisms of action that are rare 
in nature and as such, have not already encouraged a selective bias for resistant 
populations. In this study, a rapid extraction technique for bioactive compounds 
from a broad spectrum of common biological material was developed. It was 
anticipated that screening of these samples would allow the identification of new 
sources and variants of AMPs. 
 
5.1.1 Buffer Development for Bio-active Compound Extraction 
Two solutions were made for extracting antibacterial compounds from 
homogenised samples: JEB1 and JEB2. Both buffers had NaCl concentrations 
that were slightly lower than that of physiological salt levels. This was intended to 
increase the solubility of the extracted proteins and to prevent them aggregating 
through hydrophobic interactions. Glycerol was added to increase the stability of 
the peptide and prevent aggregation. Likewise, a low concentration of DMSO 
was added to each solution to act as a cosolvent and increase the stability of the 
proteins by organising and compacting water molecules onto the surface of the 
protein. This protective effect comes from the high affinity of DMSO for water but 
low preference for binding to the surface of protein molecules. The water 
molecules of the DMSO-water complex strongly bind to the surface of the protein 
due to preferential hydration while the DMSO molecules are displaced from the 
immediate surface of the protein. This helps organise and compact the water 
molecules on the surface of the protein molecule and preserves the protein in its 
native state (315, 316). Finally, EDTA was added to buffer JEB2 to prevent metal 
induced oxidation of the peptides and inhibit the activity of ion-dependent 
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proteases. Both buffers were adjusted to pH 7.8 to increase the stability of 
extracted proteins in solution.  
These buffers were designed to be non-toxic to MRSA and maintain the 
extracted proteins in their biologically-active state so that the extracts could be 
tested without removing the buffer. The toxicity of EDTA at the concentrations 
used in JEB2 made it unsuitable as an extraction buffer for testing biocidal 
potential. Buffer JEB1 was non-toxic and allowed the extraction of active 
antibacterial molecules from biological sources. This study describes a quick and 
simple extraction procedure which was successfully used to indentify 
antibacterial activity in multiple biological samples. It is likely that some of the 
compounds used in the buffer such as NaCl and glycerol could have interfered 
with the extracted molecules and masked their antibacterial activity. Therefore, 
the concentrations of the components of the buffer could be further optimised to 
increase the sensitivity of assays in which the buffer is used. 
 
5.1.2 Identification of Biological Tissue with Antibacterial Activity 
At a time where medicine is under threat of moving to a post-antibiotic era, the 
search for new antimicrobial agents could be advanced by studying established 
medicinal databases. Traditional medicine represents collective knowledge of the 
effectiveness of different treatments based on experiences, creeds and theories 
that are indigenous to a culture (317) Research into the validity of such 
treatments, using evidence based approaches, has so far, been lacking. 
However, the broadly documented customary uses and effectiveness of herbs, 
animal products and minerals provides a substantial collection of data that may 
fast track the search and discovery of new bioactive compounds.  
Based on the results presented in this study it appears that plant samples with 
more aromatic qualities, such as hops, juniper berries and cardamom seeds 
more likely to have bactericidal activity than samples in which the aroma is less 
noticeable. Generally, the volatile compounds which give the plant its ―aroma‖ are 
extracted in the essential oil of the plant. Numerous studies have identified 
antibacterial molecules in the essential oils of plants (318-322). However, 
antibacterial peptides have not been identified in plant oil extracts. The 
experiments presented in this report focused on the antibacterial activity of whole 
crude aqueous extracts of plant material, not just the essential oils. This enabled 
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the use of a non-toxic extraction buffer containing minimal organic solvents, 
which could be used to test for antibacterial activity without influencing the 
results. Fourteen of the thirty-one extracts showed antibacterial activity. Of those, 
C. chinese, E. Cardamomum, and J. Communis appeared to have bactericidal 
activity related to proteinase susceptible components.  
Surprisingly, extracts from the larvae of Lucillia sericata showed no inhibitory 
activity against MRSA. Decomposing material in which L. sericata  larvae feed 
prior to pupation, exposes the larvae to a myriad of bacterial, fungal and viral 
species (323). For this reason, it was hypothesised that for the larvae to persist in 
these environments they would need a significant repertoire of antimicrobial 
defences. Despite the results from this study, it has been shown before that 
secretions from these necrophages have antiseptic activity (324). However, it 
also appears that ingested microorganisms readily colonise the gut of the larva 
(323, 324). The persistence of these microbes continues through to adulthood, 
making the flies transmission vectors for pathogens and may even be the reason 
for the short life spans of the insects (323). It seems then that the pathogenic 
bacteria colonising the flies have already developed strategies to overcome the 
chemical defences of these insects. Therefore, carrion scavenging insects, 
especially those with relatively short life-spans, may not prove to be a reservoir of 
effective antimicrobial agents.    
All Hop flower extracts showed potent inhibition of MRSA that was independent 
of protein-based antimicrobial agents. Historically, hops have not been a 
common ingredient used in medicine, although their ability to prevent the 
spoilage of beverages has been employed since the middle ages (325, 326).  
Humulus lupulus produces three phytochemicals which have previously been 
shown to have antibacterial activity against Gram-positive species: humulone (α-
acid), lupulone (β-acid) and xanthohumol (326). It is believed that the hop acids 
transfer hydrogen ions and divalent cations across the bacterial membrane, 
which undermines the transmembrane proton gradient and disrupts proton 
motive force-dependent nutrient trafficking. This causes membrane leakage and 
impedes respiration and normal metabolism in affected bacteria (327). 
Resistance to hop compounds in bacteria is of major concern to the brewing 
industry as the antibiotic effects of hops are a major protectant against beer 
spoilage (325-328). It is not clear how bacteria resist hop acids, although it does 
appear that resistance may be dependent on a combination of mechanisms (327, 
329, 330). Behr et al. (330) have shown that resistance correlates with an 
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increased lipoteichoic acid content in the cell wall. An increase in the anionic 
charge on the surface of hop-resistant bacteria could increase the affinity of 
cationic AMPs for the cells and enhance their antibacterial activity. Additionally, 
some AMPs have enhanced antimicrobial activity at pH levels similar to that of 
beer. It has been shown that resistance to hop acids relates to the capacity of a  
microorganism to produce the foul-tasting metabolites that spoil beer (331). 
Therefore, if hop resistant strains continue to impact the brewing sector, further 
research into AMPs as sterilization agents in beer could prove cost effective for 
the whole industry. Adding AMPs to the grains in the mashing stage of brewing 
could reduce the chances of bacterial colonisation of the wort. Bacteria which 
survive peptide exposure could be more susceptible to heat-induced destruction 
in the subsequent boiling stage. If the peptides are harmful to humans, the boiling 
stage would likely denature the peptides and inhibit their toxic activity. 
Additionally, creating transgenic brewing yeast strains which produce 
antibacterial peptides could eliminate the costs of producing the peptides while 
protecting the beer throughout the brewing process.         
Two out of the five fungal extracts showed antibacterial activity: scarlet bracket 
fungus (Pycnoporus coccineus) and Australian honey fungus (Armillaria 
luteobubalina). Although, the origin of the antibacterial activity of P. coccineus 
was not explored in this project, it has been documented that Pycnoporus 
species produce phenoxazinone-based antibiotics (332). Protease treatment of 
the A. luteobubalina extracts did not inhibit its antibacterial activity. Armillaria 
luteobubalina is parasitic to trees but is non-toxic to humans if cooked, and may 
contain non-protein based antibacterial compounds that could be safe for 
antibacterial therapy (333, 334). Armillaria luteobubalina has a strong bitter taste 
if eaten raw so it is generally blanched before consumption. This heat treatment 
may inactivate antimicrobial compounds which could explain why its potential 
medicinal qualities have not yet been identified. Further investigation of the 
antibacterial qualities of Australian honey fungus appears warranted 
Extracts from C. chinese seeds and fruit had strong inhibitory activity against 
MRSA. Traditionally, these chillies have been used to alleviate joint pain, asthma 
attacks, toothache and, oddly enough, gastro-intestinal discomfort (335). The 
alkaloid capsaicin constitutes 3-5% of bhut jolokia chillies and has been shown to 
have antimicrobial activity against a broad spectrum of bacteria including S. 
aureus (335, 336). In other studies, C. annuum has been found to contain two 
peptides of 15 and 22 amino acids in length with antifungal activity (337, 338). In 
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this project, the antibacterial activity of bhut jolokia extracts was greatly inhibited, 
but not completely lost, after protease treatment. This suggests that the chillies 
contain a bactericidal compound of proteinaceous origin. Collectively it is likely 
that the antibacterial activity of capsaicin in C. chinese is augmented by one or 
more peptides that could be related to antifungal peptides previously discovered. 
Of the other bactericidal plant extracts, only juniper berries and cardamom seeds 
showed reduction in their antibacterial activity after protease treatment. Lime 
extract activity increased after protease digestion. This may indicate that Persian 
limes synthesise proteins that can be cleaved into smaller fragments that have 
greater antibacterial activity than the full-length protein. The antibacterial activity 
of cardamom seeds was completely lost after treatment with either Trypsin or 
proteinase K. This suggests that cardamom seeds contain bactericidal peptides 
with basic amino acids. In contrast, the antibacterial activity of juniper berry 
extract was inhibited by approximately 80% after exposure to either protease. In 
a study by Pepljnjak et al. (320) it was found that essential oil extracts from J. 
communis had potent broad spectrum fungicidal and bactericidal activity. The 
main compounds in juniper berry oils are the terpenes: α-pinene, β-pinene and 
sabinene all of which have been shown to possess antimicrobial activity (318, 
319). Therefore, as with the bhut jolokia chillies, these results expand on 
previous research to suggest that juniper berries contain antibacterial compounds 
that are both proteinaceous and non-proteinaceous in origin. Further 
characterisation of plant and fungal extract fractions was planned using mass 
spectrometry. Unfortunately time constraints made this impractical. 
It seems logical that drugs designed from novel compounds could be more 
effective at treating multi-drug resistant pathogens than modified versions of 
established antimicrobial agents. However, since the 1930s the rate at which new 
therapeutic agents are introduced into clinical practice has remained stable or 
declined, while the use of derivatives of already established drugs has increased 
(339). The difficulty of getting therapeutic approval for a compound with an 
original molecular structure, compared to a drug that is modelled off a previously 
approved therapeutic, may be influencing antimicrobial drug development. 
Despite this, a recent report has shown that 73% of antimicrobial agents currently 
in clinical development are compounds that have not been designed from 
patented drugs, which suggests this trend may be reversing (289). 
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5.2 Antibacterial Peptide Activity is Dependent on the Treatment 
Environment 
The reduced antibacterial activity of AMPs in different culture media was 
correlated with increased protein concentration of the medium. Survival was 
greatly reduced when bacteria were exposed to melittin or melfrag12-26 in 
phosphate buffer solutions. Previous studies have shown that NaCl can inhibit 
the activity of cationic antimicrobial peptides (340, 341) and these results 
confirmed this. The reduced bactericidal activity seen in growth media, compared 
to phosphate buffer, could be partly attributable to the salt concentration in those 
media. However, the differences observed between media with similar salt 
content, but differing protein content, suggest that media proteins may play a 
dominant role in reducing melittin toxicity. This could be attributable to the 
sequestering of melittin through binding to anionic media peptides and also to the 
reduction of melittin binding sites on the bacterial cell wall by competitive binding 
from cationic media peptides.  
It was also observed that MRSA is more sensitive to melittin at higher 
temperatures. It has been well established that bacteria can increase the amount 
of unsaturated fatty acids in their membrane to retain fluidity at lower 
temperatures (342). However, this is unlikely to be the cause of enhanced 
tolerance to melittin at lower temperatures, because membranes with a lower 
concentration of unsaturated fatty acids have previously been shown to be more 
susceptible to the membranolytic, α-helical AMP: warnericin RK, which has 
similar physiochemical properties to melittin (343, 344). Reinés et al. showed that 
Yersinia enterocolitica was more sensitive to the AMP polymyxin B at higher 
incubation temperatures (186). It was believed this was largely due to the down-
regulation of activity in certain two-component regulatory systems, which allow 
the cells to respond to changes in temperature, osmolarity and pH (186, 345). 
Similar regulatory systems have been identified in S. aureus (345) and their 
down-regulation may contribute to the increased melittin-susceptibility at higher 
temperatures, observed in this study. 
The results in this study show that the presence of exogenous proteins, high salt 
concentrations and low temperatures reduce the bactericidal efficacy of melittin. 
These apparently protective effects suggest that the efficacy of cationic peptides 
for topical treatment of clinical infections could be enhanced by thorough pre-
treatment of the infected area to remove inhibitory molecules. For example, 
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debridement of the wound with a warm, low ionic strength buffer may increase 
the effectiveness of the treatment. Additionally, multiple reports (268, 346, 347) 
have shown that substituting tryptophan and histidine residues with the bulky 
aromatic amino acids β-naphthylalanine and L-(4,4’-phenyl)alanine increased the 
biocidal activity of antimicrobial peptides against fungal and bacterial species in 
media containing high levels of salt. Where control of salt levels is impractical, 
this modification might significantly increase the efficacy of peptide treatment for 
clinical infections. 
In contrast to an earlier report (348), the melittin sub-fragments melfrag12-26 and 
melfrag12-26-L1 showed low toxicity to the S. aureus strains used in this study, 
except in phosphate buffer, and the susceptibility levels observed more closely 
match those reported by Subbalakshmi et al. (349). Likewise, results from 
experiments with the shorter melittin fragment, melfrag12-24, conflicted with 
previous findings (296) with this peptide showing no antibacterial activity against 
S. aureus. In nutrient media, melfrag12-26 showed a solubility limit of 
approximately 100 g/ml and its relatively low efficacy in culture media prevented 
the measurement of a minimum lethal concentration. Melittin also aggregated 
and precipitated at concentrations above 100 g/ml in nutrient media. The 
tendency for these peptides to aggregate at higher concentrations in nutrient 
media might partly explain the higher MLC observed in those media, compared 
with PBS. Melittin is a convenient model peptide, but even topical therapeutic use 
would be better suited by a peptide of similar antibacterial activity without the 
haemolytic function. For this reason the antibacterial activity of melfrag12-26, 
which lacks haemolytic activity was tested in this study. However, its much 
reduced activity, under the conditions used in this study, suggests that it will not 
serve that purpose. 
Experiments using the anionic peptide AP1 showed the peptide had no inhibitory 
activity against MRSA. Supplementing nutrient media with MgCl2 had no effect on 
peptide bactericidal activity. It was believed that the divalent magnesium ions 
might form a bridge between the anionic peptide and the membrane 
phospholipids, thereby increasing the likelihood of the hydrophobic components 
of the peptides interacting with the membrane surface (115, 350). On the 
contrary, treating bacteria with MgCl2 and AP1 increased the turbidity of the 
culture. This may indicate that a combination of AP1 and MgCl2 increased the 
growth rate of S. aureus. Alternatively, MgCl2 could cause AP1 to precipitate out 
of solution which would increase the absorbance of the medium. Surprisingly, 
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despite its opposite net charge, AP1 showed no antibacterial activity against 
melittin resistant MRSA. The results from other experiments in this study showed 
that melittin resistant bacteria have a lower cationic charge than wild-type 
bacteria. Therefore, it was expected that there would be less electrostatic 
repulsion between AP1 and the membrane of melittin resistant bacteria, resulting 
in the peptide being more toxic to these cells. The results from these experiments 
support the hypothesis that MRSA develops other resistance strategies that may 
be unrelated to membrane charge shielding. These resistance mechanisms may 
have evolved to protect bacteria that have masked their anionic membrane 
charges, in response to cationic peptide exposure, against anionic antimicrobial 
agents. The concentrations of AP1 used in this study were far below that of 
Dennison et al. (292) who originally reported the antibacterial properties of the 
peptide. It was believed that, under the conditions used in this study, AP1 would 
be effective at inhibiting the growth of MRSA at low concentrations. Although this 
was not observed, the potential resistance mechanism identified in melittin-
resistant MRSA suggests that these bacteria may become susceptible to AP1 at 
higher concentrations.     
 
5.3 Rapid Gain and Loss of Antimicrobial Peptide Resistance in 
MRSA 
Despite what is suggested in the literature (93, 96, 97), it is unlikely that 
pathogenic microbes would fail to develop tolerance to AMP-based therapeutic 
agents, if they were used inappropriately. In fact, the capability of some bacteria 
to invade, colonise and cause disease in animals suggests that resistance to 
these mammalian antibacterial peptides is already well established in nature. 
This study aimed to characterise the capability of selective pressure from AMP 
treatment, to generate a resistant population of MRSA. To complement this, 
environmental factors that might enhance the protective effects of the developed 
resistance, the likely cause of resistance and whether resistance decreased the 
fitness of the bacteria to other antimicrobial agents was also investigated. It was 
anticipated that the results from these experiments could assist in developing 
strategies to mitigate the protective effect of these AMP-resistance mechanisms. 
Results presented here show that resistance to two AMPs with potent 
bactericidal activity can be readily induced in different strains of MRSA when they 
are exposed to sub-lethal concentrations. These findings, along with similar 
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studies (169, 171, 351), conflict with previous reports which assumed resistance  
against AMPs was unlikely to develop in bacteria with short term exposure (352, 
172, 173). The rapidity with which resistance is initiated and enhanced suggests 
that resistance mechanisms pre-exist within populations of MRSA. Further 
experiments showed that high levels of melittin resistance, developed during 
exposure to sub-lethal concentrations, declined rapidly but not completely in the 
absence of the peptide. This finding is inconsistent with at least one previous 
study (351) which reported resistance to pexiganan in Pseudomonas fluorescens 
and E. coli, remained stable over four days when under no selective pressure. 
Scanning electron microscopy revealed that the resistant cells were markedly 
less damaged by exposure to melittin than the parental bacteria, as predicted 
from the enhanced survival. Nevertheless, protruding membrane vesicles, or 
―blebs‖ were visible on some resistant cells, indicating that melittin was able to 
bind and form transmembrane pores to some extent. Within the parental 
population, a very small proportion of cells appeared less seriously damaged by 
melittin than the majority, possibly with the potential to recover. This raises the 
question of whether a resistant population that is able to survive exposure to high 
concentrations of melittin might arise quickly by favouring growth from a specific 
sub-set of cells within the population.  
This study also showed that growing resistant bacteria without AMP selection 
pressures (reversion bacteria), decreases the MLC of the peptides substantially. 
The minimum lethal concentration, as defined by this study, was the lowest 
concentration of the peptides required to kill off 99.99% of bacteria. A survival 
rate of 0.01% means that one in 10,000 bacteria can survive peptide exposure.  
When the MLC of melittin against the melittin-reversion bacteria was measured, 
the original inoculum contained 2 x 105 CFU. This meant that a maximum of 
twenty cells could possibly have survived at the MLC. Therefore, the sensitivity of 
the assays measuring the MLC may not have been high enough to identify a 
resistant sub-population that persists in reversion bacterial populations. This may 
explain why the MLC of melittin to reversion bacteria exposed to a sublethal dose 
of the peptides for 24h increased to approximately 59% of the MLC of the 
parental resistant population. If a resistant sub-population persists in the 
reversion population, exposure to the peptides could allow these cells to emerge 
as the dominant phenotype in the culture.  
In any case, the rapid loss of resistance suggests that maintaining resistance to 
melittin has a physiological cost that may correlate with increased metabolic 
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demand. Some antibiotic resistant bacteria have slower generation rates or are 
unable to grow on nutrient depleted media. This has been suggested to be the 
cost of metabolic resources from developing antibiotic resistance (353). This is 
not universal between species or even strains of the same species as multiple 
studies have shown some antibiotic resistant bacteria have increased growth 
rates over their parental population in certain media (353-356). Additionally, two 
separate studies have shown that antibiotic resistant bacteria persisted in 
patients 1-4 years after treatment (357, 358). This casts doubt on whether the 
metabolic cost of antibiotic resistance must eventually cause a reversion of the 
population to its wild-type state if selection pressures are removed.  
In contrast to these observations with antibiotics, this study has shown that 
resistance to melittin is substantially reduced in a population after seven days 
when melittin is removed. It seems that AMPs have multiple intracellular and 
extracellular bacterial targets (95, 102, 359). Therefore, for bacteria to become 
resistant to AMPs they may have to mutate multiple aspects of their physiology 
and metabolism and this could place multiple demands on bacterial energy 
reserves. A similar dynamic is observed with fluoroquinolone resistance in E. coli 
requiring the acquisition of multiple resistance genes (360). Marcusson et al. 
(360) have shown that an inverse relationship exists between the growth rates of 
the cells and the accumulation of multiple fluoroquinolone resistant mutations. 
This relationship does not always hold true, as a triple mutant with a reduced 
growth rate had a growth rate that was similar to wild-type cells while retaining 
strong antibiotic resistance if a compensatory fourth mutation was acquired (360). 
The rapid loss of resistance to AMPs when peptide selection is removed may be 
because the metabolic cost of increasing pre-existing metabolic processes to 
increase the tolerance of the bacteria to  the peptides allows wild-type cells, 
which do not have these energy demanding phenotypes, to outcompete and 
dominate the population.    
The reduced affinity of a cationic fluorophore, Bacterisense 645, for melittin-
resistant bacteria was consistent with a reduction in the nett negative charge on 
the bacterial surface. This finding was also supported by the increased affinity of 
the anionic dye eosin to melittin resistant bacteria. A previous study has 
demonstrated a correlation between zeta potential and sensitivity to the cationic 
peptide, LL37, across 54 S. aureus strains (361). Multiple peptide resistance 
factor-mediated resistance of S. aureus against AMPs coincides with modulated 
peptide interactions with the bacterial membrane. It has been suggested that the 
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decreased affinity of cationic peptides for the membrane results from 
aminoacylation of negatively charged phospholipid head-groups with cationic 
amino acids, mediated by the mprF (311). The fluorophore-binding experiments 
in the current study confirmed the reduction in negative charge on the outer 
surface of the resistant strain tested, apparently induced by exposure to sub-
lethal doses of melittin. The ability to measure this in culture may be useful in 
future studies of mprF. 
Pulsed-field electrophoresis revealed that, for most strains, melittin resistance is 
not demonstrably dependent on the gain or loss of measurable amounts of DNA. 
Likewise, fusidic acid or bac8c resistance did not change the genetic profile of 
most strains. In WBG 8287, fusidic acid resistance increased the size of the sixth 
largest DNA fragment by about twenty kilobases: demonstrating that a large 
amount of genetic material has been acquired or duplicated in this population. 
Curiously, melittin resistance seemed to cause this additional DNA to be lost, 
while bac8c had no effect. However, loss of this DNA did not affect the cells 
capacity to tolerate fusidic acid, which suggests that this alteration is not 
essential for fusidic acid resistance. In addition, after fusidic acid exposure, WBG 
8287 still seemed to be the most sensitive to the antibiotic. This suggests that 
any large DNA sequences this population has acquired are less effective at 
counteracting fusidic acid than the smaller mutations that seem to have 
substantially increased resistance to the antibiotic in the other strains. It may be 
interesting in future experiments to investigate whether the additional DNA in 
WBG 8287 has homology with any other antibiotic resistance genes and why 
melittin resistance might be incompatible with the pathways and metabolites with 
which this genetic material is associated.  
The reduction of melittin toxicity by salts and proteins analogous to those in 
bodily tissues (341), together with the bacterial capability for quite rapid reduction 
of negative charge on their outer cell wall, could explain why endogenous AMPs 
of eukaryotes may not prevent the spread of infection once it is established. It 
has been suggested that the therapeutic use of antibacterial peptides could 
encourage the development of resistance among target organisms, which could 
stimulate cross-resistance towards endogenous antibacterial defences (282). 
These factors, coupled with the natural immune response to foreign peptides, 
may prevent the effective use of AMPs for the treatment of systemic infections. 
However, the construction of modified or substituted peptide forms might 
overcome these limitations. Perhaps more importantly, the MLC of melittin 
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against resistant bacteria decreased 57-fold when the cells were exposed to 
melittin in phosphate buffer. Therefore, resistance to AMPs may be circumvented 
in a clinical setting by debridement of a wound prior to treatment and rotating 
periods of treatment with different therapeutic agents to maximise the 
antibacterial efficiency of the peptide, which may benefit from any resulting loss 
of resistance.  
 
5.4 Antimicrobial Peptides may have Potent Intracellular Activity 
Until recently, it was believed that the main target of AMPs was the cell 
membrane. It is now becoming evident that the antimicrobial function of 
transmembrane pore formation may be more important in allowing the peptides 
access to intracellular organelles and metabolic processes than in directly killing 
the cell through cytoplasmic leakage. Multiple studies have shown that bacteria 
treated with low concentrations of AMPs do not show signs of pore formation, but 
still show inhibition of metabolic processes (128, 143). For AMPs to form pores in 
bacterial membranes in vivo, a sizeable concentration of the peptides needs to 
be synthesised and transported to the infected region. Therefore, from a 
biological perspective, it makes sense that AMPs affect intracellular processes in 
microbes by diffusing across the membrane rather than forming pores by 
grouping en masse to localised regions of the membrane.  
In this study, it was shown that a peptide with no bactericidal activity in 
bactopeptone medium, melfrag12-26 can significantly inhibit the growth of 
bacteria if transported into the cell by electroporation. Melittin, and an unrelated 
peptide, bac8c, also showed increased bactericidal activity when transported 
inside the cell. It could be suggested the increased antibacterial activity resulted 
from electroporation-induced weakening of the cell membrane. However, bacteria 
exposed to the peptides immediately after electroporation produced no significant 
reduction in survival compared to untreated controls. From these results it 
appears that the eleven amino acids missing from melfrag12-26 are required to 
form pores in bacterial membranes but are not essential for intracellular toxicity. 
As other studies have suggested, the leucine zipper motif of melittin and similar 
peptides promotes dimerization and secondary structure formation (280, 362). 
This may explain why melfrag12-26, which has lost the leucine zipper motif, is 
less haemolytic. It also suggests that without the zipper motif, melfrag12-26 is 
unable to aggregate in solution into complexes that are capable of membrane 
pore-formation. However, the intracellularly active portion of melittin still appears 
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to be present in melfrag12-26 and, once inside the cell, it is bactericidal at 
relatively low concentrations.  
 
5.5 Additive and Synergistic Action between Antimicrobial Peptides 
and Surfactants 
Detergents are amphiphilic surfactants which have a hydrophobic tail and a 
hydrophilic head (363). These molecules solubilise lipid membranes by inserting 
into and partitioning lipid bilayers. This reduces the surface tension between the 
membrane lipids and creates negative curvature on the membrane surface. This 
curvature perturbation thins the hydrophobic portion of the membrane and 
increases the tendency of the membrane to disassociate as micelles (364). The 
types of lipids in the lipid bilayer differs between bacterial and mammalian cells 
(102). In eukaryotic membranes, cholesterol and sphingolipids preferentially 
interact with each other through hydrogen bonding of the ceramide of 
sphingomylelin and the 3-hydroxyl group of cholesterol, or by binding of 
sphingolipid acyl chains to the steroid ring of cholesterol (365, 366). These 
interactions cause the lipids, in regions saturated with sphingolipids, to become 
tightly packed together and reduces their fluidity, increasing their resistance to 
detergent-mediated disorganisation (366, 367). Cholesterol is absent from 
prokaryotic membranes and most bacterial species do not produce sphingolipids 
(367). Therefore, bacterial membranes may be more likely than those of 
eukaryotic cells to become disordered and vulnerable to the pore-forming action 
of AMPs. This vulnerability may be exploited to make the bacteria more 
susceptibility to the peptides by adding a surfactant to weaken the intra-molecular 
forces between the phospholipids.  
Patel et al. (368) have shown that the permeabilizing potential of three different 
lipo-peptide antibiotics towards artificial membrane vesicles was increased in the 
presence of a non-ionic detergent. In another report, the beta-lactam antibiotic 
oxacillin was shown to be more effective against MRSA in the presence of Triton 
X-100 (369). They also showed that Triton X-100 did not affect the penicillin 
binding proteins of the cell or the susceptibility of the cell wall to lytic enzymes 
(370). Triton X-100 may not alter oxicillin resistance levels in the cells as the 
authors suggest (369, 370). Rather, oxacillin-induced inhibition of peptidoglycan 
synthesis may increase the sensitivity of the cells to membrane destabilization by 
Triton X-100.  
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In the present study, investigations into the sensitivity of MRSA to AMPs plus 
surfactants showed that the antibacterial activity of melfrag12-26 increased 
substantially with increasing concentrations of Triton X-100. The antibacterial 
activity of melittin and bac8c was also slightly increased in the presence of Triton 
X-100. The increased bactericidal activity of the AMP in the presence of Triton X-
100 suggests that the detergent permeabilizes the membrane, allowing the 
peptides rapid access to intracellular targets. Alternatively, the disassociation 
forces of both the peptide and detergent could weaken the intermolecular forces 
between phospholipid molecules to de-stabilise the membrane. The specific 
mechanism behind the increased antibacterial activity of the peptides in the 
presence of Triton X-100 or when transported intracellularly with electroporation 
was not investigated. However, bacteria that were electroporated with melittin or 
melfrag12-26 generally had a survival rate that was approximately 40-60% lower 
than those which were electroporated and then treated with the peptides. If 
electroporation was weakening membrane organisation it would be expected that 
these two samples would have the same survival rates. Therefore, these 
experiments suggest that internalisation of the peptides using electroporation or 
detergent-mediated permeabilization is likely the cause of cell death rather than 
lysis. The relatively small increase in bactericidal activity when melittin and bac8c 
were used with Triton X-100 could indicate that the dissociation forces exerted on 
the phospholipids by these peptides may be strong enough that addition of 
another permeabalising agent has only a marginal additive effect on the peptides 
activity. 
 The higher concentrations of Triton X-100 alone proved to be highly haemolytic. 
It seems then that the addition of detergents may reduce the selectivity of AMPs, 
which essentially negates one of the most promising aspects of their use as 
therapeutics. However, at 0.005% Triton X-100, melfrag12-26 and bac8c had no 
haemolytic activity while still showing augmented bactericidal activity. Cholesterol 
molecules in eukaryotic membranes decrease fluidity by filling spaces between 
phospholipids and limiting the movement of membrane fatty acyl chains (371, 
372). It has been shown that artificial membranes devoid of cholesterol are far 
more susceptible to AMP-induced lysis (373, 374). Bacterial membranes are 
devoid of cholesterol and it has been shown that membranes lacking these 
molecules are more susceptible to the perturbations of Triton X-100 (375). This 
could explain why low concentrations of Triton X-100 were able to improve the 
bactericidal activity of these peptides without affecting their haemolytic potential. 
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The use of Triton X-100 and AMPs in combination could allow the peptides to be 
used at concentrations that are non-haemolytic, non-cytotoxic and non-
immunogenic.    
 
5.5 Antimicrobial Peptide Resistance Influences Tolerance to 
Antibiotics 
Initial experiments showed that the sensitivity of melittin resistant WBG 8287 to a 
variety of antibiotics increased in comparison with melittin-naive populations. 
Fusidic acid was chosen for more comprehensive investigations because it was 
considered possible that the negatively charged antibiotic might have greater 
affinity for melittin resistant bacteria. Fusidic acid inhibits bacterial protein 
synthesis by preventing the release of elongation factor G (EF-G) from the 
ribosome, thereby halting the translocation of mRNA and tRNA along the 
ribosome ( 376). The wild-type MRSA strains were highly sensitive to fusidic acid 
even before melittin exposure. Therefore, prior to melittin resistance experiments 
all bacterial strains were made tolerant to fusidic acid by exposing the bacteria to 
sub-lethal concentrations of the antibiotic. The resulting fusidic acid resistance 
was not uniform across strains, with some showing MLCs below 20 µg/ml while 
others showed MLCs over 250 µg/ml. Contrary to previous results, melittin 
resistance did not affect fusidic acid resistance in WBG 8287 and BB bacteria 
exposed to fusidic acid. However, in strains W17S and Aus3, fusidic acid 
resistance was reduced significantly as melittin resistance increased. This 
suggested that while some mechanisms of antibiotic resistance may be 
negatively affected by the development of AMP resistance, others remain 
effective even as the cell alters its structure and metabolism to resist toxic 
peptides.   
Synergism between certain antibiotics and AMPs has been demonstrated before 
(377, 378). Nuding et al. (378) suggested that synergism is due to membrane 
active peptides compromising the outer barrier of the cell and allowing antibiotics 
access to internal targets. If this is the case, combinational therapy may improve 
antibiotic effectiveness against bacteria which alter their membrane permeability 
to resist the drugs. However, this strategy is unlikely to improve treatment against 
bacteria that employ multiple antibiotic resistance mechanisms such as efflux 
pumps, modification of drug active sites and proteolytic degradation. In this study 
it was shown that synergism between antibiotics and AMPs is not restricted to 
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concurrent use of both antimicrobial agents. Ultimately, a sequential treatment 
may be more effective than using both antimicrobial agents simultaneously as it 
seems, in some MRSA strains, AMP resistance reduces or eliminates the 
proportion of antibiotic resistant bacteria in a population. Importantly, MRSA may 
be able to rapidly develop resistance to AMPs, but this resistance may be a 
liability to the cell when treated with another antimicrobial agent. 
To gain a better understanding of how melittin resistance could be affecting 
bacterial strategies to counteract fusidic acid, the genetic profiles of the ―Fus‖ 
resistance genes in each population were analyzed. To date, two main groups of 
genetic determinants that inhibit the action of fusidic acid have been identified: 
FusA and FusB (379, 380). FusA-mediated resistance arises from mutations in 
the coding region, denoted the FusA region, for elongation factor G. This 
modifies the structure of the EF-G proteins, which reduces the affinity of fusidic 
acid for the translocase-ribosome complex (379, 380). FusA resistance was the 
first fusidic acid resistance mechanism identified. Since its discovery multiple new 
mutations in the FusA gene have been discovered in the same strains, leading to 
the hypothesis that continued use of the antibiotic is selecting for bacteria in 
already resistant populations that are even more difficult to treat (380).  
The FusB family collectively represent the most commonly distributed fusidic acid 
resistance genes in MSSA (379, 381). It is likely that this broad distribution is due 
to the genes being incorporated into multiple plasmids, including the penicillinase 
and cadmium resistance plasmid (313). Although FusB was first identified in 
mobile elements, FusB and a FusB-like gene: FusC, have now been found in the 
chromosome of some S. aureus isolates (382, 383). The FusB genes produce 
proteins which bind to and protect EF-G by preventing fusidic acid locking the 
translocase to the ribosome (384). FusB/C may also interact with the EF-G-
ribosome complex and allow it to disassociate after fusidic acid has locked the 
two together (379, 380). The FusB protein consists of two domains: an N-terminal 
region with a hydrophobic core and a cationic C-terminal with five α-helical and β-
sheet structures and a unique zinc2+ binding region (381).A separate study has 
shown that the FusC protein has a very similar structure to the FusB protein 
(385). Cationic AMPs may have a strong affinity for the anionic and hydrophobic 
N-terminal regions of FusB/C. Binding of melittin to these proteins may alter the 
function of FusB/C so that the proteins interfere with the normal functions of EF-
G causing a reduction in protein synthesis. If this were the case, it could explain 
why bacteria which produce FusB/C proteins might disappear from the population 
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if they were constantly exposed to melittin. Therefore, to investigate potential 
reasons for the increased sensitivity to fusidic acid in melittin-resistant 
populations, the presence of the FusB/C genes in wild-type and AMP-resistant 
bacteria was examined. 
PCR analysis showed variation in the dissemination of the resistance genes 
among melittin naive strains. Curiously, both FusB and FusC were amplified from 
WBG 8287. It is possible that the two peptides work synergistically to counteract 
antibiotic resistance. However, it seems redundant for a cell to produce two 
peptides of such similar structure (385) which perform the same roles. Melittin 
resistance in fusidic acid resistant WBG 8287 did not affect the sensitivity of the 
cells to the antibiotic. As might be predicted, melittin exposure did not remove the 
Fus genes from the WBG 8287 population. Fusidic acid resistance in Aus3 cells 
may be, at least in part, determined by FusB since loss of this gene in melittin- 
resistant cells coincides with increased susceptibility to the antibiotic. This 
suggests that melittin exposure can select for cells without the FusB genotype. 
Whether this is because melittin and FusB proteins form a toxic complex or 
because the metabolic demand to resist AMPs is so great that other non-
essential metabolite sequences are lost requires further investigation. FusB and 
FusC genes were not amplifiable from W17S or BB DNA. This suggests that 
fusidic acid resistance in these strains is modulated by other genes or that they 
have FusB/C genes that could not be amplified with the primers used in this 
study. If W17S does not contain the FusB/C genes it suggests that melittin 
exposure and the development of resistance is detrimental to metabolic 
pathways, in particular, those related to antibiotic resistance.  
Unfortunately, it is difficult to make any solid conclusions due to the conflicting 
results observed between the bacteria made resistant to bac8c or melittin. 
Resistance to fusidic acid in MRSA exposed to bac8c seemed to increase over 
the naïve population. Spindler et al. (386) have shown that resistance to bac8c in 
E. coli does not affect sensitivity to antibiotics that affect protein synthesis (386). 
However, their research suggested that bac8c resistance correlated with a 
reduced metabolic rate. A reduced metabolism would be expected to decrease 
the demand for protein turnover and could explain why bac8c-resistant bacteria 
were able to tolerate higher concentrations of fusidic acid. Genetically, the 
FusB/C profiles differed among colonies of the same population. This variation 
was seen in both the bac8c naïve and resistant bacteria. As such, it suggests 
that the FusB/C genes may only be present within some bacteria from a strain 
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and places doubt on the relevance of the findings of this study in regards to the 
gene being apparently lost in melittin-resistant Aus3 bacteria.  
 
5.6 Silver Nanoparticle-Loaded Gauze is not comprehensively 
Bactericidal  
A multitude of studies have challenged the effectiveness of an AMP- based 
therapeutic drug that can be used inside the body (258, 387, 388). However, the 
rapid, potent, selective, and at the same time, broad spectrum activity of these 
peptides make them attractive candidates for topical treatments of bacterial 
infections. Silver ions also have broad spectrum antimicrobial activity resulting in 
its continued use in medicine for the past 1300 years (76). It has been 
demonstrated that silver has wound healing properties and may also protect cells 
against viral infection (85). For these reasons, medical gauzes have been 
developed with silver nanoparticles incorporated into the weave to treat wounds 
at risk of bacterial infection and scarring. The nanoparticle silver-loaded gauze, 
Acticoat, is commonly used prophylactically to protect patients with significant 
burns against bacterial infections prior to eschar excision and tissue grafting. 
Multiple studies have demonstrated that Acticoat is able to decrease the bacterial 
load in the wound and reduce patient discomfort (73). However, a recent 
consensus from medical practitioners has concluded that the wound healing 
ability of silver-loaded bandages is negligible (72). Animal studies have also 
shown that Acticoat and similar bandages, may inhibit bacterial growth, but are 
not effective at eliminating pathogenic bacteria from topical wounds (71, 73, 389). 
Research in this study aimed to evaluate the efficacy of Acticoat against S. 
aureus and investigate additives that might improve the bactericidal efficacy of 
the gauze.  A porcine skin model was used to test the effectiveness of Acticoat 
against MRSA infection. In subsequent experiments, the bactericidal activity of 
the gauze was augmented by applying a surface-coating of various non-toxic 
materials in combination with AMPs.  
On agar medium the silver nanoparticles appeared to diffuse through the medium 
and inhibit the growth of cells around the Acticoat.  Textured agar medium did not 
appear to change the inhibitory effectiveness of the dressing. The exception to 
this was cells treated on agar with a blistered texture from which bacterial growth 
could be seen under the Acticoat. It seemed that the blistered texture had gaps in 
the contact between Acticoat and the agar medium which protected the cells from 
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the inhibitory effect of silver. In the clinic, if the Acticoat bandage does not have 
close contact with the wound, a barrier of air between the dressing and the skin 
could prevent the effective diffusion of silver across the surface of the wound. 
Guidelines provided to medical personnel by the West Australian Department of 
Health suggest that nanocrystalline bandages in combination with a moisturizing 
agent should be applied to burns if the wound is dry and free of exudate (390). 
Moistening the Acticoat allows a sustained release of silver into the wound. A 
moist wound may also allow the silver to spread into infected areas which are not 
in direct contact with the dressing. When Acticoat is applied directly to the skin 
without a moisturizing agent, antiseptic or analgesic cream, wound exudate may 
provide a conduit medium for the silver particles to treat a broader area of the 
infected wound. However, anionic compounds in the fluid may also interfere with 
the therapeutic activity of silver nanoparticles.  
The inhibitory effect of Acticoat seen in the initial experiments did not correspond 
to its reported bactericidal activity. Although the bacterial population was much 
reduced by Acticoat compared to that observed with filter paper controls, survival 
of MRSA on the dressing was evident when it was spotted onto fresh agar plates. 
Over the course of three days, electron microscopy consistently showed cells 
with healthy morphologies distributed across the Acticoat network. Although it is 
difficult to accurately quantify the amount of bacteria across a 1 cm2 surface 
when an electron microscope reduces the field of view to 100 µm2 or less, a 
general scan of the Acticoat strips showed that growth of the cells was not 
substantially increased or decreased as with extended exposure time. This could 
suggest that after the bacteria have adapted to their initial exposure to the silver-
loaded gauze, the growth rates of the bacterial cells is exponentially increased to 
build up numbers and develop biofilm colonies. This was supported by the 
observation that, after 24h, the number of bacterial colonies from pig skin 
underneath Acticoat was approximately 2.25 fold that of bacteria that were grown 
on pig skin without exposure to Acticoat. Once the bacteria are protected from 
the silver by biofilm shielding, the metabolic demands for maintaining biofilm 
integrity and other resistance mechanisms may reduce the growth rate of the 
cells. On the nodes of the Acticoat, columns of what appears to be biofilm-
encapsulated bacteria, protruding from the surface of the dressing, were evident. 
The difference in cell growth and biofilm secretion observed between the nodes 
and ―arms‖ of the Acticoat may be due to a difference in silver density between 
the regions. The raised nodes may also have had more surface contact with the 
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agar and therefore could have provided the cells attached to the dressing a more 
moist and nutrient rich environment. The raised areas of Acticoat seem a flawed 
design because, on a nanoscale, this greatly increases the distance between the 
network of the dressing and the pathogens in the wound, which decreases the 
surface area of the wound that is in direct contact with Acticoat. However, 
Acticoat treatment of a moist wound may not require complete contact, as a 
wetting agent may provide a conduit between the gauze and the wound. 
 
5.7 Acticoat Bactericidal Activity can be Augmented with other Non-
toxic Molecules  
Acticoat was measurably less effective against MRSA on pig skin than on agar 
medium. Importantly, the pig skin model more closely mimics an infected wound. 
However, the semi-liquid medium of agar appears to allow greater mobilization 
and activation of the silver particles. In an attempt to improve the dispersion of 
the silver from the dressing on the pig skin, strips of Acticoat were wetted with 1% 
w/v agar or agarose gels. The results showed that the gels allowed the silver to 
kill bacterial cells directly beneath the Acticoat. However, bactericidal activity did 
not extend beyond the area of the gauze strip. Addition of bac8c to the gel-
dressing complex did not improve the area of its bactericidal effectiveness. The 
anionic polymers of agropectin in the agar could be sequestering the cationic 
peptide, preventing its diffusion out of the gel. However, bac8c also proved to be 
ineffective in the agarose gel which contained no charged molecules. This 
suggests that polysaccharide-based gels may not be suitable delivery vectors for 
small antibacterial peptides. Curiously, fusidic acid also failed to increase the 
inhibitory effect of Acticoat when both were incorporated into the gels. This could 
also mean that the concentrations of antimicrobial agents used in these tests 
were too low to show any great reduction in bacterial cell survival.  
The qualitative results from the initial experiments, using bacterial growth on 
semisolid media, did not give enough detail to make any strong conclusions on 
how to improve the antibacterial efficacy of Acticoat. Therefore, in subsequent 
experiments, bacterial survival was quantified on pig skin and on Acticoat. 
Acticoat significantly inhibited the growth of bacteria on the skin and on the 
dressing itself for at least eight hours. However, after 24h Acticoat was unable to 
suppress the growth of MRSA on pig skin. Surprisingly, when the number of 
bacteria surviving on the pig skin underneath Acticoat was quantified, there were 
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more cells on the Acticoat treated samples than on the untreated control-skin. A 
flaw in the methodology of this experiment was that the control skins did not have 
an equivalent ―mock-overlay‖ to Acticoat such as filter paper or polyethelene 
strips. The increased growth rate of cells overlain with Acticoat compared to cells 
that were grown on pig skin without an overlay may be because the gauze 
prevented, or slowed, desiccation of the cells.  
An international consensus for the application of silver nanoparticle-based 
dressings suggests leaving antimicrobial gauzes on the wound for two weeks 
(72). On the Smith and Nephew website it recommends leaving Acticoat and 
Acticoat 7 on a wound for three and seven days respectively. From the results 
presented in this study, it appears that after 24h the bacteria have overcome the 
bacteriostatic activity of the dressings and will probably have clustered into 
difficult to treat biofilm communities. Therefore, in the initial 12-24h of treatment, it 
may greatly reduce the risk of recurring infection if the dressings are frequently 
changed.  
Encasing Acticoat in gels appeared to improve the inhibitory activity of silver, but 
at the cost of limiting the effectiveness of additional antimicrobial agents. 
Therefore, in subsequent experiments, wetting agents, which are generally 
benign to epithelial cells, were applied to Acticoat prior to bacterial treatment. 
Glycerol and Tween-20 were selected for this purpose because they are non-
toxic, inexpensive, routinely used in cosmetics and therapeutics and classified as 
generally recognised as safe by the U.S Food and Drug Administration. In 
combination with Acticoat, both of these wetting agents decreased the load of 
surviving bacteria on the gauze and the skin. The differences observed between 
glycerol, Tween-20 and the HpH2O-coated control suggest that simple wetting of 
the gauze is not the only factor affecting bactericidal activity. Non-ionic 
detergents like polysorbate have been shown to increase the fluidity of 
mammalian cell membranes (391). One proposed mechanism of cell death 
relating to silver is the formation of transmembrane pores in the cell membrane 
(77) and a reduction in the rigidity of the membrane from Tween-20 exposure 
could make the bacteria more susceptible to the destabilising forces exerted on 
the cell surface by silver-nanoparticles.  
Glycerol appeared even more effective at reducing the survival of S. aureus on 
both the skin and dressing, even at concentrations as low as 1%. Interestingly, 
glycerol in combination with  manganese ions, has been reported to strongly 
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promote the formation of biofilm in Bacillus subtilis (392). It could be 
hypothesised that biofilm formation by these bacteria is a defence reaction in 
response to exposure of glycerol and manganese. If the combination of 
nanoparticle silver and glycerol had any kind of biofilm promoting activity for 
MRSA, it seems that process is not sufficient to overcome the toxicity of the two 
molecules. It is unclear why glycerol was so effective at enhancing the 
antibacterial effect of Acticoat. Silver nanoparticles may be more mobile in 
glycerol than in water because of the greater volumetric mass density of the 
solvent (1.26 g/ml). In addition, at temperatures above 15°C glycerol has been 
shown to expand the surface area of artificial phospholipid monolayers (393). As 
silver appears to have antibacterial mechanisms which destabilise membranes 
(394, 395), interactions between glycerol and the phospholipid bilayer may 
weaken the bonds between phospholipids and increase the effectiveness of the 
membranolytic activity of silver.   
The data shown above suggests that a combination of an effective wetting agent 
such as glycerol and a non-toxic detergent or permeabilizing agent may work 
synergistically to activate the silver and increase its bactericidal activity. The 
increased efficacy in bactericidal activity observed when Acticoat was used in 
combination with Tween-20 suggested that the use of Acticoat together with 
another extracellularly-active antibacterial compound such as lysozyme might 
greatly improve the effectiveness of the gauze in controlling or eliminating S. 
aureus infections. Lysozyme catalyses the degradation of peptidoglycans in the 
cell wall of Gram-positive bacteria (396) which compromises the defence 
mechanisms of the bacteria against extracellular toxic molecules. Treatment of a 
high concentration of bacteria with Acticoat and lysozyme was a more effective 
bactericide than Acticoat alone, but was less effective than a combination of 
Acticoat and glycerol. Addition of an AMP increased the antibacterial activity of 
Acticoat combined with either lysozyme or glycerol. However, a combination of all 
three seems to be the most effective coating for improving the antibacterial 
activity of Acticoat. The mechanisms of the antibacterial compounds in this 
mixture appear able to complement each other to overcome bacterial defence 
mechanisms to increase bactericidal efficacy. For example, lysozyme 
degradation of the cell wall removes a protective barrier which prevents access of 
AMPs and silver ions to the cell membrane (397). Silver will also gradually 
degrade cell wall components which likely augments the activity of lysozyme and 
allows more silver ions and AMPs to reach the cell membrane (397, 398). Silver 
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and AMPs have similarities in their mechanisms of action: both being membrane-
active and able to target intracellular components (77, 102, 122, 143, 399). 
Simultaneous attack of the bacterial membrane with the two antimicrobial agents 
may be sufficient to overcome any repair mechanisms employed by the bacterial 
cell. This may result in rapid lysis of the bacteria, or could allow a concentrated 
dose of the peptides and silver ions to enter the cell.  
 
5.8 The Multifunctional Nature of Antimicrobial Peptides may 
Increase their Therapeutic Potential 
This study measured the potential of AMPs as therapeutic agents, based on the 
effectiveness of their antibacterial activity. However, it seems that in nature these 
peptides have roles that are independent of host defence against bacteria and 
the true value of the peptides may be in the multiple roles they can play in 
maintaining host homeostasis. Recent studies have shown that AMPs play 
critical roles in wound healing and angiogenesis (400-402). In addition, AMPs 
show activity against tumours and viruses, and play an important role in 
maintaining sperm viability and motility (94, 403-405). Therefore, the importance 
of these peptides is well documented and studying the multifunctional roles they 
play may lead to the development of treatments for a broad range of diseases 
that may not be related to bacterial infection.     
 
5.8.1 Wound Repair and Vascularisation 
Epithelial tissue is generally the first barrier pathogens must cross to generate 
infection. The physical and chemical defences of this barrier can be disrupted by 
injuries such as sub-dermal abrasions and burns. Such injuries lead to the 
localised release of multiple cytokine growth factors such as insulin-like growth 
factor I and transforming growth factor α, to stimulate wound healing (406, 407). 
These molecules also increase the expression and release of AMPs from 
keratinocytes and neutrophils, presumably to combat invading pathogens and 
assist in wound healing (407). Keratinocyte migration, an important process in 
the closure and healing of wounds, has been shown to increase when the AMP 
LL-37 interacts with the keratinocyte epidermal growth factor receptor (402). 
Furthermore, LL-37 increases keratinocyte and fibroblast proliferation and inhibits 
keratinocyte apoptosis by upregulating the expression of cyclo-oxygenase-2 
(408-410).  LL-37 also contributes to the recovery of the wound by initiating and 
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supporting angiogenic processes. Two separate studies have shown that topical 
application of LL-37 significantly increased neovascularisation after wounding 
(400, 411). Mice lacking the murine equivalent of LL-37 also showed decreased 
vascularisation in the wound area (411). It is believed that LL-37 activity is 
mediated by interactions with the G-protein coupled receptor: formyl peptide-like 
receptor 1, on endothelial cells (400, 411). In addition, LL-37 indirectly 
contributes to angiogenesis by attracting macrophages and neutrophils, which 
synthesise and release angiogenic stimulators to the wound (411). The defensin 
peptides also play important roles in the recovery of wounds and the initiation of 
angiogenesis. In a study by Otte et al. (412), human β-defensin 2 was found to 
increase intestinal epithelial cell migration in disrupted epithelial layers, mediated 
by the C-C chemokine receptor 6 and possibly other G-protein coupled receptors. 
The peptide also suppressed the apoptotic-activity of TNF-related apoptosis 
inducing ligand and increased the expression of mucin genes, the products of 
which form a protective barrier against chemical and mechanical damage from 
luminal contents (412).  
Other wound healing studies have shown that α- and β-defensins stimulate 
migration and proliferation of keratinocytes and fibroblasts. Furthermore, α-
defensins aid in the initial stages of wound closure and repair by up-regulating 
the expression of extracellular matrix proteins in fibroblasts (413, 414). 
Angiogenesis is an important step in wound repair. However, un-regulated 
angiogenesis can also contribute to pathologies such as tumorigenesis, and 
intra-ocular neovascular disorders (415). Economopoulou et al. (416) have 
demonstrated that α-defensins can inhibit pathological vascularisation of retinal 
endothelial cells, by obstructing the angiogenic molecule: vascular endothelial 
growth factor (416). In contrast, multiple studies have shown that certain β-
defensins and LL-37 peptides are up-regulated in oncogenic tissue, which 
suggests that angiogenic and proliferatory effects of these peptides may 
contribute to the growth of the tumour (417-419). The expression of α-defensin is 
also up-regulated in tumour cells, which suggests the peptide is of nett benefit to 
the cells, despite its anti-angiogenic activity (417). Collectively, it seems that 
topical wounds could benefit from both the antibacterial and wound healing ability 
of the peptides. However, epithelial wounding has been shown to be associated 
with the activation of oncogenes in follicular stem cells resulting in tumorigenesis 
at the wound site (420). Therefore, the tumorigenic activity of some AMPs may 
exacerbate the events that lead to malignant transformation of damaged tissue to 
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carcinoma tissue. The complex relationship between AMPs and tumour cells has 
led to new avenues of research, investigating the risks of the peptides as tumor-
agonists and the antagonistic roles other AMPs may have against cancer.             
 
5.8.2 Anti-Cancer Roles of Antimicrobial Peptides 
In 2012, 19% of all diagnosed diseases in Australia were cancer related (421). 
Early diagnosis and resection of the affected organ or tissue can increase patient 
life expectancy. However, if the malignant cells metastasise or if neoadjuvant 
therapy is recommended, chemotherapy or systemic radiotherapy may be 
required. Despite the large amount of research and development committed to 
this field, current treatments are expensive, can severely decrease the quality of 
life of the patient, and have low success rates depending on the type and location 
of the malignant tissue (422-424). When a cell becomes malignant it increases its 
membrane concentration of anionic molecules such as phosphatidylserine, sialic 
acid and heparin sulphate (425). Most, but not all cancerous cells also decrease 
the concentration of cholesterol in their membranes, thereby increasing 
membrane fluidity (94, 426). As demonstrated with bacteria, anionic membranes 
are the key selective target for antimicrobial peptides. A membrane containing 
low levels of cholesterol is less rigid and may be more susceptible to peptide 
destabilisation. These factors make AMPs more selective towards tumour cells 
than normal cells and have led to the proposal of antimicrobial peptides as 
anticancer therapeutics (94, 427).  In vivo and in vitro experiments have shown 
that antimicrobial peptides such as cecropin, magainin, melittin, achyplesin 1 and 
defensins are able to kill a variety of tumour cell types at concentrations that are 
benign to most eukaryotic cells (427-429). The antitumor mechanisms seem to 
vary between peptides and cell types. In most cases it appears that AMPs initially 
damage cancerous cells by forming transmembrane pores or by dispersing cell 
membranes into micelle particles in a manner similar to their antibacterial affect 
(94, 430, 431).  
Non-membranolytic mechanisms of action against cancer cells have also been 
discovered for AMPs. For example, mutation of the ras gene can cause hyper-
activation of pathways related to cell proliferation, angiogenesis, metastasis and 
immortality: essentially transforming a healthy cell  to a malignant cell (432). 
Melittin selectively activates the phospholipase A2 enzyme present on ras 
oncogenic cells, which in turn leads to necrosis of the cell. It has been shown that 
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melittin treatment selects against the mutated ras genotype in cancer cells and 
eventually the population will revert back to a healthy phenotype (433, 434). In a 
separate study, the AMP tachyplesin 1, isolated from the horseshoe crab, was 
shown to bind to carcinoma cells rich in the gylcosaminoglycan hyaluronan and 
to cause cell necrosis via the complement pathway of the immune system (435).  
Despite this, recent studies have shown that some AMPs can increase tumour 
cell growth, proliferation, spread, and can even transform normal cells into cancer 
cells (436-438). The angiogenic and mitogenic properties of the cathelicidin 
peptide LL-37 seem to play an important role in tumorigenesis with the 
expression of this peptide in tumour cells significantly increased over that of 
healthy cells (437, 439). Furthermore, treating cancerous breast, ovarian and 
melanoma cells with LL-37 in vitro greatly increased their proliferative and 
invasive tendencies, suggesting that the peptide acts as a growth factor for the 
cells (418, 437, 439). A study conducted by Li et al. (438) has also shown that 
murine myeloid cells that express a peptide similar to LL-37: cathelicidin related 
antimicrobial peptide (CRAMP), are far more likely to develop into tumour tissue 
than their counterparts which lack CRAMP expression (438). In summary, it 
appears that the anticancer properties of AMPs show promise but certain 
peptides may exacerbate the oncogenic potential of some cells. If the factors that 
govern the tumorigenic activity of the peptides could be identified and mitigated, 
they may prove to be a safe chemotherapy for localised and systemic cancer.   
  
5.8.3 Anti-viral Properties of Antimicrobial Peptides 
The activity of clinically applied antibiotics generally involves inhibiting biological 
mechanisms related to metabolism within the pathogen. Viral replication is 
dependent on host cell machinery, leaving no pathogen-specific metabolic 
processes that can be tackled with medication. Therefore, despite the high rate of 
clinicians prescribing antibiotics for viral infections (440), antibiotics cannot 
directly target a virus. As an alternative treatment, AMPs have been shown to 
inhibit viral activity by direct or indirect interactions with the viral envelope or the 
host cell (138). The vaccinia virus is an enveloped virus, related to the small pox 
virus, which became an effective vaccine for Variola minor and major infections 
(441). Vaccinia induces high levels of LL-37 expression in keratinocytes, which 
suggests that the peptide has immunoresponsive roles against the virus (442). 
Transmission electron microscopy of vaccinia exposed to LL-37 shows significant 
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damage to the outer viral membrane, indicating a direct deleterious activity 
against the virus (442). Likewise, LL-37 has been shown to destroy influenza 
virus type A by disruption of the viral membrane (443). Analogues of melittin have 
also been shown to inhibit viral infection of plant cells by obstructing the viral coat 
protein from binding to viral RNA (444).  
Recent studies found that melittin can also inhibit human immunodeficiency virus 
(HIV) replication in infected T-cells by disrupting viral genome expression (445). 
At sub-cytotoxic concentrations, melittin was shown to inhibit transcription of the 
HIV structural protein, group-specific antigen, in T-cells and fibroblasts without 
affecting the transcription of host cell genes (445). The mechanism behind this 
has not been fully elucidated, but it may be that the peptide is affecting the 
activity of one or more of the host enzymes exploited by HIV. For example, 
Salvatore et al. (446) have shown that α-defensin prevents the activation of 
protein kinase C (PKC) in cells infected with the influenza virus. Besides aiding in 
viral entry, PKC stimulates a variety of transcription factors that bind to and 
activate promoters of HIV replication (447). Like α-defensins, melittin may inhibit 
PKC, thereby preventing activation of HIV promoters and limiting its replication 
inside the cell. Carriel-Gomes et al. (448) found that pre-treating mammalian cells 
with a variety of AMPs inhibited the entry of herpes simplex virus type 1. 
Although the mechanism behind this was not investigated, it is likely that the 
peptides act by competitively binding to viral entry proteins on the cells, inhibiting 
internalisation of the viron. This has been demonstrated with other peptides and 
viruses. For example, HIV entry into T-cells was inhibited by β-defensin 
competitively binding to the CXCR4 receptor required for internalisation of the 
virus (449). In contrast, θ-defensin inhibits HIV entry into T-cells by binding to 
glycoproteins on the viral envelope which are required for envelope fusion to the 
cell membrane and subsequent release of the viron into the cytoplasm (450).  
In vivo, HIV can spread quickly because it is internalised by dendritic cells and 
then transfected to T-cells as part of the antigen presenting immune pathway 
(451).  Van Compernolle et al. (452) have shown that a range of AMPs isolated 
from amphibian skin can not only inhibit HIV by disrupting its envelope 
membrane, but can also disable the virus after it has been internalised by the 
dendritic cell. This suggests that the peptides may be able to enter the dendritic 
cells and attack the virus. Alternatively, the peptides may target the virus when it 
is presented by the dendritic cell for T-cell CD4 recognition.  
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Antimicrobial peptides, unlike most antibiotics, have bio-active functions that may 
be used to improve the treatment of a broad variety of disorders and diseases. 
These multifunctional roles of AMPs may complement each other so that patient 
comfort, cost, and treatment effectiveness are greatly improved. For example, an 
antimicrobial gauze or cream with α-defensins as the active component could 
protect topical wounds from infection while at the same time reducing the time for 
the wound to close. Vaginal irrigation using a wash solution with one or more 
AMPs could protect against bacterial, yeast, and viral infections, which may also 
reduce the incidence of human papillomavirus-induced cervical cancer in 
patients. The scope of research within this project did not cover the possibilities 
of using AMPs as anything other than antibacterial agents. However, evidence 
from the literature suggests that the clinical application of these peptides may 
extend beyond that of bacterial infection control. If the limitations and side-effects 
of these peptides can be counter-acted, AMPs may prove to be an effective 
solution to antibiotic resistance in pathogens while at the same time providing 
new options to treat viral infections, cancer, and improve existing wound healing 
devices.   
 
6. Conclusions and Future Work 
This work has investigated new biological sources for antibacterial peptides. 
From these investigations, it appears there are still antimicrobial compounds 
effective against MRSA which can be found in common plants and fungi. 
Contrary to some published results and speculation, MRSA was able to adapt 
rapidly to the antibacterial peptides used in this study. However this resistance 
was dependent on continued selection pressures suggesting that the metabolic 
fitness of resistant bacteria may be impaired. A melittin peptide fragment, benign 
to bacteria in growth media, was shown to have significant bactericidal activity if 
the membrane is permeabilize with low concentrations of a non-ionic detergent. 
This could enable peptides, with low bactericidal activity but that are also non-
cytotoxic and stable in vivo, to become effective topical therapeutics. Finally, this 
study has demonstrated that the effectiveness of a clinically approved 
antibacterial gauze in controlling infection can be significantly improved by the 
addition of antibacterial peptide(s) and non-toxic compounds that enhance the 
action of biocidal peptides and silver nanoparticles. 
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  In this project, it was demonstrated that the antimicrobial activities of juniper 
berries and cardamom seeds were protein-related, which has not been 
documented before. Potent antibacterial activity was also discovered in the 
Australian honey fungus. This fungus is considered non-toxic to humans (334) 
and antibacterial compounds from this source are likely to be safe for therapeutic 
use. From these investigations it is clear that antibacterial activity can be 
identified in a broad variety of plant and fungal material relatively quickly, using 
very basic techniques. Although characterisation of the compounds stopped at 
identifying their proteinaceous nature, this study was able to show that a broad 
spectrum of plants and fungi, which are considered safe for human consumption, 
have anti-MRSA properties. Preliminary chromatography separation experiments 
were conducted on the cardamom seed and juniper berry extracts but the results 
were inconclusive. Follow up experiments relying on mass spectrometry 
characterisation of the extract fractions showing antimicrobial activity was 
planned, but could not be conducted due to time constraints. It is hoped that 
future experiments will be performed to investigate the nature and identity of 
these antimicrobial compounds. It is also anticipated that the methodology 
developed in this project for extracting and screening antimicrobial compounds 
will assist in streamlining related experiments.  
Multiple studies, including this one, have shown that the bactericidal efficacy of 
AMPs is negatively affected by exogenous proteins, high salt levels and low 
temperatures (186, 340-342). Based on these observations, it appears melittin 
and similar AMPs may only be suited for treating topical infections. Furthermore, 
results from these experiments suggest that the effectiveness of treatment with 
AMPs may be greatly enhanced by pre-washing the wound with a warm, low 
ionic strength buffer and by the inclusion of mild wetting agents with the peptides. 
However, the experiments in this study focused on treating cells in planktonic 
culture. The effectiveness of changing environmental parameters to improve 
bactericidal activity of AMPs in a wound may differ from the results obtained in 
this study. Future experiments using epithelial wound models to investigate 
debridement and heating of the surrounding tissue, to improve AMP efficacy, 
should give more clinically relevant data.   
Perhaps one of the most important findings from this study is that resistance to 
melittin and bac8c in multiple MRSA and one MSSA strain can be rapidly 
induced. This resistance correlates with a decreased anionic charge of the 
bacterial surface. Growth rates and morphology appear unaffected by resistance. 
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However, it is likely that masking the negative surface charge was not the only 
resistance mechanism developed, since the peptides were still able to form 
transmembrane pores in resistant cells. When selection pressures were 
removed, resistance to the peptides diminished in the bacterial population 
relatively quickly. Despite the reduction in MLC seen in populations subcultured 
without the AMPs, a small sub-population retained a tolerance to the peptides 
that was slightly greater than that of wild-type cells. This sub-population appears 
likely to re-emerge as the dominant phenotype when the bacteria are re-exposed 
to an AMP, thereby ensuring the survival of the population in a dynamic 
environment. The short time required to bring about a substantial reduction in the 
MLC of melittin, which is observed in resistant cells, is in stark contrast to the 
reported stability of antibiotic resistance over time (353). On this basis, the results 
suggest that the capability for development of resistance to an AMP may not 
preclude its therapeutic use, as long as appropriate treatment regimes are 
followed.  
The effect AMPs have on the cell surface can be seen clearly with SEM and 
transmission electron microscopy images (453, 454). However, this reveals 
nothing of their intracellular activity. For researchers to design more effective 
antibacterial peptide-based therapeutics, a more detailed understanding of the 
intracellular targets of these peptides is needed. Using transmission electron 
microscopy or synchrotron x-ray free-electron laser imaging to investigate any 
possible morphological damage done to internal organelles by AMP exposure, 
could give valuable insight into the intracellular mechanism of the peptides. The 
lack of membrane-bound organelles in bacteria make it unlikely that the peptides 
damage the cytoplasmic organelles of the bacteria in the same way they form 
pores in the plasma membrane. However, if the peptides have specific receptors 
on the bacterial organelles, peptide-receptor interactions could cause visible 
changes in the structure of the organelles that may be observed with 
transmission electron microscopy or free-electron laser imaging.     
 Melfrag12-26 was benign to MRSA until it was inserted into the cells by 
electroporation. The activity of the peptide inside the cell shows that the twelve 
amino acid sequence, or part of it, is capable of inhibiting intracellular metabolic 
processes. It appears that the factor limiting its toxicity externally is its inability to 
create transmembrane pores or diffuse across the membrane.  Full-length 
melittin and bac8c also appear more effective at killing cells via intracellular 
means than by transmembrane pore formation. This is an interesting observation 
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because it means that enhancing the cytolytic potential of a peptide has the 
disadvantage of increasing its haemolytic activity but may be redundant if the 
peptide has intracellular toxicity and is used in conjunction with a bacterial 
membrane permeabilizing agent. This understanding could also lead to the 
creation of hybrid peptides with domains that are active inside the cell, attached 
to pore-forming sequences that are specific to microbial membranes. In practice, 
a simpler approach may be to use internally toxic peptides in conjunction with a 
membrane permeabilising agent such as a mild detergent or an organic solvent. 
In this study it was shown that the surfactants Tween-20 or Triton X-100, used in 
conjunction with the peptides, resulted in a substantial increase in bactericidal 
activity. However, it is unclear whether the detergent action could have made the 
bacterial membranes more susceptible to pore-forming activity or whether the 
increased permeability of the membrane allowed peptides greater access to 
intracellular targets. It is anticipated that future SEM studies analysing the 
morphology of the cells after AMP and detergent treatment may clarify whether 
the combinational treatment has an effect on the structural integrity of the cell 
surface, or if the damage to the cell is focused internally. However, in the case of 
melittin at least, it appears that Triton X-100 increases pore forming ability even 
at low concentrations of the detergent, which, in turn, increases the haemolytic 
potential of melittin. Conversely, the bactericidal activity of melfrag12-26 and 
bac8c was increased by the addition of a detergent with no effect on their 
haemolytic capability. Therefore, the therapeutic potential of AMPs may be 
improved by using the peptides with detergents. Additionally, the use of 
detergents would be most useful, therapeutically, if applied with non-haemolytic 
peptides. A peptide-detergent combinational treatment may be a simple and 
inexpensive way of enhancing AMP-therapy of topical wounds. As proposed 
above, the different compositions of eukaryotic membranes and prokaryotic 
membranes may allow the improvement of the antibacterial activity of the 
peptides while minimising their toxicity to eukaryotic cells. Although this study has 
shown that Triton X-100 can improve the bactericidal activity of an AMP without 
affecting its haemolytic potential, future experiments investigating a broader 
range of detergents with different solubilising affinities for different lipids could 
identify a permeabilising agent that allows any AMP to be used effectively as an 
antibacterial therapy below its haemolytic or cytotoxic concentrations.  
The presence of ―blebbing‖ structures on the surface of melittin-resistant cells 
following exposure to melittin suggests that alterations to the membrane do not 
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produce an impermeable barrier to the peptide. If melittin can still translocate into 
the cytoplasm of resistant bacteria, it is likely that the cells must have resistance 
mutations that protect intracellular organelles or pathways, to allow them to 
tolerate the peptide treatment. If this is the case, the results from this study 
suggest that these modifications could make some strains of S. aureus 
susceptible to certain antibiotics. It is also likely that the decreased negative 
charge of the membrane provides greater access to anionic antimicrobial agents, 
increasing their propensity to localise on the surface of the cells. If this reduced 
the tolerance of S. aureus to some antibiotics, it is unlikely that the development 
of widespread resistance to peptide-based therapeutics would create untreatable 
pathogens to the same extent as multi-drug resistant bacteria. However, 
resistance to the peptide bac8c appeared to make the bacteria more resistant to 
fusidic acid. This supports the possibility that bac8c has a different mechanism of 
action from melittin and that different bacterial strategies may exist for resisting 
this peptide. If this is the case, future experiments investigating bacterial 
sensitivity to a broad range of antibiotics could reveal whether the mutation that 
confers bac8c resistance might also make the bacteria more resistant to other 
antibiotics, or if this makes the cells more susceptible to other classes of 
antimicrobial agents.    
The weak electrophoretic bands representing some of the Sma1 fragments in the 
pulsed-field gel made it difficult to determine with certainty whether the induction 
of resistance in these experiments caused major changes in the bacteria. Most 
importantly, CHEF electrophoresis has a fragment separation limit of around ten 
kilobases. Therefore, the gain or loss of smaller fragments or of as single 
nucleotide polymorphisms could not be detected with these methods. More 
comprehensive genetic investigations in this study revealed that there was great 
variability in fusidic acid resistance between strains and suggest that FusB/C are 
not the only mutations providing fusidic acid resistance. FusB mediated 
resistance appears to be lost in some strains that develop melittin resistance.  
However, FusB/C genes were not identified in all strains analysed. In addition, 
the presence of the FusA mutation was not investigated in this project. It is 
possible that the alteration of the structure of elongation factor-G caused by the 
mutation makes it a target for melittin. Therefore a population exposed to melittin 
may not have the FusA mutation which may explain why it is susceptible to 
fusidic acid. Consequently, more tests are needed to conclude whether melittin 
resistance causes some populations to lose antibiotic resistance genes or 
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whether the mechanisms involved in melittin resistance enhances fusidic acid 
activity against some strains. In any case, if some peptide-resistance 
mechanisms increase the bacterial susceptibility to antibiotics and others 
increase resistance, this could complicate potential AMP treatment for bacterial 
infection. The broad mechanisms of action and resistance as well as their impact 
on the phenotypes of exposed microbial populations requires further investigation 
to discern the risks of implementing AMP-based therapy.    
Acticoat was unable to eliminate MRSA from inoculated areas of agar or pig skin. 
Surprisingly the bacteria were able to survive on the surface of Acticoat. 
Scanning electron microscopy showed that the majority of cells were localised to 
what appeared to be dense biofilm communities. It appears likely that the biofilm 
protected the bacteria from the toxic effects of silver. However, even single cells 
attached to the gauze showed a healthy morphology, suggesting that they have 
other mechanisms to cope with the effects of Acticoat. Evidently, the infection 
models used in these experiments are not ideal replicates of a natural wound. 
Furthermore, Acticoat and similar gauzes are probably safer and just as, if not 
more, effective at preventing topical infections than using broad spectrum 
antibiotics. However, patients with deep wounds, compromised immune systems 
or who have serious infections, are unlikely to benefit from this treatment if the 
limitations of the gauze are unknown to, or ignored by medical practitioners. This 
study has shown that Acticoat can be made far more effective for treating 
infected pig skin if used in conjunction with a wetting agent, a cell wall hydrolysis 
enzyme and AMPs. This combination may allow more silver ions to diffuse from 
the gauze while at the same time increasing the antibacterial effectiveness of 
silver due to lysozyme and peptide-induced weakening of the cell wall and 
plasma membrane. In their native form most AMPs are likely to be unsuitable for 
systemic use. However, from these preliminary experiments it appears that 
antimicrobial peptides could have applications in treating topical wounds with 
medical gauzes. Currently it is unknown whether using the gauze in combination 
with AMPs will augment, compromise or have no effect on their bactericidal 
activity in clinical applications. It is anticipated that this work will lead to more 
advanced trials to test the true effectiveness of Acticoat with and without 
complementary compounds, such as glycerol, in clinical applications. This 
research may help to improve the clinical effectiveness of Acticoat, with the 
potential for reducing patient scarring, discomfort and mortality.   
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8. Appendices 
Appendix A Storage and Culture of Bacteria 
Long term storage of bacterial stocks was in 25g/l bactopeptone medium 
supplemented with 15% v/v glycerol at -80°C. Bacteria used in experiments were 
spread on 1.5% bacteriological agar, 25g/l bactopeptone medium to produce 
single colonies. These inoculated plate stocks of bacteria were stored at 4°C for 
fourteen days before being discarded.     
 
Appendix B Temperature Gradient PCR for FusB/C Primers 
 
DNA from W17S, Bengal bay and WBG 8287 was amplified with FusB or FusC 
primers using reagent concentrations outlined in table 8.1. A gradient of 
annealing temperatures for the PCR reactions was used to find the optimal 
annealing temperature for the primers (Table 8.2). Although no amplification was 
seen with either primer sets for the W17S or BB strains, single amplicons were 
visible for both primer sets when used with WBG 8287 DNA, at annealing 
temperatures ranging from 55-63°C (Figure 8.1). Therefore, 59°C was chosen as 
the optimal annealing temperatures for FusB/C studies.  
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Figure 8.1 Amplified products from temperature gradient PCR  
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Lane DNA Origin Primers Temperature 
L 100 Bp Ladder NA1 NA 
1 DNA Extract FusB 55°C 
2 DNA Extract FusB 57°C 
3 DNA Extract FusB 59°C 
4 DNA Extract FusB 61°C 
5 DNA Extract FusB 63°C 
6 DNA Extract FusB 65°C 
7 DNA Extract FusC 55°C 
8 DNA Extract FusC 57°C 
9 DNA Extract FusC 59°C 
10 DNA Extract FusC 61°C 
11 DNA Extract FusC 63°C 
12 DNA Extract FusC 65°C 
13 
W17S DNA 
Extract 
NA NA 
14 BB DNA Extract NA NA 
15 
WBG 8287 DNA 
Extract 
NA NA 
B NA FusB 59°C 
C NA FusC 59 °C 
1None added/Not applicable 
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Table 8.1 PCR Reagents for Temperature Gradient PCR 
 
Table 8.2 Thermal Cycle Parameters for Temperature Gradient PCR  
 
Reagent Volume/20µl Reaction Concentration  
5xMyTaq Reaction Buffer 4µl 1x 
Forward Primer 0.4µl 2µM 
Reverse Primer 0.4µl 2µM 
Template 1µl 5ng/reaction 
Polymerase  (5U/µl) 0.1µl 0.025U/ul 
HpH2O 14.1µl 70.5% 
Step Temperature (°C) Time (Seconds) Cycles 
Initial Denaturation 95 60 1 
Annealing 55, 57, 59,61,63 or 65 15 
30 Extension 72 15 
Denaturation 95 15 
Final Extension 72 60 1 
Hold 4 ∞ 1 
